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University of Pittsburgh, 2017
Sepsis is a high mortality syndrome characterized by organ dysfunction due to a severe and
dysregulated acute inflammatory response to infection. Research into therapies for this syn-
drome has historically ended in failure, which has largely been attributed to the elevated
levels of subject heterogeneity. What may have been previously attributed to variability in
sepsis may be due to mechanistic differences between patients. Endotypes are distinct sub-
types of disease, where underlying causes such as mechanistic or pathway related differences
manifest into phenotypes of disease.
The lack of mechanistic understanding of immune mediator dynamics and the responses
they trigger necessitates a mathematical modeling approach to analyze its complexities. A
transfer function model is proposed to describe and cluster the dynamics of key inflamma-
tory mediators. Five sepsis endotypes were discovered and revealed motifs of overwhelming
inflammation, various levels of immunosuppression, sustained inflammation, and immunod-
eficiency. An accurate clinical tool was proposed to classify subjects into endotypes using
six-hour trajectories of clinical data.
A physiological ordinary differential equation model of sepsis is proposed that charac-
terizes the interactions of inflammatory signaling molecules, neutrophils, and macrophages
across the bone, blood, and tissue compartments of the body. This model used to gener-
ate individual subject fits against human sepsis data. Population-level parameter analysis
implicated macrophage cell death and cytokine half- dynamics in endotype-level differences.
Several proof-of-concept statistical models were introduced to demonstrate that it is
possible to estimate the pre-hospital time of sepsis subjects and to quantify their sepsis-
iv
induced systemic tissue damage. A nearest-neighbor-based method was verified against
animal and human data and revealed that identifying infection time-zero of sepsis patients
can be quickly estimated with high accuracy using commonly measured clinical features.
A logistic regression ensemble model demonstrated revealed early organ dysfunction were
significant contributors to systemic damage and mortality. Knowledge of time-zero and
systemic damage levels, in combination with an endotype classifier, provides clinicians with
a clear depiction of where a subject is located on their sepsis trajectory. Such a decision
support system enables therapy timing, early organ support, and targeted therapies to guide
personalized treatment and shift patients towards better outcomes in sepsis.
Keywords: mathematical modeling, sepsis, cytokines, ordinary differential equations, ma-
chine learning, statistical analysis.
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1.0 INTRODUCTION
1.1 BACKGROUND AND SIGNIFICANCE
Each year, sepsis aﬄicts millions worldwide with extensive morbidity and mortality [1]. This
syndrome predominately affects opposite sides of the age spectrum: the pediatric and the
elderly, where the incidence and mortality rates increase for each [2]. As such, mortality
exceeds 40% for the 85 and older age group [2]. Treatment of sepsis has proven to be
a challenge because of the fast-changing dynamics, multiple trajectories, and outcomes of
the syndrome [3, 4]. Clinical features of sepsis are highly variable and are dependent on the
infection site, type of infection, patient demographics, coexisting illnesses, organ dysfunction,
and time since sepsis onset [5]. In the past year, sepsis was redefined for the third time, out-
dating several diagnosis criteria, such as the Systemic Inflammatory Response Syndrome and
the Logistic Organ Dysfunction System. The prevalence of multiple criteria is indicative of
the current debate and disagreement among medical professionals [6]. As a result, there is
currently no gold standard with which to diagnose sepsis [7].
Advancements in sepsis therapeutics can be generalized as stagnant, where within the
past 30 years, the majority of clinical trials for pharmacological interventions in sepsis showed
either no effect or a negative effect on mortality [5, 8]. The most promising sepsis therapy,
activated protein-c, was briefly approved by the Food and Drug Administration (FDA)
following a successful trial in 2001. However, by 2011, a follow-up study revealed that this
therapy was ineffective at decreasing mortality and thus the FDA subsequently removed
it from the market [1]. To date, there is currently no FDA-approved drug that replaced
activated protein-C to treat sepsis [7].
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The various pathways to failure as well as the fact that sepsis is often coupled with many
comorbidities result in high inter- and intra-patient variabilities of the syndrome. This has
led to difficulties in defining, diagnosing, and treating sepsis[7].
Sepsis is a severe acute physiological response that results from the systemic effects
of a dysregulated acute inflammatory response to infection and is characterized by organ
dysfunction [7]. Acute inflammation represents the first line of defense against infection.
First, the body mobilizes immune mediators [3]. These mediators enable the body to mount
an antimicrobial response to remove the source of infection, but in doing so damages healthy
cells during the process. During severe infections and/or severe damage, overwhelming
inflammation may occur [9]. This leads to the systemic inflammation syndrome known
as sepsis. Once triggered, three outcomes are possible [3]. The first (i) is the healthy
outcome, where the body is able to remove the infection source and inflammatory pathways
are properly deactivated. The second (ii) is immunosuppression or immunodeficiency, which
can lead to recurrent infection or uncontrolled growth of the invading pathogens [3]. The
third case (iii), aseptic sepsis, is persistent inflammation where the dysregulation causes
sustained inflammation even after the infection source has been dealt with [3].
During an acute inflammatory response, there are three phases: initiation, the inflam-
mation response, and resolution. Embedded in almost all tissue, resident macrophages are
responsible for the recognizing nearby pathogens and initiating the inflammatory response
by producing a variety of inflammatory mediators including chemokines, cytokines, and va-
soactive agents [10]. Important cytokines such as Tumor Necrosis Factor-α (TNF-α) and
Interleukin-6 (IL-6) recruit neutrophils towards the site of infection by effecting change
on the cell membrane, causing neutrophils to physically roll along endothelial walls [11].
The Interleukin-8 (IL-8) chemokine stops the rolling and allows neutrophils to extravasate
through endothelial walls without erythrocyte leakage [10, 11]. Neutrophils migrate through
the tissue and, upon reaching the infection site, become activated and release toxic sub-
stances to eliminate the pathogen. Most of these substances are reactive oxygen species.
During this stage, M1 (pro-inflammatory monocyte-derived) macrophages are simultane-
ously recruited to the infection site via similar cytokine and chemokine interactions in order
to aid the elimination effort and to produce additional mediators to sustain inflammation
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[12, 13]. Upon removing the pathogen, macrophages shift production from pro-inflammatory
mediators to anti-inflammatory mediators and begin the resolution phase [10, 13]. IL-6 tran-
sitions its effect from a neutrophil recruiter to a monocyte recruiter [14]. During this stage,
recruited monocytes exhibit an anti-inflammatory phenotype and may differentiate into M2
macrophages [13]. M2 macrophages become more prevalent in tissue and are responsible for
producing Interleukin-10 (IL-10), a master anti-inflammatory cytokine [13, 15]. Addition-
ally, macrophages remove dead tissue and promote repair [10, 12]. Finally, the inflammatory
cascade is turned off due to the presence of IL-10 and by the lack of IL-6 and TNF-α produc-
ing M1 macrophages. This healthy scenario represents case (i). This process is illustrated
by the simplified diagram shown in Figure 1.1. The healthy scenario, case (i), occurs when
pathogens are fully eliminated and the anti-inflammatory compartment successfully resolves
the inflammatory compartment.
Figure 1.1: Simplified schematic of the inflammatory response. Pathogens invading the host triggers
an inflammatory response. This response eliminates pathogens, but causes unavoidable collateral
damage to healthy tissue, thereby causing damage. This damage further initiates inflammation.
Inflammation also triggers an anti-inflammatory response. The anti-inflammatory response inhibits
the inflammatory response. Adapted from Reynolds, et al, 2006 [4].
Sepsis may result when one or more aspects of acute inflammatory response become
dysregulated. This often occurs due to high pathogen load or within the immunocompro-
mised elderly. During the neutrophil-dominant stage, high levels of neutrophil activity may
trigger the aseptic sepsis case (iii). The substances released by neutrophils are highly toxic
and cause unavoidable collateral damage to nearby tissue [10]. This damage triggers further
inflammation and leads to a persistent inflammatory response, which in turn causes more tis-
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Table 1.1: Overview of Select Sepsis Therapeutic Agents and Their Efficacy in Animal Models and
in Human Trials.
Therapeutic Agent Mortality Benefit
Name Description Positive None or Negative
IL1-RA IL-1 receptor antagonist Mouse[16], Baboon[17] Human[18]
MPSS Glucocorticoid Baboon[19] Human [20]
Lenercept TNF-α receptor antagonist Baboon[21] Human [22]
CDP571 anti-TNF-α antibody Baboon[23] Human [24]
BN 5021 PAF antagonist Mouse [25] Human [26]
BB-882 PAF receptor antagonist Mouse [27] Human [28]
TCV-309 PAF antagonist Mouse [29] Human [30]
TAK-242 TLR-4 inhibitor Mouse [31] Human [32]
Tifacogin Preventing coagulation Mouse [33], Baboon [34] Human [35]
(IL1-RA: Interleukin-1 receptor antagonist, MPSS: Methylprednisolone sodium succinate,
TNF-α: Tumor necrosis factor alpha, PAF: Platelet activating factor, TLR-4: Toll-like receptor 4)
sue damage. This cycle persists even if the pathogen is fully eliminated. Organ dysfunction
and failure, prolonged ICU stays, metabolic abnormalities, and/or death are common con-
sequences of this case [7]. Another dysregulation occurs if the anti-inflammatory pathway is
triggered prior to the full elimination of pathogens, triggering case (ii). A high inflammatory
response may trigger a similarly high anti-inflammatory response too early. In this scenario,
the host immune response is unable to mount a sufficient attack on the pathogen and the
host may succumb to the infection.
1.2 PROBLEMS WITH CURRENT APPROACHES IN SEPSIS THERAPY
Given the complexities of the inflammatory pathways, much of sepsis research and exper-
iments are derived from animal models. Promising therapies in animal models have often
failed in human trials due to a lack of efficacy or due to safety concerns [36, 37]. Table
1.1 outlines several promising sepsis therapeutic agents over the years that demonstrated
significant mortality benefits in animal trials but not human trials. The historical lack of
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successful clinical trials has resulted in pharmaceutical companies referring to sepsis as a
“graveyard” [38]. The sheer amount of inter- and intra-patient variability in septic humans
contribute to this translational disconnect. For example, this disconnect may result from
patient differences in pre-existing disease burden or the timing of applied therapeutics [39–
42]. Animal models typically use identical animals with uniform levels of inflammation (low
genetic variability and controlled induction of sepsis) and controlled therapy timing (applied
exactly x hours after experimentally induced sepsis). Applying this level of control in human
trials is currently infeasible because of the inability of clinicians to quantify such variability
for each human patient.
Mechanistic understanding of sepsis may hold the answers behind sepsis heterogeneity
and differences in inflammatory pathways. The mechanistic differences in inflammatory path-
ways can result from immunosenescence, age-related differences in immunity [43]. Analysis
of genomic data from human sepsis subjects suggests that certain populations are predis-
posed to sepsis due to mechanistic implications of certain gene mutations [44]. Furthermore,
a fixed-effect analysis of this data, a statistical approach to identify confounding effects on
these gene mutations, revealed that age, ethnicity, and comorbidities may be important fac-
tors. These findings lend evidence to the idea that sepsis heterogeneity can be attributed to
pathological mechanistic differences between certain populations.
Given the long historical failure of sepsis therapies and the issues with patient variability,
the preconception of a “one-size-fits-all” therapy may be inappropriate [41, 45]. Post-hoc
analyses of several past human trials suggest several cohorts of sepsis patients may have
benefited from the experimental therapies (despite the overall conclusion of no mortality
benefit across trial subjects) [18, 46]. A targeted therapeutic approach to sepsis may be a
promising outlook for treatment. Targeted therapeutics can be developed by understand-
ing and use the disease subtypes to formulate a therapy. This has been shown to be an
effective approach in the treatment of asthma. Asthmatic research using disease subtypes
to develop targeted therapies have been successful, which lends support to the hypothesis
that a singular therapy for sepsis is inappropriate [47, 48]. An “endotype” is a disease sub-
type characterized by pathological and mechanistic differences. Sepsis subtype identification
has immense potential to improve clinical outcomes (such as lowering mortality or lowering
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multiple organ failure rates), which is why it is surprising that there is a lack of existing
literature on the topic. The existence of subtypes in sepsis has been hypothesized over the
years, but few have tried to identify and characterize them [45, 49, 50].
1.3 DECISION SUPPORT SYSTEMS
To address the clinical challenges with sepsis, mathematical model-based decision support
may provide the solution. Mathematics and in silico studies in sepsis have offered descrip-
tive models that can aid clinicians in understanding the ongoing dynamics of sepsis and
ascertain the effects of potential treatments [3, 4, 51–55]. Some of these studies have an-
alyzed parameter-based outcome bifurcations, revealing that mechanistic differences in the
parameter space may lead to death or survival states [3, 4]. However, few models in exist-
ing literature have been calibrated against human sepsis data, limiting the translatability
of its results to the clinic. The goal of this dissertation is to use mathematical models,
calibrated on human sepsis data, to produce insights into how and why sepsis endotypes
manifest and to provide clinicians with the appropriate quantitative tools to deal with the
sepsis heterogeneity.
1.4 DISSERTATION OVERVIEW
The focus of this dissertation is to identify, characterize, and analyze the subtypes of adult
sepsis. The underlying hypothesis is that providing clinicians with the ability to classify
patients into sepsis subtypes will improve sepsis therapy and improve clinical outcomes.
Endotype-driven approaches may address major components of the translational disconnect
between animal models and human trials. Identifying sepsis endotypes may capture the root
cause of much of the variability associated with the syndrome. Analysis of specific subtypes
can identify how mechanistic differences cause the dysregulations in Section 1.1. Knowledge
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of such mechanistic differences can enable the discovery of new pharmaceutical targets for
therapy or reveal cohorts that benefit from specific treatments.
The secondary focus of this dissertation is the creation of translatable clinical tools to
support clinicians in their decision-making process during the treatment of sepsis patients.
These tools aim to provide early sepsis subtype classification and enable therapy timing and
were designed with (i) low measurement burden (relatively easy to measure biomarkers) and
(ii) low temporal burden (short sequential measurements only).
The dissertation is organized as follows. Chapter 2 identifies clusters of sepsis patients
with similar clinical features using a statistical approach. Hierarchical clustering revealed
that inflammatory mediators predominately drove the formation of the clusters and that
they are associated with sepsis-related mortality and organ dysfunction.
Chapter 3 studies how the dynamics of cytokines, the aforementioned inflammatory
mediators, reveal distinct patterns. These behaviors were characterized by five distinct
groups. This work was extended as a proposed clinical tool, which quickly classified a
subject’s endotype within 6 hours of clinical presentation.
Chapter 4 focuses on the importance of cytokines and their dynamical relationship to
endotyping in sepsis. Cytokines are responsible for recruiting white blood cells, which ulti-
mately carry out the relevant antimicrobial actions during acute inflammation. To analyze
the discovered endotypes in the broader context of sepsis, a tissue and blood compartmental
mechanistic ordinary differential equation model was developed to capture both white blood
cell and cytokine dynamics. This model was used to generate endotype-specific fits, which
was used to analyze endotype pathology.
Chapter 5 describes exploratory models that address other aspects of sepsis variability
that can improve the translatability of animal research to humans. To address the tight
experimental controls with regards to therapy timing and controlled injury levels seen in
animal research, machine-learning approaches were taken to identify sepsis time zero in
patients and to quantify global tissue damage during sepsis. With the knowledge of disease
time zero and systemic damage, a clinician can be provided with a grasp of where a septic
patient is located along an endotype’s disease trajectory. This combined knowledge can be
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used to finely select suitable patients for clinical trials and may offer improvements to the
status quo of care.
Chapter 6 describes several notable mathematical tools developed for this project. A
network optimization tool is first introduced as a method to detect inflammatory pathways
in data. This tool identifies the best boolean rule network that best describes a dataset to aid
in the analysis of immune pathways and model structure design. A parameter fitting toolkit,
APT-MCMC, is then introduced as an efficient Monte Carlo method to fit such models.
APT-MCMC contains features for advanced fitting scenarios pertaining to mathematical
models in medicine, including fitting initial conditions, handling of infusions, and fitting
left-censored data.
Chapter 7 provides perspective on the contributions this dissertation makes in the field
of sepsis. Short and long-term future improvements are proposed, with the ultimate goal
envisioned as a simple to use bedside tool to enable clinicians to personalize treatment for
each septic patient under their care.
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2.0 HIERARCHICAL CLUSTERING APPROACH TO IDENTIFY SEPSIS
ENDOPHENOTYPES
Clinical features of sepsis vary greatly among patients and are dependent on pathogen fac-
tors, host factors, time elapsed between onset of infection and clinical presentation, and
interventions [5]. Failure to understand the vital interplay between these factors has con-
tributed to many failed sepsis clinical trials in the past few decades, and there is a clinical
need to revisit the current approach to sepsis research [8, 56, 57]. Sepsis research may ben-
efit by borrowing a promising technique from another disease area that may be the key to
capturing physiologic variability: the study of disease endotypes.
Asthma research has demonstrated success in applying clinical endotypes for the purposes
of clinical diagnosis and classification, predictions, and therapy development [47]. Endotypes
are disease subtypes that are caused by pathobiological differences and are often expressed
through phenotypic variability [48]. Several severe asthma endotypes and their indicative
biomarkers have been identified, enabling the research and development of targeted thera-
peutics [48]. For instance, glucocorticoids are the gold standard for asthma treatment, but
their efficacy varies, sometimes to the point of no benefit, among asthma endotypes [47].
Furthermore, asthma endotypes are being used to guide clinical study design [47]. Consider-
ation of endotypes in sepsis, which dispels the notion of a single therapeutic approach, may
lead to better targeted and more effective treatment [45].
The use of endotypes in sepsis may reveal key underlying pathobiological differences
between different host responses to sepsis and may address much of the clinical variability
observed in septic patients. In the field of asthma, researchers have demonstrated that endo-
types can be derived from clusters of phenotypes despite differences in clinical presentations
and disease severity [47].
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Several groups have previously identified sepsis clusters with differing mortality rates
[49, 50]. Fjell, et al., used an unsupervised clustering approach to segregate patients using
cytokines and other signaling molecules [49]. They identified three groups of varying cy-
tokine magnitudes. The highest cytokine group was associated with elevated mortality and
morbidity such as renal failure and coagulopathy. Knox, et al., used a self-organizing map
approach to identify four clusters with differing clinical outcomes [50]. This approach trained
a map of nodes to represent a dimensionally-reduced version of a clinical data set (with vari-
ables such as temperature, white blood cell count, etc.). The identified node clusters were
re-colored to visually demonstrate differences between clusters in sepsis-related organ failure
assessment (SOFA) scores and sepsis severity [58].
The ideal endotype classification system for sepsis would involve a combination of a few
highly informative signaling molecules (cytokines) and intuitive clinical biomarkers, such as
vital signs, to be practical in a clinical setting. The work presented by Fjell, et al., utilizes
only signaling molecules, many of which are rarely collected in an ICU. The work by Knox,
et al., takes a dimension reduction approach which renders it difficult to interpret the clinical
features of each endophenotype.
The underlying hypothesis for this work was sepsis endotypes were identifiable and sep-
arable via clinical and diagnostic biomarkers in a multi-dimensional manner. Because endo-
types are generally explained by genetic differences (or some other underlying mechanistic
distinction), the stratified groups in this work are better described as endophenotypes. The
hierarchical dendrogram clustering and heatmap approach from Fjell, et al. was adapted for
use with a rich and longitudinal human sepsis data set. This approach allowed the visualiza-
tion of defining features of each endophenotype that would be lost in a dimension-reduction
approach. Finally, an important end goal was to establish endophenotypes with distinct
clinical features, including 14-day all-cause mortality and risk of multiple organ failure.
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2.1 METHODS
A retrospective analysis of the Protocol-Based Care for Early Septic Shock (ProCESS) trial
was conducted [59]. This trial was propelled by the seminal 2001 journal article by Rivers,
et al., which demonstrated mortality benefits from early goal-directed therapy (EGDT) in
sepsis [60]. EGDT involves monitoring hemodynamics using a central venous catheter and
controlling arterial pressures and hematocrit to within pre-set therapeutic zones via fluids
and vasopressors [60]. The ProCESS trial encompassed 31 emergency departments in the
United states and enrolled 1341 subjects into one of three treatment arms to compare the
clinical outcomes of EGDT, protocol-based care (combination of EGDT and standard care),
and standard care. The primary clinical outcome was 60-day in-hospital mortality. At the
conclusion of the study in 2014, the ProCESS investigators determined that there were no
mortality differences among any of the three treatment arms. Furthermore, a retrospective
analysis of all EGDT studies (including ProCESS) in 2015 concluded that EGDT had no
effect on mortality outcomes in sepsis patients [61].
In light of this result, the ProCESS trial amassed a rich data set from its subjects.
Longitudinal and high fidelity clinical data were collected for many of the 1341 subjects. This
data was retrospectively analyzed for this chapter. 84 biomarkers were measured temporally.
The variance among different biomarkers varied in scale and those with high variance were
selected for analysis. Biomarkers were converted to the z-score (zero-mean and one standard
deviation). The biomarkers were sorted by the range in z-scores (highest range to lowest
range to represent the amount of variance within a biomarker). The top 50% of biomarkers
were selected for inclusion in the heatmap analysis.
An availability analysis at baseline, as defined by trial enrollment, was performed on the
remaining 42 biomarkers. To improve biomarker availability, missing baseline values were
substituted by a measurement within 3 hours of time-zero, when necessary. This yielded a
convenience cohort of 493 patients with the following biomarkers fully measured at baseline:
glucose, platelet count, systolic and diastolic blood pressure, urine output, temperature,
heart rate, Tumor Necrosis Factor-alpha (TNF), Interleukin-10 (IL-10), Interleukin-6 (IL-
6), lactate, blood urea nitrogen, creatinine, white blood cell count, respiratory rate, and
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Table 2.1: Comparison of convenience cohort for hierarchical clustering against the rest of ProCESS
database.
ProCESS Database Whole Cohort
Characteristic n=847 n=493
Age 61.5±17.9 60.0±17.2
Male sex – no. (%) 457 (54.0%) 290 (58.8%)
Race – no. (%)
White 575 (67.9%) 340 (69.0%)
Black 224 (26.4%) 109 (22.1%)
Other 48 (5.7%) 44 (8.9%) *
Source of sepsis – no. (%)
Pneumonia 272 (32.1%) 171 (34.7%)
Urinary Tract Infection 160 (18.9%) 124 (25.2%) *
Intraabdominal infection 127 (15.0%) 49 (9.9%) *
Infection of unknown source 112 (13.2%) 58 (11.8%)
Skin or soft-tissue infection 63 (7.4%) 33 (6.7%)
Catheter-related infection 27 (3.2%) 11 (2.2%)
Central nervous system infection 7 (0.8%) 3 (0.6%)
Endocarditis 4 (0.5%) 3 (0.6%)
Other 52 (6.1%) 33 (6.7%)
Determined not to have infection 23 (2.7%) 8 (1.6%)
Positive blood culture – no. (%) 249 (29.4%) 147 (29.8%)
Injury Severity
APACHE II 20.5±7.5 21.2±7.8
APACHE III 60.8±22.3 61.7±23.2
Charlson 2.6±2.6 2.7±2.7
SOFA 7.1±3.5 7.3±3.6
Physiological variables
Systolic blood pressure – mmHG 100.6±23.9 98.7±25.0 *
Heart rate – beats/min 103.3±20.6 103.0±20.1
Temperature – C 37.3±1.3 37.3±1.4
Respiratory rate – breaths/min 23.0±6.6 22.6±7.1
Total bilirubin – mg/deciliter 1.5±2.2 1.4±1.8
Serum lactate – mmol/liter 2.9±2.5 3.0±3.0
Outcome
14 All-cause Mortality – no. (%) 149 (17.6%) 90 (18.3%)
Mortality – days 48.6±71.8 58.3±84.7
Multiple Organ Failure – no. (%)
Baseline 468 (55.3%) 282 (57.2%)
Within 14 Days (Any) 473 (55.8%) 276 (56.0%)
New Organ Failure in the first week – no. (%)
Cardiovascular 506 (59.7%) 303 (61.5%)
Respiratory 289 (34.1%) 183 (37.1%)
Renal 27 (3.2%) 20 (4.1%)
Stay in hospital – days 12.1±11.6 10.8±10.0
ICU 5.3±7.3 4.5±4.6
Serious Adverse Events – no. (%) 53 (6.3%) 29 (5.9%)
∗ denotes p≤ 0.05 from Dunn’ or Chi-Squared tests to determine differences between continuous or categorical
variables, respectively.
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potassium. This convenience cohort was compared against the rest of the ProCESS subjects
and the statistical results are presented in Table 2.1. Very few cohort characteristics or
clinical outcomes were statistically different, indicating that this convenience cohort was
representative of the ProCESS patients as a whole.
Missing baseline biomarkers were imputed in order to increase the number of analyz-
able biomarkers within the convenience cohort. Biomarkers with less than 5% missing at
baseline were included after imputation using the predictive mean matching program from
the mice package in R. Imputed biomarkers were sodium, chloride, hemoglobin, thrombin-
antithrombin (TAT) complex, D-Dimer, and calcium. Finally, bilirubin, with 18% missing
baseline values, was imputed using a linear model, where other baseline biomarkers served
as predictors (see Equation 2.1).
Xbilirubin(0) = β0 +
N∑
i=1
βiXi(0) (2.1)
Fitting the β coefficients were performed via the linear regression function from the Scipy
package in Python. The result was a complete dataset consisting of 493 subjects and 18
biomarkers at baseline. In order to analyze changes within this cohort over time, 6 and
24-hour post-trial enrollment data were considered as well. Missing measurements at these
time points were imputed using a last measured value carried forward approach. Data values
for patients that died by 6 or 24 hours were not imputed and were left as black columns
within the heatmaps.
The final step of data processing was to normalize the data. The natural log of the
data was taken to prevent biomarkers from exhibiting large ranges (such as cytokine mea-
surements). An empirical cumulative distribution function (eCDF) was calculated for each
biomarker across the entire convenience cohort using measurement values at 0, 6, 24, and 72
hours. Measurements at 72 hours were included to provide more data points for the eCDF
but were not used to generate heatmaps due to the excessive amounts of missing measure-
ments. Each biomarker was evaluated against their respective eCDF to obtain a normalized
value between 0 and 1. This normalized value was linearly transformed to boundaries of
[-10, 10]. A value of zero (corresponding to white on a heatmap) represents the population
median for a biomarker. An important note is that a value of zero makes no indication
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of a “healthy” state. Given the large number of biomarkers included for analysis and the
severely ill cohort, no consideration was performed to account for each biomarker’s crite-
ria for healthy levels. This normalization scheme step ensured comparability of biomarkers
among endophenotypes and time points.
2.1.1 Heatmap
Identifying patterns of distinct septic responses is nontrivial and necessitates unsupervised
clustering because there is no currently accepted classification of sepsis in clinical practice.
Hierarchical clustering was selected as the clustering algorithm because clusters merges can
be visualized intuitively via a dendrogram tree. Hierarchical clustering and subsequent heat
map visualization were performed using the heatmap3 package in R. Clustering options
was set to Euclidean distance and to the complete linkage function for bottom-up clustering.
Clustering was performed on the baseline dataset with both biomarker and patient clustering
enabled. Endophenotype identification was performed by analyzing the resulting heatmap
and dendrogram. Biomarker differences in the heatmap, the heights of the patient-level
dendrogram tree, and clinical intuition informed the creation of similar groups within the
heatmap. Hourly visualizations of patient data at 6 and 24 hours were performed with
the heatmap technique and ordered using the hierarchical clustering results of the baseline
dataset to preserve the identified endophenotype groups.
Clinical outcomes were defined by 14-day all-cause mortality and 14-day multiple organ
failure rates within each endotype. Unlike the clinical outcome in the ProCESS database
(60-day in-hospital mortality), 14-day all-cause mortality isolated mortality likely due to
the septic shock rather than downstream complications of sepsis, which is consistent with
previous literature [62]. Furthermore, sepsis severity definitions were rendered obsolete by
the 2016 redefinition of sepsis and multiple organ failure rates served as a proxy for sepsis
severity for each endotype [7]. SOFA values were calculated for each of the 493 patients using
the appropriate values at baseline and then on days 1 through 14 using daily maximum or
minimum values. A distinction was made between baseline MOF and 14-day MOF in order
to distinguish patients that were sick upon clinical presentation (with baseline MOF) or
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patients who worsened (no baseline MOF, but developed within 14-days). Baseline MOF
was defined by baseline SOFA ≥ 2. 14-day MOF was defined by any daily SOFA ≥ 2.
2.1.2 Statistical Analysis
Kruskal-Wallis and Chi-squared tests were performed on continuous and discrete variables,
respectively, test for statistically significant differences in variables among each endophe-
notype (p< 0.05). Patient characteristics such as infection source, demographics, injury
severity, and baseline physiological variables were analyzed. Outcomes such as mortality,
multiple organ failure, and hospital length of stay were also evaluated. Significance testing
was used to identify comorbidity differences between each endophenotype.
Further statistical testing was performed to test if any generated endophenotype was
a time-shift of another (for example, is group A at hour 0 the same as group B at hour
6?). Pair-wise testing was performed between each time point of each endophenotype. The
energy-distance test statistic was chosen due to its ability to compare two multivariate dis-
tributions and generate a distance between them [63]. This statistic was used to generate
a multivariate distribution of clinical biomarkers (generated on raw values prior to log and
CDF transformation) for each endophenotype at each time point. Using these distributions,
the energy-distance algorithm tested for any statistical differences between each time point
of each endotype. The R package energy was used for these computations. To account for
dependency issues arising from multiple comparisons, permutation testing (10,000 replicates
for each pair-wise test, significance at p< 0.05) was conducted.
2.2 RESULTS
Figure 2.1 shows the results of the clustering algorithm and the groups are visualized via
heatmap. White (zero in the normalized scale) represented the population median for a
biomarker. Red and blue colors indicate biomarker levels relative to the population; dark
red indicated that a patient’s biomarker was elevated with respect to the population me-
15
Figure 2.1: Heatmap of clustered baseline biomarkers in 493 patients with 6 identified subclusters.
Biomarkers are individually normalized to be between -10 and 10, with 0 (white) representing
the biomarker median. Dendrograms illustrate the clustering performed on biomarkers (left) and
on patients (top). Subgroups were identified by analyzing the patient dendrogram. Group A is
characterized by high cytokinemia, high lactate, and elevated mortality and multiple organ failure
rates. Group B is characterized by medium cytokinemia and lower lactate. Group C is characterized
by elevated blood pressure and low mortality rates. Group D is characterized by low cytokinemia
and low mortality rates. Group E is characterized by a low IL-6 response and low values of creatinine
and BUN, which is indicative of renal health. Group F is characterized by high IL-10 and TNF
responses along with elevated creatinine and BUN, which is indicative of poor renal health. (BUN
= blood urea nitrogen, IL-# = Interleukin-#, TNF = Tumor Necrosis Factor-α)
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Figure 2.2: Heatmap of 6-hour biomarkers in 493 patients with 6 identified subclusters. Hierarchical
clustering was not performed. Cluster ordering and Groups A-F were preserved from Figure 2.1.
This heatmap demonstrates the progression of the 493 patients since baseline. Generally, there are
improvements in all groups. Patients with elevated cytokinemia begin to taper down (return toward
baseline). Blood pressure and urine output generally increased. Those with elevated temperatures
at baseline tended to abate by 6 hours.
dian and dark blue indicated reduced levels. The analysis of the dendrogram yielded six
endophenotypes, labeled A-F. Figures 2.2 and 2.3 demonstrate patient progression over the
next 6 and 24 hours, respectively, with patient ordering preserved (using the ordering in-
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Figure 2.3: Heatmap of 24-hour biomarkers in 493 patients with 6 identified subclusters. Hierar-
chical clustering was not performed. Cluster ordering and Groups A-F were preserved from Figure
2.1. This heatmap demonstrates the progression of the 493 patients since baseline. There are more
white biomarkers in this heatmap than in Figures 2.1 and 2.2, indicating a tendency of biomarkers
to move away from their extremes. Abatement of cytokinemia is demonstrated in Group A, but
the majority of patient IL-6 and IL-10 levels were still in the red, which portend worse prognoses.
Group D continues to have a low cytokine response.
formed from baseline clustering). Table 2.2 shows the patient characteristics and outcome
differences between each endophenotype, including significant differences in mortality, organ
failure events, and the length of ICU stay.
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Table 2.2: Comparison of endophenotypes identified via hierarchical clustering.
Endophenotype
A B C D E F
Characteristic n=158 n=64 n=30 n=46 n=78 n=117
Age 61.2±17.2 58.6±16.4 57.8±18.7 61.5±15.6 58.7±16.1 59.8±18.2
Male sex – no. (%) 100 (63.3%) 32 (50.0%) 15 (50.0%) 24 (52.2%) 48 (61.5%) 71 (60.7%)
Race – no. (%)
White 107 (67.7%) 47 (73.4%) 15 (50.0%) 31 (67.4%) 52 (66.7%) 88 (75.2%)
Black 38 (24.1%) 9 (14.1%) 13 (43.3%) 10 (21.7%) 21 (26.9%) 18 (15.4%) *
Other 13 (8.2%) 8 (12.5%) 2 (6.7%) 5 (10.9%) 5 (6.4%) 11 (9.4%)
Source of sepsis – no. (%)
Pneumonia 56 (35.4%) 23 (35.9%) 11 (36.7%) 14 (30.4%) 32 (41.0%) 35 (29.9%)
Urinary Tract Infection 42 (26.6%) 17 (26.6%) 6 (20.0%) 11 (23.9%) 14 (17.9%) 34 (29.1%)
Intraabdominal infection 15 (9.5%) 8 (12.5%) 1 (3.3%) 4 (8.7%) 12 (15.4%) 9 (7.7%)
Infection of unknown source 17 (10.8%) 6 (9.4%) 5 (16.7%) 2 (4.3%) 5 (6.4%) 23 (19.7%) *
Skin or soft-tissue infection 8 (5.1%) 3 (4.7%) 2 (6.7%) 5 (10.9%) 11 (14.1%) 4 (3.4%) *
Catheter-related infection 5 (3.2%) 1 (1.6%) 0 (0.0%) 2 (4.3%) 0 (0.0%) 3 (2.6%)
Central nervous system infection 1 (0.6%) 0 (0.0%) 0 (0.0%) 1 (2.2%) 0 (0.0%) 1 (0.9%)
Endocarditis 1 (0.6%) 2 (3.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other 13 (8.2%) 3 (4.7%) 2 (6.7%) 7 (15.2%) 3 (3.8%) 5 (4.3%)
Determined not to have infection 0 (0.0%) 1 (1.6%) 3 (10.0%) 0 (0.0%) 1 (1.3%) 3 (2.6%) *
Positive blood culture – no. (%) 75 (47.5%) 20 (31.2%) 1 (3.3%) 8 (17.4%) 18 (23.1%) 25 (21.4%) *
Injury Severity
APACHE II 23.1±8.0 21.6±8.0 20.0±8.6 18.7±6.2 17.9±7.1 21.8±7.3
APACHE III 63.4±23.5 67.8±22.0 57.4±21.8 57.4±19.9 56.1±23.8 62.5±23.1
Charlson 2.9±2.8 3.0±2.7 2.7±2.7 2.4±2.2 2.5±2.3 2.8±2.9
SOFA 8.9±3.7 7.9±3.9 5.5±3.3 5.5±2.8 6.0±2.6 6.8±3.2 *
CNS 0.8±1.2 0.8±1.2 1.3±1.4 0.5±1.1 0.7±1.2 0.9±1.3
Cardiac 2.5±1.6 2.6±1.5 0.9±1.4 1.8±1.4 2.1±1.6 1.8±1.5 *
Coagulation 1.0±1.2 0.9±1.1 0.1±0.2 0.2±0.7 0.4±0.9 0.2±0.7 *
Liver 0.8±1.0 0.8±1.1 0.4±0.8 0.2±0.5 0.5±0.9 0.3±0.7 *
Renal 1.7±1.2 1.2±1.3 0.9±1.2 1.4±1.5 0.5±0.7 1.7±1.2 *
Respiratory 2.1±1.2 1.6±1.1 1.9±1.0 1.4±1.0 1.7±1.0 1.8±1.1 *
Physiological variables
Systolic blood pressure – mmHG 95.6±25.2 90.8±13.0 134.7±28.3 97.1±28.3 97.2±22.1 99.4±21.3 *
Heart rate – beats/min 110.2±17.9 93.7±19.7 108.9±18.5 95.5±21.5 102.2±18.1 100.3±20.2 *
Temperature – C 37.8±1.4 36.4±1.4 37.4±1.0 36.9±1.1 37.8±1.2 36.7±1.2 *
Respiratory rate – breaths/min 24.7±7.9 21.4±5.9 21.2±7.9 18.4±5.3 21.9±4.3 22.7±7.4 *
Total bilirubin – mg/deciliter 1.8±2.0 2.5±3.3 0.8±0.3 1.2±1.2 1.0±0.7 1.0±1.1 *
Serum lactate – mmol/liter 4.0±3.2 3.8±4.6 2.5±2.2 1.5±1.2 2.3±1.9 2.9±2.6 *
Outcome
14 Day All-cause Mortality – no.(%) 41 (25.9%) 13 (20.3%) 1 (3.3%) 3 (6.5%) 7 (9.0%) 25 (21.4%) *
Mortality – days 35.9±67.9 62.4±76.9 78.0±73.1 116.4±103.8 84.8±110.9 56.1±82.8 *
Multiple Organ Failure – no. (%)
Baseline 120 (75.9%) 36 (56.2%) 13 (43.3%) 15 (32.6%) 32 (41.0%) 66 (56.4%) *
Within 14 Days (Any) 119 (75.3%) 40 (62.5%) 12 (40.0%) 16 (34.8%) 29 (37.2%) 60 (51.3%) *
New Organ Failure in the first week – no. (%)
Cardiovascular 118 (74.7%) 43 (67.2%) 9 (30.0%) 23 (50.0%) 42 (53.8%) 68 (58.1%) *
Respiratory 77 (48.7%) 23 (35.9%) 12 (40.0%) 9 (19.6%) 14 (17.9%) 48 (41.0%) *
Renal 14 (8.9%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (4.3%) *
Stay in hospital – days 11.2±11.9 10.4±7.7 11.4±9.4 8.3±4.3 10.3±9.0 11.5±10.5
ICU 5.3±5.4 4.5±3.2 3.8±5.0 2.9±2.8 3.3±3.2 4.9±5.1 *
Serious Adverse Events – no. (%) 19 (12.0%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 2 (2.6%) 7 (6.0%)
∗ denotes p≤ 0.05 from Dunn’ or Chi-Squared tests to determine differences between continuous or categorical
variables, respectively.
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2.2.1 High-Risk Endophenotypes
Endophenotypes A, B, and F were at high risk of cardiovascular, respiratory, and renal
failure. 14-day mortality was > 20% and 60-day mortality was > 30%. Together, these
endophenotypes represent 339 of 493 patients analyzed. Endophenotype A was highly dis-
tinctive due to the presence of elevated cytokines (Interleukin-6, Tumor Necrosis Factor-α,
and Interleukin-10) across all patients. D-Dimer, TAT-complex, lactate, and bilirubin were
elevated as well, indicating coagulation, tissue perfusion, and hepatic issues. This group
had the highest incidence of MOF (both baseline and within 14-days) and 14-day mortality.
Table 2.2 shows that this group also had the highest incidence of positive blood cultures, 28
and 60-day mortality, cardiovascular, respiratory, and renal failure, and number of serious
adverse events. This endophenotype also had the largest number of early deaths for any
endophenotype (out of 158 patients, 2 died within 6 hours and 11 died within 24 hours).
Patients with elevated creatinine and blood urea nitrogen (BUN), which is indicative of renal
deficiency or failure, were at particularly high risk, with 4 deaths prior to 24 hours. Patients
with elevated diastolic and systolic blood pressure at baseline had lower rates of MOF and
mortality. Overall, patients in this group demonstrated a severe and sustained systemic
inflammatory response to infection. At baseline, a typical patient had high cytokinemia
and multiple biomarkers indicating the beginning of multiple organ system failure. This
endophenotype was most likely descriptive of early-stage sepsis patients.
Endophenotype F patients demonstrated low baseline cytokinemia, high white blood cell
counts, platelet counts, and elevated potassium levels. In addition, TAT complex decreased
in most patients within 24 hours. Despite the apparently protective profile of these clin-
ical biomarkers, this endophenotype had the second highest levels of MOF and mortality.
Defining feature were high levels of creatinine, BUN, and lactate. Temperature, heart rate,
hemoglobin, respiratory rate, white blood cell count, platelet count, and potassium tended
to drop among patients. Two patients died within 24 hours. Table 2.2 showed that this
group had the highest incidence of infection from an unknown source. Furthermore, this
group was at high risk of cardiovascular and respiratory failure. Overall, biomarker pro-
gressions indicate that this group was most likely succumbing to infection during late-stage
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sepsis. A possible mechanism could relate to the emergence of an immunosuppressed profile,
as indicated by an elevated IL-10 and decreased IL-6 among most patients. Furthermore,
most endophenotypes did not exhibit clear or consistent trends in white blood cell counts
(WBC), while group F patients uniformly exhibited elevated levels at baseline that depleted
over a 24-hour period.
A portion of Endophenotype B patients presented with baseline cytokinemia, but cy-
tokine magnitudes and clinical outcomes were more favorable than that of A or F. Glucose
and systolic blood pressure were uniformly decreased in this group. Half of the patients
exhibited elevated lactate, creatinine, and BUN (Figure 2.1, group B, left, highest branch of
the vertical dendrogram), while half did not (Figure 2.1, group B, right, highest branch of
the vertical dendrogram). There were no significant biomarker changes over 24 hours except
for decreasing IL-6. Table 2.2 showed that this group had the second highest incidences
of positive blood culture and second highest 60-day all-cause mortality. Additionally, this
group had the highest levels of baseline APACHE III severity of illness score and Charl-
son burden of chronic illness score [64, 65]. This suggests that this group of patients may
have been enrolled later in the course of illness, possibly after peak cytokine levels had been
reached [66]. This endophenotype launched a (relatively) appropriate inflammatory response
to infection. However, the late complications of sepsis, rather than the initial insult, were
responsible for the high mortality.
2.2.2 Low-Risk Endophenotypes
Endophenotypes C, D, and E demonstrated lower rates of MOF and mortality. These groups
were characterized by low to no cytokinemia and low lactate. Furthermore, the 154 patients
from these groups presented with low injury severity scores and low SOFA scores.
Endophenotype C contained patients exhibiting elevated baseline heart rates, hemoglobin,
platelet count, lactate, and diastolic and systolic blood pressures. This group was not af-
flicted with cytokinemia: despite varying levels of TNF and IL-10, IL-6 was uniformly low
among this cohort. Except for blood pressure, biomarkers had decreasing trends within 24
hours. While only 1 of 30 patients died within 14-days, Table 1 revealed elevated rates of res-
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piratory failure and 60-day mortality. This suggested that deaths within this endophenotype
were caused by later complications rather than the initial sepsis insult.
Endophenotype D contained patients with low or nonexistent baseline cytokinemia, low
lactate values, and elevated platelet counts. This group had the lowest risk of MOF and
14-day mortality. Table 1 showed that this group had the lowest 60-day mortality as well,
indicating fewer late-stage complications.
Endophenotype E contained patients with elevated temperatures, and low creatinine
and BUN values. Few patients had baseline cytokinemia. This group had slightly higher
rates of MOF and mortality than endophenotypes C and D. One patient died within 6
hours and another died within 24 hours. Over time, IL-6 decreased faster than IL-10. This
group appeared to have a normal inflammatory response and baseline biomarkers were not
indicative of any organ deficiency.
2.2.3 Similarity between Endophenotype
Figure 2.4 illustrates the results of the multivariate distance matrix to compare the similarity
between each endophenotype and their time points. Many of the 0-vs-6 hour comparisons and
the 0-vs-24 hour comparisons yielded significant differences, which further support the notion
that the identified endophenotypes were not mere time-shifts of one another. Endophenotype
A at 0 and 6 hours were significantly different from most other endophenotypes and time
points. Furthermore, none of the pair-wise comparisons yielded low dissimilarity statistics
between any test (no dark colors). The darkest region occurs within the 24-vs-24 hour
comparisons, indicating that there were some similarities among endophenotypes at 24 hours.
This demonstrated that patients that segregate into different baseline endophenotypes may
progress to similar clinical states after a period, but their baseline clinical values and time-
series progression may still play a larger role in determining outcomes.
Interestingly, endophenotypes A and F had similar 14-day mortalities, demonstrating
that distinct baseline profiles and sepsis trajectories may have similar risks of death. The
largest notable difference between these endophenotypes was the level of cytokinemia present
at baseline. Furthermore, white blood cell counts within endophenotype F were uniformly
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Figure 2.4: Multivariate energy-distances between endophenotypes A-F and their time points. The
distances are displayed in a heatmap where darker colors represent similar groups and lighter colors
represent differing groups. Most group-vs-group comparisons do not reveal any similarities. Some
similarities are present between different groups at time 24 hours. Cells with an asterisk indicate
that the null hypothesis (of equal multivariate distributions, p < 0.05) is rejected.
elevated at baseline and decreased over time, while patients within endophenotype A split
(half were elevated and half decreased at baseline) and remained unchanged over time.
2.3 DISCUSSION
Despite improving understanding of sepsis pathology, one of the critical issues aﬄicting sepsis
therapies and research is high inter-patient variability and the need for better patient stratifi-
cation. The goal of this study was to explore clinical values to identify the types of subgroups
that may exist in clinical sepsis populations. Outside of differing clinical outcomes, there
were clear differences between each endotype presented in Figure 2.1. Most notable were
the differences in cytokinemia and lactate. However, endotype F demonstrated that even
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low baseline cytokinemia may lead to high mortality and MOF and that biomarker progres-
sion over time is worthy of additional study. This exploratory work supports the notion of
endotype-specific therapies. Heat map clustering of patient cytokines and other laboratory
and clinical features is a promising method to group patients into distinct endotypes. Avail-
ability of additional domains of data would enhance the richness of their description, offer
further segregation of endotypes, and potentially offer insight as to underlying mechanisms.
Classification of these endotypes can act as a basis for more precise therapies even at the
rather coarse level of the description presented. The high-risk endophenotypes A, B, and F
are distinctive enough to warrant specific treatment or therapy options. Immunosuppression
drugs would likely be harmful to the slightly immunosuppressed patients in endophenotype
F, but could be beneficial for the high cytokinemia patients in endophenotype A. Knowledge
of sepsis endotypes has the clear potential to shift the current paradigm of research and trial
design towards better outcomes. For example, clinical trials can benefit from better patient
characterization at enrollment, to better match intervention and presumed pathophysiology,
or later, to interpret subgroup benefit of such interventions.
The identified groups in this work were dubbed endophenotypes due to their discovery
using observable clinical biomarkers (phenotypes). However, these biomarkers were hypoth-
esized to be clinical manifestations of distinct underlying pathophysiological differences (en-
dotypes). Along the spectrum between endotypes and phenotypes, the identified groups fall
somewhere in the middle. The visualization of clinical data as heatmaps revealed areas of
similarity and dissimilarity between groups, which indicated that clinical biomarkers alone
cannot fully explain the endotypes present in sepsis. The ability to discriminate the under-
lying endotype from the clinical phenotype with good accuracy is a strength of the current
approach. Clinical decisions are based on what clinicians can readily observe and measure,
and many of the markers characterizing endotypes, even at the coarse level we present, are
not readily available in a timely fashion. This issue will presumably be amplified as endo-
type enriching work proceeds. Thus, there is a trade-off between extensive knowledge of
endotypes with their implied underlying biology, and the pragmatic decisions clinicians are
facing when treating sepsis. Thus, endotype characterization allowing precise therapies to
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be applied in a timely fashion is key to the translational relevance of detailed endotyping
work.
In previous reports on sepsis clustering, Kellum, et al., studied cytokine (IL-6 and IL-10)
longitudinal profiles in the GenIMS cohort of patients admitted with community-acquired
pneumonia. These authors identified cytokine-based clusters with different outcomes. Specif-
ically, high cytokinemia trajectories in IL-6 and IL-10 corresponded to a higher overall bur-
den of inflammation and mortality, which corroborates our findings with endophenotype A.
Fjell, et al., analyzes signaling molecules and cytokines using a similar hierarchical clustering
method, but their biomarkers were pre-selected and did not include any clinical biomark-
ers [49]. Our approach using a non-biased feature selection (based on standard deviations
and subject to data availability) demonstrated biomarker progressions over time within each
endophenotype. Knox, et al., used similar clinical variables, but underwent a dimension
reduction technique, rendering it difficult to interpret the resulting clusters in a clinically
meaningful way [50]. The resulting clusters had to be recolored to present one variable at a
time, while the approach we took presented all clinical information in a multivariate way.
It has been demonstrated that the baseline time point in human sepsis data may not
be meaningful due to the variability associated with each patient’s pre-hospital time, but
this time could be recovered using clinical measurements [41]. Thus, the biomarker simi-
larity within each endophenotype suggests that the pre-hospital time (or true sepsis time
zero) for grouped subjects appears to be close, and patients are at similar points along the
endotype-specific sepsis trajectory. A dissimilarity test indicated that each heatmap was not
similar enough to be grouped together at any time point or cluster. The implication is that
classifying a patient into an endotype may be sufficient to estimate his or her pre-hospital
time (true sepsis time zero) and may be a one-step procedure for tailoring a suitable therapy.
Comorbidities played an influential role in each endophenotype. High-risk endopheno-
types A and F had the highest rates of renal failure as a comorbidity. Diabetes was most
prevalent in endophenotype F and lowest in B and E. Endophenotype B had the largest
population of AIDS patients (10%), which partially explains why B also had the largest
population of immune-compromised patients. Endophenotypes E had the highest incidence
of unknown infection source, which may suggest that these patients may not have received
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appropriate or timely antibiotic coverage. The lowest 14-day mortality groups, endopheno-
type C and D, were predominately characterized by the hypertension comorbidity (70%+
within either cohort). This suggested that hypertension may be somewhat protective during
the initial onset of sepsis.
2.3.1 Study Limitations
This work can be improved via validation using a larger dataset. Despite the small co-
hort sizes used in this study, the ProCESS database is still one of the largest of its kind.
A validation database would enable the exploration of other clinically interesting variables
because many had to be eliminated for this work due to low sample sizes or rates within
the ProCESS population. Furthermore, there is an element of subjectivity in the current
approach. Determining the height to “cut” the dendrogram tree in Figure 1 affected the
resulting groups, ranging from 2 groups at the top level to 493 groups at the bottom-most
level. While endophenotype A was clearly distinct from the rest (largest height on den-
drogram tree), the division of the remaining groups was based on cutting the dendrogram
to yield visually distinctive regions. As a result, segregating the data required a degree of
human intervention. Despite the subjectivity, Table 2.2 revealed many differences between
the endophenotypes discovered.
2.3.2 Application into Temporal qSOFA Trajectories
The hierarchical clustering approach outlined in Section 2.1 was extended to explore the
predictive capability of sequential measurements of the quick Sequential Organ Failure As-
sessment (qSOFA) score with respect to mortality. The qSOFA score was recommended by
the recent sepsis redefinition (Sepsis-3) as a fast method of assessing a patient with suspected
infection without the need of laboratory tests [7]. The qSOFA score consisted of measuring
respiratory rate, systolic blood pressure, and the Glasgow Coma Score (GCS). Each clinical
feature may contribute 0 or 1 to the overall qSOFA score for a total of 3 points (worst score).
The manuscript for this work is pending co-author review (Kievlan, Zhang, et al., Evalu-
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Figure 2.5: Clustered Trajectories of qSOFA scores in patients with suspected infection. Shades of
red indicate the severity of qSOFA scores and gray indicates missing measurements. Patients with
low baseline qSOFA scores (qSOFA=0,1, survivors) were more likely to remain low over 48 hours
than nonsurvivors. Two patients with a baseline qSOFA score of 3 survived.
ation of repeated qSOFA measurements among patients with suspected infection; awaiting
submission to American Journal of Respiratory and Critical Care Medicine).
27
A retrospective cohort study among adult hospital encounters (age /geq 18 years) with
suspected infection in 2012 at twelve community and academic hospitals in southwestern
Pennsylvania was conducted. From this data, qSOFA scores were calculated for each patient.
Within the first 48 hours, data was broken into six-hour intervals and the maximum qSOFA
score was calculated from each interval. The heatmap hierarchical clustering outlined in
this section was used to group these trajectories together to evaluate the trends in qSOFA
trajectories among differing baseline values and survivors/nonsurvivors.
The cohort consisted of 37,591 subjects with baseline qSOFA measurements. Of these
subjects, 4.7% (1,769) died in the hospital. Figure 2.5 illustrates that survivors tended to
have improving qSOFA trajectories. Nonsurvivors’ qSOFA scores remained higher for longer.
The majority of the baseline qSOFA=3 subjects belonged to the nonsurvivor group and gen-
erally did not see any decrease in their qSOFA scores over time. Among the low baseline
qSOFA subjects, those that survived tended to remain low while nonsurvivors’ qSOFA trajec-
tories tended to increase over 48 hours. Furthermore, the survivors with baseline qSOFA=2
tended to improve over time while the nonsurvivors tended to deteriorate. This suggests
that in clinics where regular SOFA scores are difficult to obtain, qSOFA monitoring over
time provides a fast risk/mortality assessment method.
2.3.3 Summary
In summary, these findings suggest that biomarkers offer discriminatory power upon clinical
presentation to segregate subjects into clusters of distinct clinical trajectories. Each cluster,
dubbed an endophenotype due to their basis in observable clinical features, has distinct rates
of mortality and organ failure. These clusters suggest the existence of separate endotypes in
sepsis, which is currently not well understood. The results of this work motivate the following
chapters under the hypothesis that research into these endophenotypes will reveal richer
features and improved mechanistic understanding behind these clusters. The end goal is to
classify incoming septic patients from readily available clinical and serum biomarkers into
an endotype which suggests potential dysregulation mechanisms and may lead to targeted
therapies.
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3.0 MIXTURE MODELING APPROACH TO IDENTIFY SEPSIS
ENDOTYPES
Chapter 2 identified clusters of subjects with similar clinical features and demonstrated
the existence of distinct sepsis subtypes. This motivated further research into sepsis endo-
types by refining these clusters and characterizing the biological mechanisms behind these
distinctions. This Chapter builds upon this work by addressing two major clinical concerns
associated with sepsis in critical care. First, the identified clusters in Chapter 2 were deemed
endophenotypes because no mechanistic considerations were involved during the clustering
process. There is currently a lack of mechanistic understanding behind sepsis and much
is unknown about the dysregulated pathways that lead to sepsis [67, 68]. Mathematical
models of sepsis have previously demonstrated success in characterizing the dynamics and
mechanisms of inflammatory pathways in sepsis, but have not been validated against human
data [3, 4, 69, 70]. This deficiency is caused by the second concern: the clinical practice
of defining subject baselines at the time of clinical presentation renders characterization of
sepsis difficult. From a dynamics point-of-view, analyzing data without initial conditions
introduces significant ambiguity to mathematical findings. The clinical status quo is the
result of a lack of knowledge of a subject’s pre-hospital time and trajectory. When queried
about the duration of their acute inflammatory response, subjects in the ProCESS cohort
estimated time-spans of up to one year [59]. The lack of consideration of pre-hospital dura-
tions weakens the findings and translatability of current sepsis research, including the results
from Chapter 2.
This section improves upon the previous method of hierarchical clustering by addressing
clinical concerns via the development of a novel mathematical modeling-based approach to
the identification of sepsis endotypes. Considerations for inflammatory dynamics and subject
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pre-hospital times were taken into account using a mathematical model that initiated at the
beginning of the inflammatory response. A mixture-modeling-based approach is introduced
where each subject was parameterized in accordance with the mathematical model and then
clustered based on their parameters. The resulting clusters were deemed endotypes rather
than endophenotypes because of the mechanistic focus on the inflammatory response rather
than the phenotype-based method in Chapter 2.
As readouts of the inflammatory response, cytokines are desirable candidates for mod-
eling and characterizing inflammatory pathway endotypes. Although cytokines represent a
minute portion of the extensive inflammatory response to a pathogen, they are highly potent
mediators that are vital for initiating, sustaining, and suppressing inflammation [37, 71]. The
very small concentrations of cytokines that are produced upon encountering pathogens elicit
large systemic changes [10]. Interleukin-6 and Interleukin-10 (IL-6 and IL-10, respectively)
are well-known cytokines with distinctive trajectories during sepsis [39]. Thus, it is reason-
able to posit that endotypic differences might be reflected in cytokine expression patterns,
even if such patterns do not represent a comprehensive endotypic characterization. The cur-
rent clinical consensus is that both the pro-inflammatory response and the anti-inflammatory
response are important in clearing an infection, allowing tissue recovery, and determining
sepsis outcomes [5]. A cytokine was selected as the proxy of the pro-/anti- inflammatory
response.
Interleukin-6 (IL-6) is a pro-inflammatory cytokine that is characterized by a fast rise
during the inflammatory response. IL-6 is initially secreted by tissue-resident macrophages
and is responsible for mobilizing and recruiting neutrophils and monocytes to the site of
infection. Recruited monocytes may differentiate into macrophages of the pro-inflammatory
phenotype, M1, which further produce IL-6 [14]. This positive feedback is responsible for
the fast rise in IL-6. Experiments involving endotoxin challenges in healthy volunteers reveal
that many cytokines follow a fast rise and fall dynamic. In the case of IL-6, it peaks at 3
hours and returns to baseline by 8 hours after endotoxin challenge [39]. However, research
has shown that cytokine responses differ between endotoxin challenges and sepsis, which is
likely attributed to the fast clearance of endotoxin versus the sustained presence of infection
in sepsis [37]. In sepsis, IL-6 peaks later and has a long protracted decline [37, 39]. As such,
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IL-6 serves as a good proxy of the pro-inflammatory response and provides information on
infection severity/injury and the type of host response [68].
Similarly, IL-10 is the de facto anti-inflammatory cytokine. IL-10 has a fast rise, peaks
slightly after IL-6, and has a long protracted decline during sepsis [15, 39]. It is secreted by
monocytes and M2 macrophages and prevents the synthesis of pro-inflammatory mediators
[13, 39]. The timing and trajectory of IL-10 are extremely important and, if inappropriate,
can lead to uncontrolled infection or dysregulated inflammation [15].
Knowledge of sepsis endotypes, as defined by pro- and anti-inflammatory responses,
can reveal the underlying pathobiological differences between different host responses to
sepsis and capture some of the clinical variability observed during sepsis. Consideration of
endotypes in sepsis, which dispels the notion of a single therapeutic approach, can lead to
better targeted and more effective treatment [45]. It was assumed that a finite number of
characteristic sepsis responses exist and that each case manifests into distinct IL-6 and IL-10
trajectories, given their importance as master regulators of inflammation.
Identification of sepsis endotypes is an exercise in unsupervised clustering and proved an
interesting engineering challenge. First, there is a lack of clinical understanding regarding the
mechanisms that lead to sepsis because current clinical work is heavily focused on identifying
phenotypes that predict outcomes. Mathematical models of sepsis (such as mechanistic
compartmental ordinary differential equation models) can supplement or improve clinical
understanding, but few exist in the literature that has been validated against human sepsis
data. Second, human sepsis data is inherently left-censored (because data collection can
begin only after clinical presentation) and this causes problems in generating unique clusters.
Figure 3.1 illustrates the problems posed by left-censorship. Suppose an arbitrary cytokine
is measured from two separate subjects at 0, 6, and 24 hours after they arrive in the hospital
(or are enrolled in the study, as shown in Figure 3.1A) and that these subjects belong to
the same sepsis endotype (demonstrated in Figure 3.1B). By disregarding the dynamics that
describe how these trajectories manifest, they would be binned into two clusters (Figure
3.1A) by popular algorithms such as K-means or ‘proj-traj’ [72].
31
Figure 3.1: Schematic of clustering challenge associated with endotype identification. A: Diagram
illustrating a sample result from traditional clustering methods based on time since enrollment.
Magnitude heavily affects clusters. Blue and red time courses are binned into separate clusters. B:
Diagram illustrating that the previous blue and red time sources may come from similar trajectories.
Magnitude differences are attributed to different sampling time points along a single trajectory.
Due to the sparsity of temporal cytokine data from sepsis subjects and the variability
in patient pre-hospital time prior to measurements, traditional clustering techniques were
ineffective and necessitated a dynamics-based approach. This requires a mixture modeling
approach that can simultaneously (i) recover dynamics from censored trajectories of IL-6 and
IL-10 and (ii) conduct unsupervised clustering on recovered dynamics. The resulting method
utilized a combination of systems analysis, hierarchical clustering, and mixture models.
3.1 METHODS
A retrospective analysis of the Protocol-Based Care for Early Septic Shock (ProCESS) trial
was conducted [59]. A description of this trial is available in Chapter 2. The ProCESS trial
collected rich longitudinal and high-fidelity clinical data from its subjects. A convenience
cohort of 390 subjects was selected from the database of 1341 subjects in accordance to
the selection criteria of IL-6 and IL-10 measurement availability at 0, 6, and 24 hours,
where the zero baseline was the time of trial enrollment. This was different from the 493
subject cohort in Chapter 2, where the selection criteria were the availability of certain
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Table 3.1: Comparison of convenience cohort for mixture model against the rest of ProCESS
database
Analyzed Cohort Rest of ProCESS
Characteristic n=390 n=951
Age 61.0±16.9 60.9±17.9
Male sex – no. (%) 236 (60.5%) 512 (53.8%) *
Race – no. (%)
White 268 (68.7%) 648 (68.1%)
Black 88 (22.6%) 245 (25.8%)
Other 34 (8.7%) 58 (6.1%)
Source of sepsis – no. (%)
Pneumonia 133 (34.1%) 310 (32.6%)
Urinary Tract Infection 93 (23.8%) 191 (20.1%)
Intraabdominal infection 37 (9.5%) 140 (14.7%) *
Infection of unknown source 46 (11.8%) 124 (13.0%)
Skin or soft-tissue infection 25 (6.4%) 71 (7.5%)
Catheter-related infection 15 (3.8%) 23 (2.4%)
Central nervous system infection 3 (0.8%) 7 (0.7%)
Endocarditis 3 (0.8%) 4 (0.4%)
Other 29 (7.4%) 56 (5.9%)
Determined not to have infection 6 (1.5%) 25 (2.6%)
Positive blood culture – no. (%) 138 (35.4%) 258 (27.1%) *
Injury Severity
APACHE II 20.8±7.4 20.7±7.7
APACHE III 61.4±22.8 61.1±22.5
Charleson 2.5±2.4 2.7±2.7
SOFA 7.3±3.6 7.1±3.6
Physiological variables
Systolic blood pressure – mmHG 97.9±24.1 100.7±24.4 *
Heart rate – beats/min 104.1±20.5 102.8±20.4
Temperature – C 37.3±1.4 37.3±1.3
Respiratory rate – breaths/min 22.7±7.2 22.8±6.6
Total bilirubin – mg/deciliter 1.3±1.6 1.5±2.3
Serum lactate – mmol/liter 4.5±2.9 5.0±3.4 *
Outcome
14 Day All-cause Death – no. (%) 39 (10.0%) 200 (21.0%) *
Mortality – days 72.0±88.2 45.6±71.6 *
Multiple Organ Failure – no (%)
14 Days 250 (64.1%) 631 (66.4%)
Stay in hospital – days 11.8±9.5 11.5±11.6 *
ICU 5.2±5.2 4.9±6.9 *
Serious Adverse Events – no. (%) 15 (3.8%) 67 (7.0%) *
∗ denotes p≤ 0.05 from Dunn’ or Chi-Squared tests to determine differences between continuous or categorical
variables, respectively.
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biomarkers at 0 hours. Treatment arm was not included in the selection criteria because the
ProCESS trial concluded that clinical outcomes among all three arms were effectively similar
[59]. A comparison of the cohort against the rest of the ProCESS database is available in
Table 3.1, which demonstrates that the convenience cohort was not entirely representative of
the ProCESS cohort. Specifically, the convenience cohort contained a higher population of
males, lower serum lactate, higher 14-day all-cause mortality outcomes, and fewer numbers
of serious adverse events than the rest of the ProCESS cohort. This was reasonable because
the selection criteria identified a group of subjects that (i) survived up to 24 hours and
(ii) was clinically stable enough to have blood drawn for cytokine assays. In contrast, the
convenience cohort contained a higher percentage of patients with blood infections and lower
systolic blood pressures, which are correlated with negative outcomes. This suggested that
the convenience cohort also responded better to sepsis despite having worse infections.
Of the 390 subjects, 165 had an additional IL-6 and IL-10 measurement at 72 hours
post-trial enrollment. 72-hour cytokine measurements for the remaining 225 subjects were
imputed via a nearest neighbor technique based on their measured vital signs and blood-
based biomarkers (refer to Chapter 5) [41]. Specifically, the first 6 hours of measurements
of respiratory rate, heart rate, temperature, urine output, systolic blood pressure, tumor
necrosis factor α (TNF), IL-6, and IL-10 were used. These biomarkers were matched against
those of the 165 subjects with 72-hour cytokine measurements. The one nearest neighbor
within the 165 cohort provided the imputation results. Finally, any measurements less than
10 pg/ml were treated as 10 pg/ml. Due to the different assaying techniques used by the
multiple centers that participated in the ProCESS trial, there were many different lower
limits of cytokine detection (LLD) present in the data, with 10.0 being the highest LLD.
3.1.1 Systems Analysis and Mixture Modeling
The pro- and anti-inflammatory responses were modeled after a mass-spring-damper response
to a bump (see Figure 3.2). This physical system was simplified using transfer functions and
their step response. Transfer functions provide a mathematical formalism where model pa-
rameters can be directly linked to dynamics characteristics of the system response (such
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Figure 3.2: Schematic of a mass-spring-damper system serving as a physical analog to the inflam-
matory response. The cytokine response was likened to a mass-spring-damper physical system.
Cytokine trajectories were modeled as the unit step response of a second-order transfer function
to a pathogen presence (analogous to a car suspension responding to a “road bump”). The steady
state gain of the response was set to unity.
as oscillation, overshoot, etc.), thereby facilitating model identification from data. Further-
more, transfer functions represent entire classes of mathematical systems exhibiting a desired
behavior. The inflammatory response (output) may be characterized as the response to a
rectangular wave of infection for a specified duration (input). However, the short temporal
length of the cytokine data from the ProCESS trial (up to 72 hours after trial enrollment),
in combination with an assumption that subjects still had ongoing infection by 72 hours, led
to the simplification of this input to a step change (as shown in Figure 3.2, bottom right). A
similar cytokine modeling approach (authors used a state-space realization of second-order
transfer functions) was taken in a journal article by Yiu, et al [73].
Analysis of the cohort cytokine data revealed three types of step response dynamics,
which are represented by the second-order transfer functions in Figure 3.3). The first transfer
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Figure 3.3: Sample unit step responses of the three transfer functions used. Each response reaches
a steady state output value of 1.0 but the trajectory to reaching steady state is characteristically
different for each model. The first category, oscillatory response, is a three-parameter system (τ ,
ζ, τ3) characterized by a damped oscillating approach to 1.0. The second category, overshoot
response, is a three-parameter system (τ1, τ2, τ3) characterized by a fast rise followed by a decline
to 1.0. The third category, rising only response, is a two-parameter system (τ1, τ2) characterized
by a rising trajectory to 1.0 with no overshoot.
function enforced an oscillatory response to capture the primary rise and fall motif and a
secondary lower-magnitude peak. Such peaks have previously been observed in the clinic
[74]. The damping parameter of this transfer function, ζ, was of particular interest. ζ
controls the oscillatory nature of the system and bounds were set to prevent it from taking
low values near zero, thereby preventing the system from oscillating for many periods at a
relatively high magnitude. The second transfer function captured the primary rise and fall
motif only. Finally, the third transfer function enforced a rising only behavior to capture
subjects whose inflammatory responses keep rising.
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The data from the convenience cohort was normalized to account for extensive magnitude
differences between subjects.The normalization criterion consisted of dividing each patient’s
IL-6 and IL-10 trajectory by their respective 72-hour measurements. The normalization
procedure was assumed to normalize both the magnitude of inflammatory response and the
magnitude of infection for each patient. A benefit of this normalization was that it removed
the need to estimate a gain for the transfer function model. The dynamics of the resulting
normalized pro- and anti-inflammatory responses were clustered.
The first step was fitting the 390 subjects’ IL-6 and IL-10 responses (after taking the
log10 of cytokine concentrations) to each type of transfer function response. The 0, 6, and
24 cytokine measurements were normalized by dividing by their respective IL-6 or IL-10
72-hour measurement. The normalized IL-6 and IL-10 trajectories were fit against each of
the three transfer function categories in Figure 3.3. Parameter fitting was performed using
the Levenburg-Marquardt algorithm provided by the Python lmfit package.
This approach fully addressed the problem previously illustrated by Figure 3.1. Step
responses for second order transfer functions always begin at 0. This enabled the objective
function to also fit a discrete hourly time shift parameter (bounded to [0,78] hours) to
estimate the pre-hospital time for each patient. Each patient was then classified into one of
nine categories (three possibilities each for IL-6 and IL-10, yielding 9 combinations) based
on the lowest sum of squared errors.
The next step further split each of the 9 categories by identifying similar clusters of
subjects in parameter space. Splitting within each category allowed for the possibility of
different behaviors of the oscillatory, overshoot, and rising-only responses. Parameters for
each subject were assumed to be distributed about a Gaussian mixture. Gaussian mixtures
were identified via the expectation maximization algorithm and subjects were segregated
in accordance to the highest probability of membership to a certain Gaussian. Expecta-
tion maximization is a well known statistical algorithm that (i) calculates a probability of
membership for each subject (expectation-step), (ii) calculates all Gaussian component pa-
rameters (µi, σi) via the maximum likelihood approach in accordance to each component’s
membership (maximization-step), and then (iii) repeat steps (i)-(ii) iteratively. The learning
step and mixture modeling were performed via the sklearn package in Python. The number
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of components in the Gaussian mixture model for each of the 9 categories was a user input
and was varied over multiple simulations until a minimum Bayesian Information Criteria
(BIC) was obtained. Low membership clusters (n < 10) were removed and those subjects
were reassigned to the next most similar cluster.
The third step generated a master inflammatory response trajectory for each remaining
cluster. The parameters from each cluster were averaged and used to generate a representa-
tive IL-6 and IL-10 trajectory for the cluster. Subjects within each cluster were then shifted
in time (original measurement intervals were preserved) to best align their IL-6 and IL-10
trajectories to the respective master response trajectory.
Clinical outcomes were defined by 14-day all-cause mortality and 14-day multiple organ
failure rates. This was done for the same reasons outlined in the previous chapter. No
distinction was made between baseline MOF and 14-day MOF because this method iden-
tifies patient time zeros, which overrides the clinical definition of baseline (time of clinical
presentation).
Statistical analysis of the resulting clusters was conducted on patient demographics,
outcomes, and clinical biomarkers taken within 6 hours of trial enrollment. Statistically
significant differences (p < 0.05) were identified using the non-parametric Dunn’s test for
continuous variables and the Chi-squared test for categorical variables. Multiple pair-wise
testing, to specifically identify which clusters were different from each other, was performed
via Dunn’s test and Chi-squared tests. Bonferroni corrections were applied to counteract
the error effects of multiple comparisons.
3.2 RESULTS
Figure 3.4 shows the resulting five distinct inflammatory responses that were identified across
the 390 subjects. Cluster 1 illustrates a fast and high magnitude pro- and anti-inflammatory
response to infection. This cluster had the highest 14-day mortality and the highest incidence
of 14-day multiple organ failure (MOF). This high-risk cluster also described the most sub-
jects, with nearly 30% membership. Cluster 2 illustrates a fast and medium magnitude pro-
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Figure 3.4: Results from cluster identification process (5 sepsis subtypes). Each row of subplots
represents a distinct cluster. The left subplots show the IL-6 (pro-inflammatory) response and the
right subplots show the IL-10 (anti-inflammatory) response. The Y-axis represents the normalized
log10 values of the associated cytokine. The bold black curves indicate the master response for
each cluster. Subject data (dots) was time-shifted to best align with these trajectories.
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and anti-inflammatory response. Compared to Cluster 1, the anti-inflammatory response
of Cluster 2 had a slower, protracted decline. Cluster 3 illustrates a low magnitude and
slower pro-inflammatory response. The anti-inflammatory response was steadily increasing.
This cluster had the lowest 14-day mortality and lowest incidence of 14-day MOF. Cluster 4
represents a fast rise and then sustained pro-inflammatory response. The anti-inflammatory
response rose to a magnitude higher than that of Cluster 1 and then descended swiftly. Clus-
ter 5 shows a medium magnitude (similar to Cluster 2) pro- and anti-inflammatory response
characterized by a faster rise and decline. Cluster 5 was unique in that it represents a fast-
inflammatory response while all other clusters demonstrated protracted responses. Table 3.2
summarizes the dynamics of five clusters.
Table 3.2: Summary of the Five Identified Endotypes
Endotype Description
1 Overwhelming inflammatory response to infection (elevated cytokinemia)
2 Prolonged anti-inflammatory response, (mild immunosuppression)
3 Rising only anti-inflammatory response, (immunosuppression)
4 Prolonged pro-inflammatory response, (sustained inflammation)
5 Fast dynamic response that ends within two days (immunodeficiency)
The calculation of a model-based master response trajectory within each cluster allowed
the time-axis to start at the estimated onset of infection rather than to the start of data
collection. Subjects were shifted up to 78 hours (representative of pre-hospital time) to best
align with cluster master trajectories. It appears that subjects in Cluster 5 were enrolled
into the ProCESS trial earlier along their disease timeline due to the shorter estimated onset
times. In contrast, Cluster 1 subjects were enrolled later, with the majority of subjects within
20-60 hours after infection onset. The subjects within Cluster 4 were enrolled even later,
between 40-80 hours after infection onset, as evidenced by their sustained IL-6 response.
Clusters 2 and 3 appeared to have a larger variety of patient onset times.
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Table 3.3: Comparison of baseline characteristics and outcomes between each endotype.
Endotype
1 2 3 4 5
Characteristic n=116 n=67 n=69 n=63 n=75
Age 63.4±17.7 60.6±16.5 58.1±16.8 62.6±15.1 58.9±16.9
Male sex – no. (%) 74 (63.8%) 38 (56.7%) 38 (55.1%) 36 (57.1%) 50 (66.7%)
Race – no. (%)
White 81 (69.8%) 50 (74.6%) 50 (72.5%) 43 (68.3%) 44 (58.7%)
Black 23 (19.8%) 13 (19.4%) 13 (18.8%) 16 (25.4%) 23 (30.7%)
Other 12 (10.3%) 4 (6.0%) 6 (8.7%) 4 (6.3%) 8 (10.7%)
Source of sepsis – no. (%)
Pneumonia 45 (38.8%) 24 (35.8%) 24 (34.8%) 15 (23.8%) 25 (33.3%)
Urinary Tract Infection 24 (20.7%) 17 (25.4%) 13 (18.8%) 20 (31.7%) 19 (25.3%)
Intraabdominal infection 17 (14.7%) 3 (4.5%) 5 (7.2%) 6 (9.5%) 6 (8.0%)
Infection of unknown source 12 (10.3%) 8 (11.9%) 8 (11.6%) 9 (14.3%) 9 (12.0%)
Skin or soft-tissue infection 9 (7.8%) 7 (10.4%) 5 (7.2%) 1 (1.6%) 3 (4.0%)
Catheter-related infection 5 (4.3%) 3 (4.5%) 2 (2.9%) 2 (3.2%) 3 (4.0%)
Central nervous system infection 0 (0.0%) 0 (0.0%) 1 (1.4%) 1 (1.6%) 1 (1.3%)
Endocarditis 0 (0.0%) 1 (1.5%) 0 (0.0%) 0 (0.0%) 2 (2.7%)
Other 4 (3.4%) 4 (6.0%) 7 (10.1%) 9 (14.3%) 5 (6.7%)
Determined not to have infection 0 (0.0%) 0 (0.0%) 4 (5.8%) 0 (0.0%) 2 (2.7%) *
Positive blood culture – no. (%) 52 (44.8%) 21 (31.3%) 13 (18.8%) 29 (46.0%) 23 (30.7%) *
Injury Severity
APACHE II 21.0±7.5 21.2±6.8 19.7±6.4 20.8±8.3 21.1±7.9
APACHE III 65.1±20.8 52.3±19.1 60.7±21.5 63.0±25.2 62.8±25.4
Charleson 2.5±2.4 2.5±2.5 2.5±2.2 1.9±2.1 2.9±2.7
SOFA 8.1±3.7 7.0±3.1 5.9±3.2 7.7±3.8 7.0±3.8
Physiological variables
Systolic blood pressure – mmHG 94.9±23.4 96.8±21.4 100.2±24.8 100.0±24.6 99.9±25.6
Heart rate – beats/min 108.9±17.9 102.0±19.5 97.7±21.6 103.5±22.9 104.8±20.1 *
Temperature – C 37.5±1.2 37.2±1.3 37.0±1.1 37.0±1.7 37.3±1.7
Respiratory rate – breaths/min 23.9±7.0 22.9±7.2 20.4±5.8 22.4±8.2 23.1±7.4 *
Total bilirubin – mg/deciliter 1.5±1.9 1.3±1.7 0.9±0.5 1.7±2.3 1.2±0.9
Serum lactate – mmol/liter 4.9±2.9 4.1±2.9 3.6±2.5 5.3±3.6 4.6±2.4 *
Outcome
14 Day All-cause Death – no. (%) 14 (12.1%) 7 (10.4%) 4 (5.8%) 6 (9.5%) 8 (10.7%)
Mortality – days 84.8±110.9 63.2±67.8 109.6±108.9 47.1±41.7 47.5±55.4
Multiple Organ Failure – no (%)
14 Days 85 (73.3%) 43 (64.2%) 33 (47.8%) 46 (73.0%) 43 (57.3%) *
Stay in hospital – days 11.5±10.7 12.3±8.2 11.5±9.8 13.6±10.1 10.5±7.4 *
ICU 5.6±6.0 4.7±4.1 4.7±5.4 5.4±4.3 5.2±5.4
Serious Adverse Events – no. (%) 7 (6.0%) 2 (3.0%) 5 (7.2%) 1 (1.6%) 0 (0.0%)
∗ denotes p≤ 0.05 from Dunn’ or Chi-Squared tests to determine differences between continuous or categorical
variables, respectively.
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3.2.1 Statistical Analysis of Endotypes
Patient demographics, vital signs at hospital admission, baseline physiological variables, and
outcomes from each cluster endotype are shown in Table 3.3. The most striking difference
between endotypes was the differing levels of 14-day incidence of multiple organ failure
(MOF). Clusters 1 and 4 had the largest population of subjects that tested positive for
blood culture infections, which corresponded with high rates of MOF. Clinical biomarkers
such as heart rate, respiratory rate, and serum lactate demonstrated significant difference
as well. Overall, Table 3.3 does not reveal many statistically significant differences among
the five endotypes. This lack of significant differences reveals that patient demographics and
admission vital signs were unable to fully classify subjects into a cytokine response cluster.
Figure 3.5 shows the 47 clinical biomarker trajectories that were analyzed. Of these, 29
biomarkers were identified to be significantly different between clusters. This demonstrated
that, despite being similar to measurements taken at hospital admission, these biomarkers
diverged within six hours. Other biomarkers such as cytokines, urine output, and white blood
cell adhesion molecules were significantly different between clusters. Furthermore, pairwise
testing revealed that these biomarkers offer high discriminatory power among clusters. For
example, all pair-wise testing of IL-6 values involving cluster 1 were significantly different
from all other clusters.
A comparison of endotype memberships between the cohort described in Section 3.1
and Chapter 2 is illustrated in Table 3.4. Chi-Squared testing revealed that the endotypes
from both Chapters were not independent. The subjects of high cytokinemia endotype 1
predominantly belonged to high-risk endophenotypes A from Chapter 2 and some were split
into high-risk endophenotypes E and F. The anti-inflammatory dominant endotype 3 was
mostly represented by endophenotype D. However, endotypes 2, 4, and 5 were spread out
across endophenotypes A-F.
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Figure 3.5: Omnibus testing (Dunn’s test) on 6-hour biomarker trajectories from each endotype.
A significance cutoff of p≤ 0.05 was applied (shown on right panel). Paired numbers on each
row reveal pair-wise differences revealed by Dunn’s test pertaining to that biomarker. Note that
x-axis spans of left and right plots are different. The phrase ”None” indicates that single pair-wise
endotype differences did not exist.
3.3 DISCUSSION
A model-based approach to identify clusters of similar cytokine responses was presented.
Five distinct types of IL-6 and IL-10 responses were discovered. Table 3.3 shows that patient
demographics and baseline vital signs were unable to distinguish between patients in different
clusters. While seemingly similar at the beginning of the ProCESS trial, differences were
clearly expressed in cytokine responses over time. This suggested that patient differences
were rooted deeper than clinical phenotypic manifestations.
Endotypes 1 and 3 represent drastically different inflammatory responses and highlight
the need for a more personalized approach to sepsis therapy. Intuitively, the predominately
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Table 3.4: Contingency table comparing endotype memberships between Chapters 2 and 3.
Chapter 2 Cohort 321 of 493
A B C D E F
∑
1 47 8 1 4 20 16 96
Chapter 3 Cohort 2 19 12 2 1 9 13 56
321 of 390 3 2 5 8 36 6 10 61
4 20 4 6 0 4 16 50
5 19 13 2 4 6 14 58∑
107 42 19 39 45 69 321
Chi-Squared test of independence between the endotype memberships between the two chapters rejected
the null hypothesis with a p-value < 0.00001.
anti-inflammatory response of cluster 3 corresponded with a low MOF and mortality while
the characteristically high magnitude responses of endotype 1 resulted in high MOF and
mortality. Furthermore, 29% of patients in endotype 3 returned to baseline IL-6 and IL-10
values (lower limit of detection) by 72 hours while only 6% returned in endotype 1. Endotype
1 may not benefit from immune-stimulating therapies and endotype 3 may not benefit from
immune-suppressing therapies. Interestingly, the other endotypes had low rates of returning
to baseline (< 5%).
Figure 3.6 illustrates the progression of commonly used clinical biomarkers in sepsis
for each endotype. To normalize biomarkers for easy comparison, an empirical cumulative
distribution function (eCDF) was calculated for each biomarker over the entire convenience
cohort. This process was described in detail in Chapter 2.1. The resulting normalized dataset
ranged between [-10, 10] for all biomarkers, and 0 represented median values. Each patient
data column was then organized in the order they were sorted in Figure 3.4 to present a clear
map of biomarker progression over each endotype’s disease timeline. Biomarkers within each
endotype clearly diverged over time. Endotype 3 had overall lower levels of bilirubin, lactate,
TNF, IL-6, and IL-10. Endotypes 1 and 4 were defined by higher initial levels of creatinine,
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Figure 3.6: Heatmap illustrating clinical biomarker progression over each endotype. Columns
(unlabeled) consist of time, relative to estimated time of infection as estimated from Figure 3.4.
Individual subjects were not distinguished in heatmaps. Rows consist of commonly measured
clinical biomarkers. A cumulative distribution function-based method was used for biomarker
normalization to enable comparability (refer to Chapter 2.1).
TAT complex, blood urea nitrogen (BUN), and potassium. Blood pressure, sodium, chloride,
platelet count, and white blood cell counts followed similar trends in both clusters. Figure
3.6 demonstrate that the identified endotypes manifest into several observable phenotypic
differences once pre-hospital times are used to temporally organize the data.
3.3.1 Study Limitations and Potential Improvements
The biggest assumption with this method was the use of a 72-hour measurement for normal-
ization. Analyzing step response behavior forced the method to assume a nonzero steady-
state value. Converting each subject’s IL-6 and IL-10 trajectories to end at a value of unity
was convenient for the method, but required an assumption that cytokines were at pseudo-
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Figure 3.7: Machine Learning Derived regions of mortality based on IL-6 and IL-10 values at 72-
hours. Using a 60/40 training-test split on the convenience cohort, a multi-layer perceptron classifier
(neural network) was able to learn the regions of varying 14-day all-cause mortality based on 72-
hour measurements of IL-6 and IL-10. The sklearn package in Python (MLPClassifier function,
α = 1 and other options set to default) was used. The algorithm was able to generate mortality
predictions with 91% accuracy. Regions of uniform color represent regions of similar outcomes.
The top right, associated with elevated levels of 72-hour IL-6 and IL-10, corresponds with high
rates of mortality.
steady-state by hour 72. As a result, the mixture model method focused on the dynamics,
rather than magnitude, of the inflammatory response up to 72 hours. The lack of mag-
nitude consideration removed the need to estimate a steady state gain from the transfer
function models but can be improved upon, considering a large body of clinical literature
associating cytokine magnitudes with sepsis severity and mortality [74–77]. Furthermore,
long-term daily cytokine measurements in a separate study revealed that cytokine values in
severely septic patients do not stabilize by 72 hours [66]. While the ProCESS dataset is one
of the richest sepsis datasets, the method can benefit from a dataset with longer and more
frequently measured cytokine trajectories.
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Figure 3.8: Schematic of impulse-response behaviors to explore in order to address current method-
ological weaknesses. Impulse-response behaviors prevent the need to assume any steady-states in
cytokine trajectories. The bottom set of three graphs illustrate the types of behaviors this system
is capable of depending on the value of the damping parameter, ζ.
Magnitude considerations may be integrated into the current method by using the IL-6
and IL-10 values at 72-hours to provide further stratification. For example, each cluster may
be further stratified into low, medium, or high IL-6 and IL-10 72-hour magnitudes. Statistical
modeling revealed distinct mortality regions in their magnitudes. These mortality regions
were distinctive (see Figure 3.7) and machine learning algorithms can learn these regions
and generate updated risks of 14-day all-cause moralities.
The next step was to consider transfer functions with impulse-response inputs, rather
than the steps used in Section 3.1. A major benefit of this approach is that impulse-response
behaviors always decay back to 0, removing the need for any steady-state assumptions in
the inflammatory response. A system is proposed in Figure 3.8, which illustrates a slight
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modification to the oscillatory system in the method. This system can generate a variety of
responses depending on the value of the damping parameter, ζ.
Finally, a major difficulty with the use of mixture models is the tendency of such methods
to collapse all subjects into one cluster. The iterative process of recovering dynamics from
cytokine segments and clustering them was very sensitive to (i) initial conditions, steady-
state gain, and/or magnitude of the input, (ii) the types of transfer functions and how
different their responses were, and (iii) the time shift parameter to realign subjects to a
master trajectory. Currently attempts with the impulse response model illustrated in Figure
3.8 have resulted in one cluster because the model was subject to all three problems. In
contrast, the method in Section 3.1 removed the need to estimate the parameters that cause
issue (i) and used 3 transfer function models with step-responses that allowed sufficient
separation (issue (ii)). A potential solution to improve the impulse response model is to
estimate pre-hospital times via a separate approach (thereby tackling issue (iii)), which may
improve the identifiability of model parameters, including steady-state gain.
3.3.2 Bedside Endotype Classification Tool
The endotypes identified within this section necessitated the development of a bedside clas-
sification tool to guide clinical decisions. The requirements of this tool are twofold: (i) it
makes accurate endotype predictions and (ii) it generates predictions quickly upon clinical
presentation of a subject. To accommodate requirement (ii), predictors for this tool were
artificially limited to the first six hours of measurements (relative to the ProCESS trial start).
First, the entire selection of machine learning classification algorithms from the Python
SciKit-Learn package was tested. The 29 significant biomarkers identified in Figure 3.5 were
used to train each classifier and were broken into 70%-30% training-test sets. The best per-
forming algorithms were decision tree-based algorithms, which yielded up to 54% accuracy
on the test set. Confusion matrices of algorithmic performance revealed that algorithms were
able to predict endotypes 1 and 3 accurately, but missed endotypes 2, 4, and 5. This sug-
gested that endotypes 1 and 3 were clearly distinguishable, which was important considering
the differing clinical support required by either endotype.
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Second, a decision-tree support vector machine (SVM) was trained on the data [78].
This approach breaks a multi-class classification problem into separate problems: use a
SVM to separate one class from others, then repeat over the remaining classes to generate
predictions in a decision-tree-like process. The algorithm, using radial basis functions, yielded
between 75% to 89% accuracy on one-class-versus-rest problems. However, overall endotype
accuracy was 30% to 45%, which is an improvement on a null result of 20% accuracy (random
assignment to 5 clusters). Further analysis revealed that the SVM accurately identified
subjects from endotypes 1 and 3, but were unable to fully distinguish between endotypes 2,
4, and 5.
Finally, a nearest neighbor algorithm yielded the best results [41]. The imputation
method to obtain 72-hour cytokine measurements of 225 subjects utilized only biomarkers
collected within 6 hours. A one nearest neighbor approach was tested to verify if 0 and 6-hour
measurements of IL-6 and IL-10 can provide endotype segregation. Matching normalized (by
imputed 72-hour values) IL-6 and IL-10 measurements, limited to 0 and 6 hours, to one of
the 5 master response curves in Figure 3.4 yielded 73% endotype prediction accuracy. This
result suggests that a 6-hour temporal trajectory of vital signs combined with 0 and 6-hour
measurements of cytokines can be used to predict patient endotypes with good accuracy. This
algorithm satisfied both requirements of the bedside classification tool. However, this tool
warrants further research via a traditional machine learning algorithm given the promising
statistical segregation suggested by Figure 3.5.
3.3.3 Clinical Implications
The 73% classification accuracy of the aforementioned classifier demonstrated that a clini-
cian, rather than having to measure a subject’s cytokines over 72 hours, may instead iden-
tify a patient’s endotype with high accuracy using a mixture of cytokines and vital signs
measured over six hours. This provides a clinician a potential bedside tool to gauge the
endotype-associated risk of mortality and MOF, which may improve patient outcomes in the
clinic. High-risk patients may receive preemptive organ support therapies before the onset
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of MOF. For patients with low risk of succumbing to the initial septic shock in 14-days,
clinicians can focus on preventing downstream complications.
Endotypes of sepsis have not been extensively studied, but the ability to identify them
has profound implications on how sepsis research is conducted in the future. The results
suggest that a one-size-fits-all approach to sepsis therapy may be inappropriate or even
detrimental to certain scenarios. For example, Figure 3.6 highlighted significant biomarker
differences between endotypes 1 and 3, suggesting that an endotype-specific therapeutic
approach might be warranted. Specifically, an immuno-modulatory drug may benefit the
high magnitude responses characteristic of endotype 1, but may be harmful to patients
exhibiting the low magnitude IL-6 response in endotype 3. By identifying cohorts that may
be harmed or benefit from certain treatments, endotype stratification may explain why so
many clinical trials in sepsis have failed in the past [57]. Furthermore, improvements can
be made in patient populations enrichment in future clinical trials. This method may allow
clinicians to pre-screen candidates for endotype, and possibly pre-hospital times, to select
those who may benefit from a proposed therapy.
3.3.4 Summary
This Chapter provides an extension of the work in Chapter 2 by incorporating mechanistic
understandings into the clustering of the inflammatory response to sepsis. A novel method-
ology for endotype identification was developed by simultaneously reconstructing the dy-
namics of IL-6 and IL-10 trajectories and clustering on these dynamics. Reconstruction
of these dynamics was performed by parameterizing each subject via mathematical models
and estimating pre-hospital time. Representative master trajectories of the pro- and anti-
inflammatory response were calculated for each endotype. These master trajectories revealed
distinct and varied responses within a 390 subject cohort from the ProCESS trial. Statis-
tical analysis of these endotypes revealed significant differences within 6 hours of patient
enrollment, but an accurate early-detection classification tool (current accuracy is at 73%,
which needs improvement) from phenotypic patterns is not yet available. The five endo-
types identified in this Chapter were not fully explainable by phenotypes alone. Additional
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research will further improve mechanistic understandings of these endotypes, discover novel
segregation strategies, and reveal richer features, all of which will enable the translation of
sepsis endotyping into the clinic.
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4.0 MECHANISTIC DIFFERENCES BETWEEN ENDOTYPES
The key to improving sepsis therapies starts with understanding the mechanisms involved in
the dysregulations that cause a normal inflammatory response to turn into a sepsis response.
For example, Chapter 6.1 reveals that there are age-related immune pathway differences in
mice which manifests into longer inflammatory durations within older mice. Such differences
support the notion of mechanistic differences driving the five distinct sepsis behaviors seen in
Chapter 3. Improved understanding of these pathobiological differences can provide targets
for pharmaceutical intervention.
Mathematical modeling provides a quantitative framework to understand the mechanisms
behind the complex sepsis syndrome. A myriad of mechanistic sepsis models exist to capture
the representative inflammatory behaviors, but few have been calibrated against human data
[3, 4, 52, 55, 70, 79, 80]. The models that have been calibrated against human data are based
on endotoxin responses, which is mechanistically different from sepsis [37, 81–83].
A mechanistic model, tailored for the ProCESS data, was generated in response to the
shortcomings of existing mathematical models. The model focused on fitting the temporal
white blood cell (monocytes and neutrophils) and cytokine (TNF-α, IL-6, IL-10) measure-
ments within the ProCESS data in a compartmental-based (blood, bone marrow, infected
tissue) framework. The model characterized known phenomenological dynamics and inter-
actions of each state to mimic the inflammatory response. Model structure was modified to
include additional pathways that were deemed necessary to capture desired behaviors in the
data. First, the methods of model calibration are discussed. Second, the final iteration of
the model is presented. Finally, an endotype-level (from Chapter 3) parameter analysis of
the subjects is conducted and discussed.
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4.1 METHODS
The model initiated as a project to fit a porcine model of sepsis (unpublished data, Soheyl
Bahrami, Ph.D., Ludwig Boltzmann Institute of Experimental and Clinical Traumatology).
14 pigs were subject to surgically induced peritonitis (introduction of bacteria into the ab-
dominal organs), 7 of which were given an experimental super-oxide dismutase therapy. The
7 control pigs were used for model fits. Measurements of serum TNF-α (TNF), IL-6, IL-8 (a
chemokine that attracts neutrophils from serum into tissue), IL-10, neutrophils, and mono-
cytes were available in 2-hour increments up to hour 12 post sepsis induction. The model
development phase was broken into three steps. First, as drivers of the inflammatory re-
sponse, cytokines TNF, IL-6, IL-8, and IL-10 were independently fit using the step-response
transfer function method outlined in Chapter 3.1. The step-response of the overshoot-type
transfer function was used. The step-response was appropriate here because the nonzero
lower limit of detection was treated as a steady-state value, which was modeled by a steady-
state gain. A delay term (e−θs) was included to account for the delay between the onset of
sepsis (start of peritonitis) to the initial rise of each cytokine. Once these cytokine models
were developed, the next step was to use them to develop the model structure governing
white blood cell dynamics. Filter functions of TNF and IL-6 were generated to account
for the delays and timing of downstream white blood cell dynamics. Three compartments,
Bone, Tissue, and Blood, were designed to account for the relevant recruitment dynamics
of white blood cells. The third step was to use the resultant white blood cell model to replace
the transfer function cytokine models with a mechanistic one.
With model structure defined, calibration was performed using a human endotoxin infu-
sion experiment [84]. Although the endotoxin inflammatory response is not entirely mecha-
nistically similar to sepsis, the model structure tweaks in this step served as a transitional
step to adapt the model for human data. Endotoxin was administered at 10, 20, and 40
ng/kg for three groups of subjects. Measurements were taken of serum TNF, IL-6, IL-8,
IL-10, neutrophils, and monocytes at hours 0 (start of experiment), 1, 1.5, 2, 3, 4, 6, 8, 12,
and 24.
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The porcine experimental data helped develop the white blood cell and cytokine model
structure. The human endotoxin experiment was used to adjust the IL-6 and IL-8 filter
functions to reflect the slower dynamics in humans compared to the porcine response. Fur-
thermore, the fast circulating neutrophil dip within 2 hours justified the addition of an LPS
state to allow for IL-8 independent recruitment of neutrophils into the Tissue compartment.
The ProCESS data described in Chapter 2.1 was used for model fitting. Temporal tra-
jectories of serum TNF-α, IL-6, IL-10, and neutrophils were available for model calibration.
Serum monocytes were not explicitly available but given measurements of total white blood
cell counts and neutrophil counts, an upper bound for serum monocytes were available. Un-
der normal conditions, monocytes account for less than 10% of white blood cells. During
inflammatory periods, monocyte composition increases, but numbers were not available in
literature. An assumption was to limit monocytes to an upper limit of 40% of the non-
neutrophil white blood cell counts. Dynamics began at the onset of infection and patient
data were shifted in accordance with the estimated pre-hospital times in Chapter 3.2. Sim-
ulation time was 0 to 150 hours post-infection (first week of sepsis) to fit the assumptions
made in Chapter 3.1 (maximum pre-hospital time was bounded at 78 hours and a patient
may have up to 72 hours of cytokine measurements).
4.1.1 Model Formulation and Simulation
Parameter-fitting was performed using the Pyomo Python package and the IPOPT solver
using the ma86 linear solver. Pyomo is a framework of tools designed to convert a model
specified in Python into the algebraic modeling programming language (AMPL) for use with
a variety of numerical optimization solvers [85, 86]. IPOPT was used for optimization and
is a solver that uses the interior point method. This method uses barrier functions to solve
linear programming problems and a well-written explanation is provided by Robere [87].
Take, for instance, a generic LP:
min cTx (4.1)
s.t. Ax = b
x ≥ 0
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The inequality constraint can be replaced with a barrier function and reformulated into a
similar problem while preserving the Karush–Kuhn–Tucker conditions of the original problem
(when µ = 0).
min cTx− µ
N∑
i=1
lnxi (4.2)
st. Ax = b
The benefit of solving Equation 4.2 over Equation 4.1 is that it relaxes the inequality con-
straints via nonzero values of µ. Interior point methods iteratively solves Equation 4.2 for
decreasing values of µ, which effectively traverses the interior of the feasible region as it
approaches an inequality constraint. At µ = 0, the optimum to Equation 4.2 is also the
optimum to Equation 4.1 as well.
The Pyomo framework comes with a differential algebraic equation (DAE) package which
enables numerical optimization of problems involving ordinary/partial differential equations.
The DAE package converts algebraic differential equation expressions into forward or back-
ward finite difference approximations or orthogonal collocation on finite elements. For this
Chapter, all parameter fitting was conducted on ordinary differential equations (ODEs) with
the Pyomo DAE package set to the backward finite difference approximation option. The
objective function was formulated as the minimization of the weighted sum of squared errors
between the data and their relevant model states. Weights were applied on the TNF and
white blood cell states to capture the quick responses to inflammation.
On the ProCESS database, a regularization term was included (λ = 1) to penalize
nonzero values of cytokines by hour 150, which was a phenomenon that tended to occur in
the absence of a data-driven reason. To prevent numerical issues pertaining to scaling, all
data was scaled (divided by 10i) to homogeneously range within [0,100]. Finally, an addi-
tional inequality constraint was posed on monocytes to enforce the aforementioned maximum
monocyte limit.
Pyomo requires setting bounds on each parameter, which was a difficult task because
most of the parameters have no literature sources. Initial parameter-fitting simulations were
performed in APT-MCMC (see Chapter 6.2) using large, uninformative bounded uniform
57
distributions to obtain the posterior distribution of parameters. A posterior distribution is
the distribution of a parameter after it has been conditioned upon observed data (fitted in
accordance to the maximum likelihood estimator) and APT-MCMC calculates these distri-
butions via Baye’s Theorem (Equation (6.18)). The posterior distributions from the initial
APT-MCMC simulations on the ProCESS data informed the Pyomo parameter bounds.
4.1.1.1 Initiation of Inflammation and the Cytokine Storm
dTNFT
dt
= (VmtMacro+Rmacro)
P
Kpmt + P
− µttTNFT − dtTNFt (4.3)
dIL6T
dt
= Vm6Macro
(
P
Kpm6 + P
)(
K106
IL10T +K106
)
− µ6tIL6T − d6IL6T (4.4)
dIL8T
dt
= (Vm8Macro+Rmacro)
(
P
Kpmt + P
)(
K86
IL10T +K86
)
− µ8tIL8T − d8IL8T
(4.5)
dIL10T
dt
= (Vm10Macro+Rmacro)
(
P
Kpmt + P
)
+ Vn10µntNT
(
1− TNFT
Ktn + TNFT
)
(4.6)
− µ10tIL10T − d10IL10T (4.7)
The inflammatory response begins with the presence of Pathogen (P ) in the infected Tissue
compartment. Resident macrophages that reside in the infected tissue detect the presence
of pathogen via a Michaelis-Menten dynamic: P/(Ki + P ) and produce cytokines: TNF,
IL-8, and IL-10 (TNFT , IL8T , IL10T , respectively) [13, 55, 73]. IL-6 is also produced by
macrophages (recruited and resident macrophages), but the model does not allow resident
macrophages to produce IL-6 to enforce a delay between TNF and IL-6 peaks [39]. These
cytokines leave the Tissue compartment via two pathways: natural decay/degradation (µit
term) and diffusion into the Blood compartment (di term). Once cytokines diffuse into the
blood, they each take on different inflammatory roles.
Eventually, blood monocytes are recruited towards the infected tissue. Upon arrival,
recruited monocytes differentiate into macrophages (Macro) where they begin to produce
TNF, IL-6, IL-8, and IL-10. This production is governed by a rate constant (Vmi) and the
aforementioned Michaelis-Menten dynamic. Together, recruited and resident macrophages
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produce large amounts of cytokines to emulate the cytokine storm phenomena during the
early phases of sepsis [73]. While neutrophils are able to produce cytokines, monocytes are
able to synthesize cytokines at a rate that is 50-100 times faster [88]. The model simplifies
this dynamic by delegating the role of cytokine production to monocytes/macrophages only.
IL-10 is an anti-inflammatory cytokine and its primary mechanism for countering the
pro-inflammatory response is to halt macrophage production of TNF, IL-6, and IL-8 [15].
This mechanism is governed by a non-competitive inhibitory Michaelis-Menten dynamic:
1− IL10T/(Ki + IL10T ) = K ′i/(IL10T +K ′i)
This inhibitory behavior blocks macrophage production of IL-6 and IL-8. IL-10 inhibition
of TNF was not included in the model because TNF was used to drive the early dynamics
of the inflammatory response. A fast and high magnitude peak of TNF is desired and
necessary to trigger model dynamics and the inclusion of IL-10 inhibitory effects damped
such behaviors. Finally, there is an additional IL-10 dynamic associated with neutrophils
that will be discussed in Section 4.1.1.3.
4.1.1.2 Cytokine Diffusion and their Roles
dTNFB
dt
= dtTNFT − µtbTNFb −KTconsumeTNFB(MC +NC) (4.8)
dIL6B
dt
= d6IL6T − µ6bIL6b − k6consumeIL6B(MC +NC) (4.9)
dIL6F1
dt
= d6IL6b − d6IL6F1 (4.10)
dIL6F2
dt
= d6IL6F1 − d6IL6F2 (4.11)
dIL6F3
dt
= d6IL6F2 − d6IL6F3 (4.12)
dIL6F4
dt
= d6IL6F3 − d6IL6F4 (4.13)
dIL8B
dt
= d8IL8T − µ8bIL8B − k8consumeIL8b
Nc
Knc8 +Nc
(4.14)
dIL8F1
dt
= d8IL8b − d8/3IL8F1 (4.15)
dIL10B
dt
= d10IL10t − µ10bIL10b (4.16)
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Once cytokines diffuse into the Blood compartment at a rate of di, they undergo natural
decay/degradation (µib). To capture the fast decline of TNF, IL-6, and IL-8 within the
porcine and human LPS data, an additional sink term, with the rate constant kiconsume,
was added. Biologically, this represents the binding of these cytokines onto the receptors
of circulating (in the blood) neutrophils and/or monocytes to activate/prime them. While
more detailed neutrophil models exist differentiating circulating neutrophils into activated
and not-activated pools, none of the neutrophil data in the available data was granular
enough able to justify such distinction [70]. The kiconsume rate constant has no effect on
neutrophil or monocyte behavior and exists merely as a Blood compartment cytokine sink.
IL-8 is a chemokine that is responsible for recruiting neutrophils into the tissue by way of
extravasation (movement through endothelial walls) [89]. IL-6 is a pro-inflammatory cytokine
that is able to recruit neutrophils and monocytes [14]. IL-6 and IL-8 both have filter functions
which serve as delays in their induction of specific inflammatory pathways. These were
deemed necessary during the migration from time-delayed transfer function cytokine models
to mechanistic cytokine models during the porcine model calibration step. Furthermore,
the filter functions captured cytokine migration towards their appropriate target (such as
diffusion into the spleen to recruit marginated neutrophils into the blood) without explicitly
modeling additional compartments.
The primary role of blood TNF in the model is to recruit monocytes into the infected
Tissue compartment to sustain the inflammatory response. Monocyte recruitment is a
complex process that is not well understood in humans [12]. Human monocyte recruitment is
likely the result of a combination of CC-chemokine receptor 2 (CCR2) and CX3C-chemokine
receptor 1 (CX3CR1), which was not measured in any of the calibration datasets [12]. Blood
TNF took on the role of CCR2 in the model due to its fast acting pro-inflammatory profile.
Blood IL-10 has no role in the model because the majority of its role lies in the Tissue-
level inhibition of the macrophage production of cytokines [15]. Blood IL-10 was explicitly
modeled because all three data sets contained serum measurements of IL-10.
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4.1.1.3 Neutrophil Dynamics
fNexchange = kP (1 + 5
IL8F1
Knr8 + IL8F1
)NM − 5kP (1− IL8F1
Knr8/5 + IL8F1
)NC (4.17)
Under homeostatic conditions, the majority of neutrophils are under intravascular margina-
tion, where they are stored in the spleen (primarily), bone marrow, and liver [90]. Despite
being kept in storage, radio-labeling techniques have revealed that neutrophils are able to
migrate from the marginated pool into blood within 2-10 minutes [90]. The size of the
marginated neutrophil pool is currently unknown and under much debate. An assump-
tion was made that the marginated neutrophil pool was 5 times larger than basal circulat-
ing neutrophil levels to capture the fast rise in neutrophils seen in the human endotoxin
data. Furthermore, because neutrophil margination storage occurs in several compartments
throughout the body, the model simplified this mechanism to a single state within the Blood
compartment. Equation (4.17) describes the rate of exchange between the circulating and
marginated neutrophil pools (NC and NM , respectively) and was formulated in a journal
article by Ho, et al [91]. In Equation (4.17), a positive sign indicates flow into the circulating
neutrophil pool.
During non-inflammatory conditions, to maintain a 1:5 (circulatory to marginated pool)
ratio, neutrophils flow into the circulating rate at kp and flow back into the marginated
pool at 5kp. Under inflammatory conditions, a delayed IL-8 signal (due to transit time from
blood flow into these marginated compartments) was used to modify kp to greatly prefer
transit into the circulating pool [92]. During inflammation, circulating neutrophils typically
dip within the first 2 hours and is followed by a fast rise to above basal levels [88]. This
can also be seen in the porcine and human endotoxin data sets. The marginated-circulating
mechanism prevented neutrophil depletion and provided a source for the fast increase in
neutrophil count.
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Prog
dt
= KtrmProg
(
Mcbasal
Mc
)γm
−KtrmProg (4.18)
+KtrnProg
(
Ncbasal
Nc
)γn
−KtrnProg (4.19)
dT1N
dt
= KtrnProg −KtrnT1N (4.20)
−Kn6 IL6F4
Knr + IL6F4
T1N
1
NM +KT3NM
1
KT inhibit + T3N
1
KT inhibit + T2N
(4.21)
dT2N
dt
= KtrnT1N −KtrnT2N −Kn6
IL6F4
Knr + IL6F4
T2N
1
NM +KT3NM
1
KT inhibit + T3N
(4.22)
dT3N
dt
= KtrnT2N −KtrnT3N −Kn6
IL6F4
Knr + IL6F4
T3N
1
NM +KT3NM
(4.23)
The time span of the ProCESS data was three days and with the pre-hospital time shift,
the model simulated one week of inflammatory dynamics from the infection onset. The
long timespan necessitated a slower-acting source of neutrophils to supplement the dead
neutrophils within the body. Neutrophil recruitment from the bone marrow is governed by
G-CSF and various chemokine receptors [91, 93, 94]. Within the bone marrow, progenitor
cells called hematopoietic stem cells differentiate into common myeloid progenitor (CMP)
cells that can differentiate into monocytes or neutrophils [13, 89]. Under the neutrophil dif-
ferentiation pathway, the CMP cells (Prog) differentiate into metamyelocytes (T1N ), band
cells (T2N ), and then segmented granulocytes (T3N ) [91, 95]. The results provided by Friberg,
et al., and Ho, et al. both reveal that the bone marrow is capable of increasing the circulat-
ing neutrophil pool within 5-10 days, which is an appropriate time frame for the ProCESS
data [91, 95]. Between Prog and T1N -T3N , Ktrn governs the natural maturation rate that
it takes for cells to mature into each classification and includes the non-inflammatory mi-
gration of segmented granulocytes into the circulating pool. The progenitor cells receives
a feedback signal from the Blood compartment:
Ncbasal
Nc
γn
, which induces progenitor cell
growth if circulating neutrophils levels fall below normal levels.
In the model, the immature neutrophils within the bone marrow are available for emer-
gency recruitment source should the marginated neutrophil pool subceed a certain level
(governed by an inhibitory mechanism: 1/(NM + KT3NM )). The body first draws upon the
segmented granulocytes (T3N ) if the marginated neutrophil pool is too low. It then draws
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upon the band cells (T2N ) and finally the metamyelocytes (T1N ).This model formulation was
provided by Ho, et al [91].
dNM
dt
= −fNexchange (4.24)
dNC
dt
= fNexchange − Vn8Nc IL8T
Kn8 + IL8T
+ ktrnT3N − µnbNc(1−
TNFB
Ktn + TNFB
) (4.25)
+Kn6
IL6F4
Knr + IL6F4
(4.26)
∗ 1
NM +KT3NM
(
1
KT inhibit + T3N
(
T1N
1
KT inhibit + T2N
+ T2N
)
+ T3N
)
(4.27)
−KlnNcLPS (4.28)
The model uses filtered IL-6 to drive the recruitment from bone marrow into blood.
The fourth IL-6 filter was used as a way of approximating the pro-inflammatory signaling
cascade (chemokines and chemokine receptors) that interact with the relevant bone marrow
cells [96]. This interaction was modeled with Michaelis-Menten kinetics. The recruited
neutrophils migrate into the circulating neutrophil pool where they can be stored in the
marginal pool, undergo natural degradation, or migrate into infected tissue.
IL-8 forms a chemotactic concentration gradient which attracts circulating neutrophils
[89]. Specifically, circulating neutrophils migrate towards regions of increasing IL-8 concen-
trations via endothelial wall rolling, adhesion, and then intraluminal crawling [96]. This pro-
cess, called extravasation, is governed by many chemokines and receptors, but the model sim-
plifies these dynamics with a single Michaelis-Menten term on Tissue IL-8: Vn8IL8T/(Kn8+
IL8T ). The attempts involving a difference term to represent the chemotactic gradient
(IL8B − IL8T ) caused unexpected model behavior because the term often changed signs.
Neutrophils are capable of also following chemotactic gradients produced by endotoxins
and lipopolysaccharide (LPS), which are molecular patterns indicative of a pathogen [88].
This mechanism provides quick neutrophil response into infected tissue prior to IL-8 driven
recruitment and explains why the inflammatory response is typically faster in endotoxin
experiments than in sepsis [37]. This term is represented by a simple kinetic rate constant,
Kln. LPS is modeled separately from pathogen to represent the release of endotoxin/LPS
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into nearby tissue, thus forming a separate chemotactic gradient that can independently
recruit neutrophils.
dNT
dt
= Vn8NC
IL8T
Kn8 + IL8T
− µntNT
(
1− TNFT
Ktn + TNFT
)
+KlnNcLPS (4.29)
Once neutrophils have entered the infected Tissue compartment, its only sink is death by
degradation. Natural neutrophil degradation occurs at rates µnbNC and µntNT in the blood
and tissue, respectively. However, TNF is known to prolong neutrophil lifespans [11, 97].
Within the model, the natural degradation term is modulated by 1− TNFj/(Ktn + TNFj)
to represent a prolonged lifespan under inflammatory conditions.
The death of neutrophils contributes to the resolution of inflammation [97]. Neutrophils
may die via one of two pathways: necrosis or apoptosis. Necrosis contributes to further
inflammation because the cellular walls of neutrophils break down and release toxic, pathogen
killing, molecules into the tissue. Apoptosis represents a “healthy” neutrophil death which
involves signaling nearby macrophages for safe clearance of the dying neutrophil and its
toxic contents [97–99]. Neutrophil apoptosis promotes the synthesis of IL-10 and other anti-
inflammatory signals [97]. The model uses a rate parameter, Vn10, to govern the induction
of IL-10 production due to apoptotic neutrophil death:
Vn10µntNT
(
1− TNFT
Ktn + TNFT
)
The model does not currently separate neutrophil death into apoptotic or necrotic stages
due to the lack of monocyte measurements in the ProCESS database.
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4.1.1.4 Pathogen Dynamics
dP
dt
= Kp1P
(
1− P
P∞
)(
P − 
P + 
)
− kNPNT P
Kp2 + P
(4.30)
dLPS
dt
= kppP − kpp2LPS (4.31)
Pathogen is located in the infected Tissue compartment and is introduced via a nonzero
initial condition. Pathogen grows at a rate of Kp1 but is limited by the P∞ term to rep-
resent growth limitations due to the conditions within the Tissue compartment (nutrition
availability, unfavorable environmental conditions, etc). A similar approach was taken in
a journal article published by Reynolds, et al [4]. The  term was introduced to prevent
oscillations at low values of pathogen close to zero. Tissue neutrophils kill pathogen with a
Michaelis-Menten kinetic, kNPP/(Kp2 + P ). Finally, pathogens release LPS (LPS) into the
tissue, which forms a chemotactic mechanism that can drive Tissue neutrophil recruitment.
4.1.1.5 Macrophage Dynamics
fMexchange = kpm(1 +
IL6F1
Km6 + IL6F1
)MM − 3.5kPM(1− IL6F1
Km6 + IL6F1
)MC (4.32)
Similar to neutrophils, monocytes circulate the blood and are sequestered in marginated
compartments during non-inflammatory conditions at an estimated 1:3.5 circulating to marginated
count ratio in human studies [12, 13, 100].Marginated monocytes, MM , was represented as
a single state within the Blood compartment. The dynamic sequestration exchange of MM
with circulating monocytes, MC , is represented by Equation (4.32). Current knowledge
monocyte recruitment from marginated compartments are not well known. The model as-
sumes that a pro-inflammatory signal, represented by a filtered IL-6 (IL6F1), biases Equation
(4.32) towards MC to increase circulating monocyte levels.
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dT1M
dt
= KtrmProg −KtrmT1M (4.33)
dT2M
dt
= KtrmT1M −KtrmT2M (4.34)
dT3M
dt
= KtrmT2M −KtrmT3M −Kr
IL6F4
Kt6 + IL6F4
T3M
1
MM +KT3MM
(4.35)
Monocytes are derived from the same progenitor cells (CMP, represented by Prog) that
differentiate into neutrophils [12]. Decreases in basal monocyte levels result in a growth
signal to the CMP cells:
Mcbasal
mc
γM
. Monocyte development can also be staged into 3 phases:
progenitor granulocyte-macrophage progenitor (T1M ), macrophage/dendritic cell progenitor
(T2M ), and common monocyte progenitor (T3M ). While little is known about immature
monocyte recruitment during inflammatory conditions, recent literature suggested that this
mechanism occurs in mice [101]. A conservative assumption was made to use only the
common monocyte progenitor state to replenish monocytes under inflammatory conditions.
The model utilizes IL6F4-driven recruitment from the T3M immature state when the marginal
monocyte pool becomes low.
dMM
dt
= −fMexchange (4.36)
dMC
dt
= fMexchange (4.37)
− kmmtMc ∗ TNFB
Ktm + TNFB
(4.38)
+ ktrmT3M − µmbMc (4.39)
+Kr
IL6F4
Kt6 + IL6F4
T3M
1
MM +KT3MM
(4.40)
Circulating monocytes are affected by the exchange dynamic in Equation (4.32) and re-
plenished from the T3M state (ktrm represents normal replenishment and Kr represents in-
flammatory driven replenishment). MC decays at a rate of µmb in the blood. Unlike neu-
trophils, there are no lifespan prolonging mechanisms for monocytes. Monocyte recruitment
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into tissue is driven by a complex chemokine signaling pathway that is approximated by a
Michaelis-Menten interaction involving TNFB.
dMacro
dt
= kmmtMC
TNFB
Ktm + TNFB
− µmt(1 +Macro
P
kmtp + P
) (4.41)
Monocyte, upon entering the Tissue compartment, differentiate into macrophages (Macro).
While macrophages are able to eliminate pathogens directly via phagocytosis, this interac-
tion occurs on the orders of minutes compared to seconds for neutrophil-related elimination
[99]. Macrophage elimination of pathogens is not modeled due to this rate difference. The
primary role of macrophages is to synthesize cytokines. The secondary role of macrophages is
phagocytosis and efferocytosis. Efferocytosis refers to the removal of apoptotic cells (mostly
neutrophils) [98, 99]. Macrophages that undergo phagocytosis have been shown to exhibit
elevated rates of death [102, 103]. The model includes macrophage death at a constant basal
rate of µmt due to the longevity of macrophages. Under inflammatory conditions, this rate
can be accelerated due to phagocytosis via a simplified mechanism involving pathogen levels:
P/(kmtp + P ).
4.1.2 Model Post-hoc Analysis
Figure 4.1 illustrates the aforementioned model structure. The model has 58 parameters
and 28 states. Of the 28 states, the initial conditions for circulating monocytes, circulating
neutrophils, and initial pathogen concentration were fitted (as part of the 58 total param-
eters). Initial conditions for marginated monocytes and neutrophils were set to 3.5x and
5.0x their respective circulating counterpart’s initial conditions. The initial conditions for
the progenitor cells and the immature white blood cell states within the Bone were set to
1000 105/mL. All other initial conditions were set to zero.
Individual fits for every subject within the 390 cohort in Chapter 3 was conducted using
Pyomo and IPOPT. Cytokines TNF, IL-6, and IL-10 were scaled to fall within a range of
[0,100] and their units were 101pg/mL, 102pg/mL, or 103pg/mL. Circulating neutrophils
and monocytes were scaled to 105/mL and 104/mL, respectively.
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Figure 4.1: Diagram illustrating the sepsis ODE model. The tissue compartment is in yellow, blood
in red, and bone in gray.
From each endotype, the 10 subjects with the lowest objective function values were
considered to be “representative” patients of that endotype and selected for post-hoc anal-
ysis. Two tests were used to identify endotype-specific parameter differences. First, the
Anderson-Darling omnibus test was used to identify differences between parameters within
each endotype. Pair-wise differences (1 vs 4 and 2 vs 3) were tested with the Anderson-
Darling test and a Bonferroni correction. Second, a nonlinear fixed-effect model using the
covariates age, gender, and endotype was used. This model explicitly included age and
gender, two well-known covariates that confound parameter differences between groups.
K = θ exp
(
η0 +
∑
i
ηiXi
)
(4.42)
logK = log θ + η0 +
∑
i
ηiXi (4.43)
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Equation (4.42) represents the nonlinear fixed-effects of X={Age, Gender, Endotype} on an
arbitrary parameter, K. Taking the log of both sides yields Equation (4.43), which results in
a linear model. The package statsmodels in Python was used to conduct linear regression for
57 parameters (the parameter for the initial condition of pathogen was excluded). The F-
statistic of overall significance was calculated to reveal the significance of the ηi coefficients.
A p-value≤ 0.05 cutoff was used to determine if a covariate was significantly better than an
intercept-only model.
4.2 RESULTS
Figures 4.2-4.6 shows sample fits from each one of the five endotypes. The filtered states for
IL-6 and IL-8 are not shown. For the subjects that had neutrophil data, monocyte upper
bounds were calculated and represented in green dashed lines. The bottom row of each figure
demonstrate the cytokines. For TNF and IL-6, there were often scale differences between the
blood (red trajectories) and tissue (blue trajectories) concentrations. As a result, their units
varied to ensure similar scaling. Blood and tissue y-axes were the left and right, respectively.
Figure 4.2 illustrates a subject from endotype 1, which was representative of a high mag-
nitude pro-inflammatory and anti-inflammatory response followed by a fast decline. Large
amounts of pathogen were estimated for this subject. LPS immediately recruited circulating
neutrophils, which accounted for the fast dip during the first day. Cytokines rose slowly
and peaked on the second day, which was the estimated time of clinical presentation. IL-6
and IL-10 declined sharply during this day, which was a characteristic feature of endoype
1. The fourth filtered signal of IL-6 reached the bone marrow during day 3, which recruited
immature neutrophils and monocytes from the Bone compartment into the Tissue, causing
the hour 80 peaks. At 5 days, IL-8 was no longer present in the body and enabled the
accumulation of circulating neutrophils.
Figure 4.3 illustrates a subject from endotype 2, which was representative of a pro-
tracted anti-inflammatory response and a fast-acting pro-inflammatory response. This sub-
ject’s neutrophils and monocytes were quickly depleted following an aggressive and fast pro-
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Figure 4.2: Sample fit for endotype 1, which was characterized by overwhelming inflammation.
Subject 200039 is shown.
inflammatory response on the first day of infection. There was a sustained IL-10 response
during the entire week, which indicated an immuno-suppressed state. This was further
evidenced by a nonzero pathogen level by the end of the simulation.
Figure 4.4 illustrates a subject from endotype 3, which was representative of a rising-
predominant anti-inflammatory response. This subject eliminated all pathogen by the 5th
day, but the pro-inflammatory cytokines TNF, IL-6, and IL-8 were elevated during the entire
70
Figure 4.3: Sample fit for endotype 2, which was characterized by a protracted anti-inflammatory
response. Subject 560054 is shown.
duration. IL-10 was sustained during this duration and caused the shark fin-like shape in the
pro-inflammatory cytokines. The secondary IL-10 peak was caused by neutrophil apoptosis
following the elimination of pathogens at hour 100. Finally, the lag between the steep decline
of IL-6 at hour 100 (on day four) and the filter functions of IL-6 caused the circulating
neutrophil dip around 110 hours, which ended immature neutrophil recruitment.
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Figure 4.4: Sample fit for endotype 3, which was characterized by immunosuppression. Subject
210085 is shown.
Figure 4.5 illustrates a subject from endotype 4, which was representative of a sustained
inflammatory response and an ineffective anti-inflammatory response. The TNF and IL-10
response in the Tissue rises quickly and remains elevated until pathogen elimination at 100
hours. However, the IL-6 presence remained elevated for days after pathogen elimination.
The sustained inflammatory response caused rapid depletion of neutrophils and monocytes
in both the circulating and marginal compartments. The unique aspect of this subject was
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Figure 4.5: Sample fit for endotype 4, which was characterized by sustained inflammation. Subject
360025 is shown.
that the pathogen generated a large number of LPS, which also contributed to neutrophil
depletion. Within one week, the values of T3M and T3N significantly declined. Due to the
sustained pro-inflammatory response, neutrophils were recruited into tissue after pathogen
elimination.
Figure 4.6 illustrates a subject from endotype 5, which was representative of a quick rise
and fall of both pro- and anti-inflammatory responses. The TNF, IL-6, and IL-8 responses
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Figure 4.6: Sample fit for endotype 5, which was characterized by a quick and short inflammatory
response. Subject 420021 is shown.
for this subject comprised of a fast up-down response and reach a nadir by hour 60 (on
day 2). The body detected a rise in pathogen around this time and a secondary response
occurred. As a result, full pathogen elimination occurred late (on day 5) compared to the
other endotypes (with the exception of Figure 4.3 representing a subject from endotype 2).
IL-10 dipped around hour 20 due to the decrease in pathogens. The subsequent IL-10 rise was
caused by the neutrophil apoptosis mechanism (due to elevated levels of tissue neutrophils).
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For this subject, IL-10 appeared to be heavily influenced by the apoptosis mechanism, which
indicated a preference towards immuno-suppression.
The Anderson-Darling statistical test revealed two parameters to be different between
endotypes. The first parameter was µmt , which governed macrophage cell death rate (which
could be accelerated by phagocytosis). Pair-wise testing revealed that µmt was significantly
different between endotypes 4 and 5 versus 1, 2, and 3. Furthermore, it was also revealed
that µmt within endotype 5 was different from 1, 2, 3, and 4. The second parameter was
µ10b , which governed the decay of IL-10 in the blood. Pair-wise testing revealed that this
value was significantly different between endotypes 1 and 2 versus endotypes 3, 4, and 5.
The covariate model revealed several parameters of interest. First, endotypes had a
significant effect on the parameters kmtp, µ10b , and µtb . The parameter kmtp is the half-
max term of the Michaelis-Menten term describing accelerated macrophage death due to
phagocytosis. Specifically, the relevant term is 1 +MacroP/(kmtp + P ). The parameter µtb
describes the natural decay rate of TNF within the Blood compartment. Second, age had
a significant effect on the parameters Knr and KTconsume. The parameter Knr is the half-
max term of the Michaelis-Menten kinetic that governs immature neutrophil recruitment
from the bone compartment. The parameter KTconsume governs the mechanism of neutrophil
activation by blood TNF. Finally, age had a significant effect on the parameters dt, µtb , and
KTconsume.
4.3 DISCUSSION
Figure 4.7 shows the estimated distributions for the four parameters that were found to be
significantly different among endotypes. Parameter kmtp demonstrated bimodal peaks. En-
dotypes 1 and 2 were predominantly distributed at low values for kmtp, which resulted in a fast
rate of macrophage death. These two endotypes were characteristic of high cytokinemia. One
possibility was that overproduction of cytokines caused macrophage death. Alternatively,
the overproduction of cytokines may have been a response to macrophage death: more TNF
was needed to replace the dying macrophages to sustain the inflammatory effort. Endotypes
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Figure 4.7: Distribution of significant parameters among endotypes. Stacked histograms, color
coded by endotype, are shown. A Gaussian kernel density estimation (shaded trajectory) within
each panel is shown. X-axis represents the log value of the parameter. Y-axis is not shown because
the Gaussian densities are not normalized and scaled to encompass the histograms.
4, and 5 were distributed between high and low values of kmtp. Most subjects within endo-
type 3 consisted of high values of kmtp, which resulted in a slower macrophage death rate.
Slower macrophage death resulted in a smaller TNF signal because monocyte recruitment
was unnecessary given the large presence of macrophages in tissue. The presence of large
numbers of macrophages may have also contributed to the resolution of inflammation (and
therefore a predominant anti-inflammatory state) via the neutrophil apoptosis mechanism.
Parameter µ10b demonstrated a similar bimodal behavior: endotypes 1 and 2 preferred
low values and endotypes 3, 4, and 5, were distributed between high and low values. Slow
IL-10 degradation may partially explain the high cytokinemia response in endotypes 1 and
2.
Parameter µtb had bimodal peaks as well. Endotype 3 preferred low values of the TNF
blood decay parameter while the other endotypes were fairly spread out. It is possible that
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TNF signals are prolonged (due to longer half-life) within endotype 3 and the high anti-
inflammatory response is caused by a compensatory mechanism to offset the TNF response.
Subjects from endotype 1 also dominated low values of µtb . TNF may have contributed to
the high cytokinemia response that was characteristic of this endotype. A negative con-
sequence of high cytokinemia and longer cytokine lifespans is the improper recruitment of
neutrophils, misdirecting them into healthy tissue, which may explain the high organ failure
rates associated with endotype 1 [9, 91].
Parameter µmt was primarily distributed within the [-4,0] log values. However, several
subjects from endotypes 3, 4, and 5 formed a smaller peak at lower values of µmt , which
indicated longer overall macrophage lifespans.
Two parameters involving macrophage death dynamics were identified to be significantly
different among endotypes and were subject to further analysis. Figure 4.8 illustrates a joint
density plot for log parameter values of kmtp and µmt . The majority of subjects had low
values of kmtp, which the lower bound set in Pyomo for that parameter during optimization.
Two subjects from endotype 1 exhibited both low kmtp and low µmt , a combination that
resulted in a decreased natural macrophage death rate, but increased macrophage death
rate during inflammatory conditions. There was a cluster of subjects, mostly consisting of
endotype 5, that exhibited high values of kmtp and low values of µmt . This behavior was
associated with decreased natural macrophage death rate and decreased inflammatory-driven
death. The long lifespan macrophages precluded the need for a sustained inflammatory signal
and may explain the fast decline of cytokines in endotype 5. For high values of µmt , there
were two regions. The region with high kmtp and high µmt consisted of subjects from every
endotype. This parameter space described a high macrophages natural death rate and a low
inflammatory death rate. Endotype 3 had a greater presence in this area. The region with
low kmtp and high µmt also consisted of subjects from every endotype. However, endotypes
1 and 2 was almost located within this region. This parameter space described fast dying
macrophages: both the natural death rate and the inflammatory death rate were high.
Figure 4.9 illustrates the joint density plot for log parameter values of µ10b and µtb . This
plot describes the parameter space concerning cytokine decay for blood IL-10 and TNF.
Endotypes 1 and 2 were located exclusively in regions of low µ10b values, which may be
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Figure 4.8: Joint distribution plot of significant macrophage parameters. X-axis is the log of kmtp,
the half-max parameter in Michaelis-Menten term that accelerates macrophage death. Y-axis is
the log of µmt , the non-inflammatory death rate of macrophages. Histograms of the parameters are
shown at the top and right edge of the figure. Contour lines represent Gaussian kernel estimates.
Scatter plots of parameter locations for each color-coded endotypes are shown.
responsible for the high cytokinemia in those groups. Endotype 3 was centered around low
µ10b and low µtb , a parameter region that resulted in the slow decay of IL-10 and TNF.
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Figure 4.9: Joint distribution plot of significant cytokine decay parameters. X-axis is the log of
k10b , the decay of blood IL-10. Y-axis is the log of µtb , the decay of blood TNF. Histograms of the
parameters are shown at the top and right edge of the figure. Contour lines represent Gaussian
kernel estimates. Scatter plots of parameter locations for each color-coded endotypes are shown.
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Endotype 4 was centered in regions of high µ10b (fast IL-10 decay), which supported the
hypothesis in Chapter 3 that it represented a sustained inflammatory response. Endotype 5
was spread out across the entire distribution and did not appear to have a central location.
4.3.1 Study Limitations
The 390 subjects from the ProCESS trial offered many challenges in parameter fitting:
fitting initial conditions, unknown pre-hospital time, and the lack of dense temporal data.
White blood cell measurements were rarely collected in the 390 patients. Furthermore, IL-
8, a crucial driver of neutrophil dynamics, was not measured. These deficiencies limit the
translatability of these results into the clinic.
The lack of dense temporal data resulted in high parameter confidence intervals. Profile
likelihood, a popular method in systems biology to determine parameter identifiability and
confidence intervals, could not be applied to the existing model [104]. A profile likelihood
simulation was run but did not finish by the end of two months. The combination of the lack
of dense fitting data and the complexity of the model caused non-identifiability problems
and extremely large confidence intervals, rendering profile likelihood, as a method, infeasible
for this application.
Mathematical insights from sepsis ODE models cannot be obtained without dense tem-
poral data. There are numerous difficulties associated with obtaining human sepsis data,
but the results in this Chapter suggests that data collection may be worth the resources and
effort.
4.4 SUMMARY
A mathematical model of sepsis was developed and fitted to human sepsis data from the
ProCESS trial. The 390 subjects from Chapter 3 were individually fit to the model and
an omnibus post-hoc analysis was conducted to identify population-level differences in pa-
rameters between endotypes. Macrophage cell death was an important distinguishing fac-
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tor between endotypes because two parameters affecting the death rates of macrophages
were deemed statistically significant. Furthermore, cytokines IL-10 and TNF had endotype-
specific rates of decay, which may explain why some septic patients have high cytokinemia
while others have low cytokinemia. These mechanistic insights begin to shed light on the
innate differences between sepsis endotypes and the causes of variability in the syndrome.
Such insights may also provide targets for pharmaceutical therapy to address the underlying
cause of inflammatory dysregulation in sepsis rather than treat the symptoms of it.
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5.0 IDENTIFICATION OF TRUE SEPSIS TIME-ZERO AND
QUANTIFYING SEPSIS-INDUCED DAMAGE
5.1 PRE-HOSPITAL TIME IDENTIFICATION
Chapter 3 lacked to the ability to identify pre-hospital times for sepsis subjects in the clinic.
Such an ability can improve clinical outcomes and significantly change how sepsis therapies
are developed. Because of the dynamic nature of the physiologic response to infection, both
the nature and the timings of potential interventions are likely to be determinant factors in
influencing outcome [3, 105]. For example, an abrogation of the early TNF response increased
mortality in some animal models, while most pre-clinical treatment models showed benefit
[106, 107]. This may explain, at least in part, why many sepsis therapies that showed promise
from animal models, where timing is known, failed in human studies.
In addition to clinical benefits of a pre-hospital time estimation tool, mathematical mod-
els of sepsis can significantly improve and reveal valuable mechanistic insight. Several math-
ematical and statistical models have been posed to elucidate the fast-acting dynamics of sep-
sis and to offer predictions regarding the potential effects of interventions and their timing
[3, 4, 51, 69, 70, 108]. However, training and fitting parameters of these models for indi-
vidual patients is challenging, in part due to the aforementioned timing issues with human
data collection. For the purposes of such models, a population mean is typically computed
from data pooled at time points relative to the time of enrollment. Na¨ıve pooling becomes a
problem because these data points are located at various points along temporal trajectories
of individual patients. Methodological obstacles in developing robust models, such as inter-
individual timing and variability and response, combined with a lack of familiarity of the
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research community with such computational tools have delayed the introduction of such
advanced tools as core to the design of clinical trials of sepsis.
Identifying the time of onset of infection offers two advantages in human sepsis research.
First, it potentially enables the revisiting of previously failed trials with the purpose of
analyzing, a posteriori, possible relationships between the elapsed time from onset and effec-
tiveness. Second, identifying onset time enables patient biomarker data to be shifted relative
to the time of infection, therefore, allowing more effective translation between animal results
and human expectations. Further, mathematical models can be properly trained and pro-
vide more accurate predictions if mechanistically-based, biomarker-driven interventions are
contemplated.
There are currently no proposed methods to identify the time of onset of an inflammatory
challenge for sepsis or non-sepsis data. This motivated the development of a tool to estimate
pre-hospital times with the requirements of (i) estimation generation within a few hours of
hospital admission and (ii) the use of commonly measured clinical features.
5.1.1 Methods
A baboon sepsis dataset was retrospectively analyzed for this work [109]. The original ex-
perimental design was to investigate the therapeutic effects of a nitric oxide synthase (NOS)
inhibitor of septic shock. Thirty-three baboons of the species Papio ursinus were sedated
and 2 ∗ 109 colony forming units/kg of Escherichia coli (E. Coli) were infused intravenously
into each subject over two hours. Fluid resuscitation and antibiotic therapy were provided
to all subjects throughout the experiment. The proposed NOS inhibitor treatment began
after hour 12 on sixteen subjects. Animals were treated in accordance with National Insti-
tutes of Health guidelines. The experimental protocol was reviewed and approved by the
Institutional Animal Care and Use Committee of Biocon Research Laboratories, Pretoria,
South Africa. 73 biomarkers were obtained as time series for each baboon including vital
signs, arterial blood gases and lactate, hemodynamic parameters, complete blood counts
and differential, and biochemistry. Baseline measurements were taken 30 minutes prior to
E. Coli infusion. Additional measurements were collected at specified times throughout the
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experiment. Subjects that survived the experiment had final measurements taken prior to
sacrifice. Biomarkers that were intermittently measured throughout the experiment were
eliminated from the analysis. This reduced the number of biomarkers to 29, where measure-
ments were available for all baboons at hours -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 11, and 12, where
hour 0 marked the beginning of the E. Coli infusion. This time point was considered the
true time of onset of infection. Time points past 12 hours post-infection were not utilized in
this analysis. Baboons in the sham and treatment groups were combined for analysis. The
biomarkers evaluated herein are listed in Table 5.1.
For validation of the method, two pig datasets were used. The first dataset contained
14 pigs that were subjected to surgically induced peritonitis, of which 7 subjects received a
super-oxide dismutase treatment. Measurements were collected at 2, 4, 6, 8, 10, 12 hours after
abdominal closure. Both groups were combined during analysis because trajectories between
groups were not significantly different. The second dataset included 22 pigs subjected to
one hour infusions: 12 subjects received 1 µg/kg/h and 10 received 10 µg/kg/h. Half of
the animals received biliverdin. Measurements were collected at 0, 1, 2, 3, 4, 5, 7 hours
after the start of infusion. Despite significant differences in trajectories between E. Coli
doses, all groups were combined during analysis to test the method’s performance on a
non-homogeneous database. In both porcine studies, baboon-comparable biomarkers were
utilized.
5.1.1.1 One-Nearest-Neighbor
Figure 5.1 provides an illustration of the process to estimate the time of onset of infection
for a given subject. The temporal trajectories of biomarkers for this subject were left censored
at all possible time points to simulate prospective monitoring at any given moment along the
subject’s sepsis trajectory. Trajectories were right censored to 1,2,3, or 4 consecutive points
to simulate a time period of monitoring. The one-nearest-neighbor method compared the
subject’s sub-trajectory against a database of equal length from the remaining 32 subjects,
identified the most similar sub-trajectory, and assigned the time of onset as the known time
of onset for the most similar sub-trajectory.
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Table 5.1: Dictionary of biomarker acronyms. Acronyms used for physiological measurements
obtained longitudinally in the animal experiments, the means through which these measurements
were obtained, and whether these means are considered invasive, minimally invasive, or noninvasive.
Column three indicates how the biomarker was measured within the baboon data. Column four
indicates the feasibility of measuring the biomarker in patients within a clinical setting.
Acronym Meaning Method of Measurement
WBC White blood Cell count Arterial and mixed venous blood sample M
HR Heart Rate Straightforward N
HCO3A Bicarbonate Arterial blood gas analysis M
SVR Systemic vascular resistance Arterial catheter I
HB Hemoglobin Arterial and mixed venous blood sample M
CO Cardiac output Thermal-dilution technique with Swan-Ganz catheter Ia
CI Cardiac index Calculated from CO and body surface area N
CcO2 Capillary oxygen content Calculated from APO2 I
ABEA Arterial base excess Calculated from HCO3A and pHA M
MAP Systemic arterial pressure Arterial catheter Nb
PVR Pulmonary vascular resistance Arterial catheter I
PaO2 Arterial oxygen tension Arterial blood gas analysis M
RBC Red blood cell count Arterial and mixed venous blood sample M
CaO2 Arterial oxygen content Calculated from arterial and mixed venous blood sample I
PLT Platelet count Arterial and mixed venous blood sample M
APO2 Alveolar oxygen tension Arterial catheter M
HCT Hematocrit Arterial and mixed venous blood sample M
PWP Pulmonary wedge pressure Pulmonary artery catheter I
RAP Central venous pressure Arterial catheter I
PaCO2 Arterial carbon dioxide tension Arterial blood gas analysis M
TEMP central blood temperature Swan-Ganz catheter Nb
O2DEL Oxygen delivery Calculated from respirometry and AaDO2 I
SATAO2 Arterial oxygen saturation Calculated from arterial blood sample N
b
MPAP Mean pulmonary artery pressure Arterial catheter I
RR Respiratory rate Straightforward N
HOROW Horowitz index Calculated from PaO2 and fraction of inspired oxygen M
QUOTIENT Respiratory quotient Respirometry N
PHA Arterial pH Arterial blood gas analysis M
AaDO2 Alveolar-arterial oxygen difference Calculated from PaO2 and APO2 I
N=noninvasive-to-measure, M=minimally invasive-to-measure, I=very invasive-to-measure.
aCardiac output can be estimated via an ultrasound technique, but this technique is not widely adopted.
bWidely accepted noninvasive methods exist to obtain or closely estimate this value.
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Figure 5.1: Schematic demonstrating data preparation process for testing of the pre-hospital time
estimation tool. An entire white blood cell count trajectory (normalized to healthy baseline) is
shown for a baboon and is censored prior to testing the nearest-neighbor method. Left censoring
(left shaded area) was performed to simulate the passage of time between the onset of sepsis and
the first measurement taken at simulated hospital enrollment. All subsequent time points were
renumbered to simulate clinical time points where data is relative to hospital enrollment time.
Right censoring (right shaded area) was performed to emulate sparseness of human data. In this
case, measurements ended at 2 hours post enrollment for a total of 3 subsequent measurements
(right censor level 3).
Suppose a three hour WBC data segment was available for a study subject. A Euclidean
distance was calculated between this segment and all possible three consecutive WBC points
in the database. Figure 5.2 conceptualizes this methodology. This process was repeated for
each additional biomarker and their distances were summed. The three-hour length sub-
trajectory in the database with the shortest distance to the study subject’s was identified
as the nearest-neighbor. The first time point of this sub-trajectory was used to estimate
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Figure 5.2: Schematic demonstrating the method of the pre-hospital time estimation tool. The
normalized and censored white blood cell count (WBC) trajectory from Figure 1 was compared
against the WBC database of the remaining 32 baboons (normalized to respective healthy baseline).
The 3-point WBC trajectory was compared against every group of three sequential points in the
database by calculating a Euclidean distance. Each type of line visualized represents one such
comparison. If additional biomarkers were included for analysis, the Euclidean distances from all
biomarkers were summed.
the study subject’s elapsed time since infection. Using more than one nearest-neighbor was
tested, but it did not improve the accuracy of results.
Xbaselinei = β0 +
N∑
j=1,2,..N ;j 6=i
βjXbaselinej) (5.1)
To account for scaling differences across biomarkers and for inter-baboon variability, data
were normalized on a per-baboon basis. Each subject’s biomarker trajectories were normal-
ized to its respective baseline (value at t=-0.5hr prior to infusion). However, the baseline
values for the study subject were unknown due to left censoring. A linear regression model
for estimating baseline was created for each biomarker using all time points in the database.
87
This is represented in Equation 5.1, where the baseline value for biomarker Xi estimated
using available baseline measurements. The intercept, β0, represents a population average
baseline and the slope parameter, β1, represents a subject-specific shift to this baseline.
Once all missing baseline values were imputed, each study subject’s biomarker trajectory
was normalized by their specific baseline measurements.
To test estimation accuracy, we use leave-one-out validation. For each of the 33 subjects,
every possible left censoring within the interval [0.5hr, 12hr] was tested to emulate a maxi-
mum of 9 possible “arrival” times. Estimations were generated for each of these cases and
accuracy was determined by dividing the number of correct estimations by the total number
of estimations generated. An estimated infection time within a tolerance of pm one-time
point from the actual infection time was deemed correct.
5.1.1.2 In Silico Experiments and Validations A combinatorial search was per-
formed in order to find the set of biomarkers that yielded the highest accuracy in estimating
time of infection while minimizing the number of invasive clinical measurements required.
The majority of the 29 biomarkers within the dataset were the result of invasive measure-
ments and some of these are difficult to collect from human patients. To improve the clinical
feasibility of the method, the search was performed involving single point measurements of
minimally invasive biomarkers, i.e., blood samples and vital signs.
The first accuracy experiment tested the individual estimation capacity for the time of
onset of each of the 29 biomarkers across various levels of right censoring. The best biomark-
ers were identified by calculating the mean accuracy across the four right censoring durations
and selecting the top ten. Additionally, the null hypothesis was tested by making estimations
based on randomly generated trajectories sampled from a zero mean lognormal distribution.
The second accuracy experiment exhaustively searched all possible combinations of the pre-
viously identified top ten biomarkers. A combinatorial 10Cn search, where n ∈ 2, 3, ..., 10,
was performed to identify the best n combinations of biomarkers that identify infection time.
This search was performed for each of the right censoring options.
The first feasibility experiment tested the ability of a mixture of time series biomarkers
and single point measure biomarkers to estimate infection time. Vitals heart rate (HR),
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mean arterial blood pressure (MAP), temperature (TEMP), oxygen saturation (SATAO2),
and respiratory rate (RR) are noninvasive-to-measure and were made available in time series.
Minimally invasive biomarkers white blood cell count (WBC), PaO2 , and platelet count (PLT)
were chosen due to their diagnostic abilities as listed in the Surviving Sepsis Guidelines (1).
Additionally, the top three minimally invasive biomarkers from the first accuracy experiment
were included as well. All combinations of these vitals and minimally invasive biomarkers
were tested for their infection time estimation accuracy. This experiment was repeated for
right censoring at 2, 3, and 4 hours. The second feasibility experiment further explored
this combination of time series biomarkers and single-point biomarkers by comparing two
diagnostic panels that can be realistically performed at the time of patient enrollment. Two
minimally invasive diagnostic panels were chosen: arterial blood gas test (yielding: arterial
base excess [ABEA], PaO2 , arterial bicarbonate [HCO3A]) and blood analysis (yielding:
WBC, PLT, HB). Similar to before, vitals were available in time series and this panel of
biomarkers was available at the time of simulated enrollment for a given emulated patient. All
combinations of the aforementioned vitals (except for RR) were tested with data from either
or both diagnostic panels. RR was excluded because it was not among the top performers
in the previous experiment. This experiment was repeated for right censoring at two, three,
and four hours.
For validation, the first accuracy experiment (single biomarker search) and the first feasi-
bility experiment (vitals+1 search) were repeated on each of the pig datasets. The biomarkers
used in those experiments were selected to be comparable to those of the baboons’.
5.1.2 Results
Table 5.2 shows the infection time estimation accuracy of individual biomarkers. Only the
top 15 best-performing biomarkers are shown in addition to the null hypothesis test. The
entire table displaying the results for all tested biomarkers are available in Appendix A1. The
first right censor duration tested only a single time measurement and yielded low accuracies
throughout the table. Accuracy increased as more of the study subject’s temporal points
were included in the search. Biomarkers were sorted by decreasing mean accuracy across
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Table 5.2: Time-of-infection estimation accuracy over varying right censor values (temporal dura-
tions).
Baboon Accuracy Pig Peritonitis Accuracy Pig LPS Accuracy
Biomarker R 1 R 2 R 3 R 4 Mean R 1 R 2 R 3 Mean R 1 R 2 R 3 Mean
WBC 51.8% 67.0% 83.0% 93.1% 73.7% 60.7% 58.6% 76.8% 65.4% 46.5% 64.4% 73.4% 61.4%
HR 42.1% 58.2% 74.6% 84.8% 65.0% 64.6% 83.8% 87.0% 78.5% 47.2% 61.0% 69.1% 59.1%
HCO3A 48.5% 56.2% 67.8% 75.3% 62.0% - - - - - - - -
SVR 32.7% 59.3% 72.0% 79.7% 60.9% 50.0% 57.4% 63.0% 56.8% 50.7% 63.6% 66.0% 60.1%
HB 34.8% 58.2% 70.8% 79.2% 60.8% 53.6% 67.1% 83.9% 68.2% 52.8% 73.7% 84.0% 70.2%
CO 33.6% 54.5% 68.9% 84.8% 60.5% 46.3% 51.5% 64.8% 54.2% 45.8% 55.1% 63.8% 54.9%
CI 32.1% 51.9% 72.0% 84.4% 60.1% - - - - - - - -
CcO2 33.9% 55.9% 70.8% 79.7% 60.1% - - - - - - - -
ABEA 44.8% 51.5% 65.9% 74.5% 59.2% 59.8% 73.5% 77.8% 70.4% 50.4% 63.9% 69.6% 61.3%
MAP 33.0% 50.8% 65.9% 82.7% 58.1% 43.9% 50.0% 61.1% 51.7% 53.5% 65.3% 77.7% 65.5%
PVR 38.5% 52.5% 66.7% 74.5% 58.0% - - - - - - - -
PaO2 45.2% 49.5% 63.6% 70.6% 57.2% 53.7% 51.5% 64.8% 56.6% 47.2% 49.2% 61.7% 52.7%
RBC 29.7% 49.8% 67.4% 78.8% 56.4% 52.4% 74.3% 87.5% 71.4% 54.2% 73.7% 83.0% 70.3%
CAO2 30.9% 51.2% 64.0% 77.1% 55.8% 51.2% 50.0% 57.4% 52.9% 47.9% 56.8% 57.4% 54.0%
PLT 50.9% 49.2% 56.1% 60.6% 54.2% 61.9% 70.0% 82.1% 71.3% 41.5% 50.0% 61.7% 51.1%
Mean Null 26.6% 29.0% 32.3% 36.7% 31.2% 38.1% 44.7% 55.0% 45.9% 42.7% 49.1% 57.7% 49.8%
Results were generated with available biomarkers from the baboon data and then sorted by mean accuracy.
The top 15 performing biomarkers are shown in addition to the null hypothesis (Full Table is available in
Appendix A1). The null hypothesis, tested with randomized biomarkers, performed worse than all of the
tested biomarkers. This method was repeated on the two porcine data sets for validation. Only 3 right
censor durations were tested due to the sampling rate and duration limitations of those experiments.
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the four right censor durations. WBC was the top biomarker in all columns and yielded a
maximum estimation accuracy of 93.1% when using four sequential hourly points. Jackknife
resampling of the data revealed that the standard deviation of accuracies across biomarkers
and right censor durations had a mean of 0.7%. No entry within Table 5.2 fell below their
respective right censor level null accuracy. The mean null hypothesis accuracy increased
with higher right censor levels due to the shrinking of estimation possibilities.
All possible combinations of the top ten biomarkers from Table 5.2 were tested to max-
imize the accuracy at each level of right censorship. The top result for each right censor
level is shown in Table 5.3. Remarkably, single time point measurements of six biomark-
ers yielded roughly 70% estimation accuracy. WBC was selected in all cases. There was a
strong preference given to arterial blood gas measurements, hemoglobin, and cardiovascular
measurements.
5.1.2.1 Feasibility Experiments
The goal of the feasibility experiments was to identify a parsimonious set of biomarkers, in
Table 5.3: Multiple biomarker prediction accuracy. All possible n biomarker combinations of
the top 10 (baboon) biomarkers from Table 5.2 were tested for their predictive accuracy. The
best biomarker set is shown for each right censor duration under baboon accuracy. Validation of
these biomarkers were performed on the porcine datasets. Arterial bicarbonate, cardiac index, and
capillary oxygen content were unavailable for the porcine datasets and were respectively substituted
by pH, cardiac output, and PaO2 .
Accuracy
Right Censor Length Biomarkers Baboon Pig Peritonitis Pig LPS
1 time points WBC HCO3A HR SVR CI ABEA 72.70% 71.95% 58.87%
2 time points WBC HCO3A MAP HB CO CcO2 85.90% 70.59% 72.41%
3 time points WBC HR HCO3A MAP SVR HB 93.20% 87.04% 93.48%
4 time points WBC HR MAP CO CcO2 HCO3A HB CI 97.80% - -
LPS = lipopolysaccharide, HCO3A = arterial bicarbonate, HR = heart rate, SVR = systemic vascular
resistance, CI = cardiac index, MAP = mean arterial blood pressure, HB = hemoglobin, CO = cardiac
output, CcO2 = capillary oxygen content.
Dashes indicate measurements not available in porcine experiments.
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both time series and single-point measurements, which were minimally invasive to measure in
humans and yielded a good accuracy in their ability to estimate the time of infection onset.
HCO3A, hemoglobin (HB), and cardiac output (CO) were the top performing minimally
invasive biomarkers in Table 5.2 and were included in the experiment. Table 5.4 shows
the best results from each measurement collection (one minimally invasive biomarker plus a
combination of vitals in time series), organized by right censor duration. For comparison,
accuracies were calculated for each entry with vitals alone and with all biomarkers in time
series. The inclusion of a point measurement had the greatest impact on accuracy for the
lower right censor durations. A single value of WBC combined with two hours of HR data
improved accuracy from 58.2% to 71.4%. HCO3A and WBC were consistently selected
throughout the table. Point measures of biomarkers helped many entries achieve over 90%
estimation accuracy.
Time series of invasive measurements did not improve accuracy, thus not warranting the
extra probing of subjects. For example, two measurements of HR and WBC yielded an
estimation accuracy of 81.1%. The same accuracy was achieved by using two measurements
of MAP and HR along with a single measurement of HCO3A. Furthermore, the use of MAP,
SATAO2 , and HR + 1x HCO3A outperformed the majority of entries in each right censor
category.
The second feasibility experiment tested the accuracy of using multiple single point
biomarkers with time series vitals. The top three results from the combinatorial search are
shown in Table 5.5 with results sorted based on accuracies from the “Both Panels” column.
The information gained by administering both diagnostic panels aided in almost all entries
of the 2 and 3-time point right censor levels, achieving maximum accuracies of 84.2% and
90.2%, respectively. Regardless, despite the added data from the diagnostic panels, many
entries from Table 5.4 using a point biomarker yielded equal or higher accuracies.
5.1.2.2 Validation on Porcine Data
Table 5.2 shows single biomarker accuracies for both pig experiments. Accuracies were, in
general, equivalent or higher than those of the baboons. Time of onset estimation differed
slightly among the models. For example, HB, TEMP, and HCT performed better in both
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Table 5.4: Prediction accuracy of longitudinal vital signs With a single blood biomarker.
Accuracy
Right Censor Time Series Biomarkers Point Biomarker No Point With Point Time Series Point
HR WBC 58.2% 71.4% 81.1%
HR HCO3A 58.2% 70.0% 71.7%
MAP HCO3A 50.8% 69.4% 70.0%
MAP HR HCO3A 70.0% 81.1% 81.1%
MAP HR WBC 70.0% 77.8% 81.1%
2 time points SATAO2 HR WBC 60.3% 76.1% 81.8%
MAP SATAO2 HR HCO3A 76.8% 81.8% 81.5%
TEMP MAP HR HCO3A 73.4% 81.1% 81.1%
TEMP MAP HR PAO2 73.4% 79.1% 81.1%
TEMP MAP SATAO2 HR HCO3A 75.4% 81.8% 81.8%
TEMP MAP SATAO2 HR WBC 75.4% 80.1% 82.2%
TEMP MAP SATAO2 HR PAO2 75.4% 80.1% 81.8%
HR WBC 74.6% 76.9% 86.4%
MAP HCO3A 65.9% 75.8% 81.8%
HR HCO3A 74.6% 75.4% 78.4%
MAP HR HCO3A 87.5% 89.8% 92.0%
MAP HR HB 87.5% 89.0% 90.5%
3 time points MAP HR PAO2 87.5% 88.3% 92.8%
MAP SATAO2 HR HCO3A 88.3% 92.0% 92.8%
MAP SATAO2 HR PAO2 88.3% 91.3% 93.9%
MAP SATAO2 HR HB 88.3% 89.4% 91.7%
TEMP MAP SATAO2 HR HCO3A 87.5% 92.0% 92.8%
TEMP MAP SATAO2 HR PAO2 87.5% 90.5% 93.9%
TEMP MAP SATAO2 HR HB 87.5% 89.4% 91.3%
MAP HCO3A 82.7% 88.3% 89.2%
MAP WBC 82.7% 86.1% 94.4%
HR HCO3A 84.8% 85.7% 88.7%
MAP HR WBC 94.4% 94.8% 94.4%
MAP HR HCO3A 94.4% 94.8% 95.2%
4 time points MAP HR HB 94.4% 93.9% 94.4%
MAP SATAO2 HR HCO3A 95.2% 96.1% 96.5%
TEMP MAP HR WBC 93.9% 95.2% 93.9%
MAP SATAO2 HR WBC 95.2% 95.2% 94.8%
TEMP MAP SATAO2 HR WBC 95.7% 95.2% 94.8%
TEMP MAP SATAO2 HR HCO3A 95.7% 95.2% 96.5%
TEMP MAP SATAO2 HR PAO2 95.7% 95.2% 97.0%
HR = heart rate, HCO3A = arterial bicarbonate, MAP = mean arterial blood pressure, SATAO2 = arterial
oxygen saturation, TEMP = temperature, HB = hemoglobin.
Results from the first feasibility experiment where vital signs in time series were combined with single-
point measurements (at the time of simulated enrollment) of minimally invasive biomarkers to estimate
infection time. Vitals temperature, mean arterial blood pressure, arterial oxygen saturation, heart rate,
respiratory rate, or in any combination thereof, was tested in conjunction with a single blood biomarker for
their prediction accuracy. The top three biomarker sets for each combination and right censor duration are
shown, with their accuracies listed in the “with point” column. “No point” shows the estimation accuracy
for the vitals without the point biomarker. “Time series point” shows the estimation accuracy when all
biomarkers (vitals and point) were available in time series.
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Table 5.5: Prediction accuracy of longitudinal vitals With different diagnostic blood panels.
Accuracy
Right Censor Time Series Biomarkers Both Panel Blood Panel ABG Panel
MAP 81.8% 74.7% 69.0%
HR 79.5% 71.0% 70.4%
TEMP 77.4% 65.0% 58.3%
MAP HR 82.2% 78.8% 78.8%
MAP SATAO2 77.8% 76.1% 70.0%
2 time points TEMP MAP 77.4% 76.1% 70.0%
TEMP MAP HR 82.8% 79.8% 78.5%
MAP SATAO2 HR 82.2% 80.5% 78.5%
TEMP MAP SATAO2 77.8% 77.1% 69.7%
TEMP MAP SATAO2 HR 84.2% 81.1% 77.8%
MAP 86.7% 77.7% 75.8%
HR 85.6% 70.5% 75.4%
TEMP 81.1% 62.2% 54.9%
MAP HR 83.7% 84.5% 84.5%
3 time points TEMP MAP 79.9% 78.4% 75.8%
MAP SATAO2 79.6% 80.7% 76.9%
TEMP MAP HR 83.7% 85.2% 84.8%
MAP SATAO2 HR 83.7% 86.0% 85.2%
TEMP MAP SATAO2 80.7% 80.3% 77.3%
TEMP MAP SATAO2 HR 90.2% 86.7% 85.2%
MAP 90.5% 84.8% 81.8%
HR 89.2% 80.5% 78.8%
SATAO2 87.5% 68.4% 64.5%
MAP HR 89.6% 95.2% 88.7%
4 time points MAP SATAO2 87.0% 87.0% 83.5%
TEMP MAP 86.2% 85.3% 82.7%
TEMP MAP HR 90.0% 94.8% 89.6%
MAP SATAO2 HR 89.6% 95.7% 90.9%
TEMP MAP SATAO2 87.5% 87.0% 83.5%
TEMP MAP SATAO2 HR 93.5% 95.2% 90.9%
ABG = arterial blood gas, MAP = mean arterial blood pressure, HR = heart rate, TEMP = temperature,
SATAO2 = arterial oxygen saturation. Results from the comparison of two types of diagnostic panels:
arterial blood gas (arterial bicarbonate, PaO2 , and arterial base excess) and blood analysis (WBC, platelet
count and hemoglobin). Vitals temperature, mean arterial blood pressure, arterial oxygen saturation, heart
rate, or in any combination thereof were tested in conjunction with either or both diagnostic panels for
their estimation accuracy. The top performing combinations are shown.
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pig data sets. Alternatively, PLT performed similarly between the baboon and the pig LPS
data but was more informative in the pig peritonitis data. This may be the result of the
differences in sepsis induction protocols across the three models and suggestive towards the
existence of sepsis endotypes characterized by distinctive biomarker trajectories.
The vitals+1 biomarker search on the porcine data revealed MAP, TEMP, and SATAO2
to provide highly accurate estimates (LPS: 70 to 90+%, peritonitis: 80 to 90+%) when used
in conjunction with a single WBC or PHA measurement. Detailed porcine results from this
search are available in Appendix A3-A2 .
5.1.3 Discussion
A one-nearest-neighbor approach was selected to tackle the problem of identifying infection
time from left and right censored data. Serial measurements of non-invasive vital signs,
when combined with a single minimally invasive, yet routinely done, blood work, yielded
good accuracy to identify the time of onset of infection in an experimental baboon model of
sepsis. The method was further confirmed in two additional animal models. The one-nearest-
neighbor method was developed based on the hypothesis that cohorts of septic subjects exist
with similar characteristic biological responses. The baboon study chosen for analysis rep-
resented a homogenous cohort that all exhibited leukopenia following the E. Coli infusion.
Pig validation sets did not share this feature. Given a censored and normalized trajectory
for a study baboon, one-nearest-neighbor identified the most similar trajectory within the
database. The temporal information of this trajectory provided the time-of-infection esti-
mate for the study baboon. Nearest-neighbor is a popular non-parametric approach in data
mining and was selected here to find similarities among biomarker trajectories.
The exhaustive biomarker search revealed that certain biomarkers provide highly accu-
rate estimations of time of onset of infection. WBC, HR, HB, MAP, and HCO3A were
the top performers in Table 5.2 and had many appearances in Table 5.3. In contrast to
CO or SVR, both of which requires the insertion of an arterial catheter, WBC, HR, HB,
MAP, and HCO3A are relatively easy to measure. The modest accuracy increases from the
inclusion of CO or SVR is of doubtful clinical significance and did not seem to justify the
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invasive measurement. This suggested that more invasive to measure biomarkers might be
unnecessary and that this time of infection onset can be estimated with easily-measured,
patient-friendly biomarkers. It is also interesting to note the consistent appearance of many
biomarkers across animal models.
Most clinicians do not perform consecutive hourly blood sample tests, and only noninva-
sive biomarkers are likely to be acquired in time series. Many biomarkers in the baboon data
cannot be obtained hourly (or ever) in human patients due to practical reasons (no avail-
able commercial assay, slow turnovers) or to unjustifiable expenses. Patients with suspected
sepsis upon enrollment sometimes have a panel of diagnostic tests administered, including
arterial blood gas tests and a WBC measurement. These measurements are typically only
taken once at the time of enrollment. In contrast, vital signs such as HR, MAP, TEMP,
and oxygen saturation are continuously monitored and universally measured in time series.
The feasibility experiments addressed these issues by using clinically-obtainable data from
humans and yielded interesting results. Specifically, they showed that: (i) the addition of
a minimally invasive point measurement generally improved time-of-infection accuracy over
the use of time series vitals alone, (ii) taking minimally invasive measurements in time series
may be unnecessary for estimating time-of-infection, and (iii) there existed a data saturation
limit where one-nearest-neighbor did not benefit from additional data.
5.1.3.1 Study Limitations
The main limitation associated with this method was the small sample size of all three
datasets. This method worked well for the heterogeneous pig datasets at least in part
because of the uniformity of the insult within datasets, thus improving the chances of a
relevant “closest looking” animal in the cohort. If the database does not contain sufficiently
similar subjects to an incoming subject for which an estimation is to be made, the method
might not be able to generate a meaningful estimate.
Three main challenges currently prevent this method from being directly translated to
human patients. First, developing a human model requires access to a temporally rich collec-
tion of physiologic markers at baseline and following time-of-infection. The second challenge
is human variability, demanding that the dataset is of sufficient size to be representative of
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most endotypes. Third, human sepsis often happens in conjunction with other inflamma-
tory stressors, such as surgery or trauma. To address these challenges, a human dataset of
sufficient breadth could potentially be assembled in a cohort of patients developing sepsis
in association with an invasive procedure, therefore bounding time of onset to within a few
hours. The impact of the procedure itself on biomarkers time series would constitute useful
additional information.
5.1.4 Translation into GLUE Grant Human Trauma Subjects
The Inflammation and the Host Response to Injury “Glue Grant” database was the result
of a multi-center initiative to collect rich longitudinal data for trauma patients undergoing
hemorrhagic shock (www.gluegrant.com). This database consists of 2007 adult subjects
with known pre-hospital times (time of trauma was known, in minutes). While trauma is
different from sepsis, the inflammatory dynamics occurring between the two are similar.
The nearest-neighbor method was validated on the Glue Grant database. The parallels
between the syndromes of hemorrhagic shock in trauma and sepsis enable using trauma data
as a human validation cohort. Given the aforementioned problems associated with collecting
human sepsis data, trauma serves as a decent proxy. Figure 5.3 illustrates the distribution of
pre-hospital times within the Glue Grant database. Correlation analysis yielded few clinical
features with linear relationships to pre-hospital time. Subsequently, patients were binned
into 10 discrete intervals of pre-hospital times and one-way non-parametric ANOVA (via
Kruskal-Wallis tests) was conducted on all measured clinical features to identify nonlinear
relationships with pre-hospital time.
Several biomarkers were identified to have significant differences between various pre-
hospital interval groups (p ≤ 0.05). Fluid resuscitation data was discovered to be significantly
different between each group, but these measurements were discarded due to potential causal
relationships with pre-hospital time. The remaining clinical features were systolic blood
pressure, hypotension, diastolic blood pressure, heart rate, Glasgow coma score, lactate,
respiratory rate, hemoglobin, and the INR (international normalization ratio, a measure of
coagulopathy).
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The one-nearest-neighbor method was tested on this dataset. Unfortunately, hourly
measurements were not available in the Glue Grant. As a result, temporal trajectories of pre-
hospital measurements (in-ambulance measurements) and emergency room measurements
were used for analysis, if possible. Otherwise, biomarkers were used as point measurements.
After removing missing values, a cohort of 946 subjects. A 60-40 training-test split revealed
that the method estimated pre-hospital times correctly, to within 60 minutes, with a test set
accuracy of 68.1%. Various modifications of the nearest-neighbor methods were attempted,
ranging from filtering the nearest-neighbor database by injury severity score to modifying
the list of predictive biomarkers. Accuracy to 75-82%, but at the cost of reduced cohorts
sizes.
Figure 5.3: Histogram of pre-hospital times in the Glue Grant database. Vertical dashed lines
represent each hour.
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5.1.5 Summary
A novel application of the nearest-neighbors application was developed to estimate the onset
time of infection (specifically, a patient pre-hospital time relative to onset) within artificially
censored baboon and porcine sepsis data. High accuracies were achieved with varying sets
of biomarkers, but some biomarkers are difficult to measure clinically in humans. A com-
promise was made between minimizing the invasiveness of measurement and maximizing
the estimation accuracy. A feasible set of clinically-measurable biomarkers was identified;
combinations of vital signs in time series and minimally invasive point measurements yielded
similar but slightly lower accuracies.
The clinical tool presented in section 3.2.1 provided suggested an accurate early classifi-
cation of a subject’s endotype was possible, but such a tool lacked estimations of pre-hospital
time. However, promising results from a human trauma database suggested that translation
of the nearest neighbor approach may be viable for sepsis data, but such a temporally-rich
sepsis database is not yet available.
There are no other approaches to estimating time-of-infection in sepsis, and the method
developed here may have profound, paradigm-shifting implications if successfully extended
for use with human data. Septic patients would be able to be grouped into early, middle,
and late infection times and treated differently, which may play a clinically meaningful
role in patient outcome. Clinical trials may be revisited or new therapeutic targets may
emerge because treatment timings can be more effectively controlled with respect to the
temporal span of infection. Finally, computational models of sepsis and immunomodulatory
interventions used in the design of such trials may immediately benefit from the knowledge
of infection times.
5.2 SYSTEMIC DAMAGE MODELS
Chapter 3 presented endotypes with distinct rates of multiple organ failure (MOF). The
ProCESS data revealed that subjects on any type of organ support therapy (e.g dialysis or
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respiratory support) fared much worse than those without. MOF is a serious clinical incident
and a clinical tool to detect MOF early on can be beneficial. Clinicians, with early knowledge
of imminent MOF, can apply preventative therapies and respond accordingly. The clinical
need for quantifiable sepsis-induced damage motivates this section.
Mathematical models of sepsis may similarly benefit from quantifiable damage. Figure
1.1 outlined the basic acute inflammatory response. Currently, well-studied proxies for the
inflammatory and anti-inflammatory responses exist. The damage compartment is a key
player in inflammatory dynamics, but the lack of quantifiable damage during sepsis prevents
this compartment from being accurately modeled. As a result, current mathematical models
insufficiently characterizes the feedback loops that may lead to a sustained inflammatory
response. Mathematical models of sepsis in literature either ignore this dynamic or exist
within the realm of theory [3, 4]. Malkin, et al published a mathematical model of neutrophils
in sepsis, and modeled kidney damaged based on creatinine clearance data [80]. However,
creatinine clearance is a measure of kidney health and only proxies kidney damage rather
than other organs which can fail during sepsis such as the respiratory system or the liver.
Quantifying the amount of sepsis-induced damage to the body can be done by character-
izing the level of systemic tissue damage. Acute Physiology and Chronic Health Evaluation
(APACHE) and Sequential Organ Failure Assessment (SOFA) are commonly used methods
to assess damage in the clinic. Furthermore, multiple organ failure is based on the SOFA
score (≥ 2 failed organ systems). However, these assessment scores are granular assessments
and do not provide clear trajectories of how patients evolve temporally. A novel and data-
driven damage assessment tool is presented to augment APACHE and SOFA scores. The
goals of this tool are twofold: (i) provide damage trajectories using easy-to-measure biomark-
ers to reduce measurement burden and (ii) provide robustness to missing measurements to
accommodate hectic conditions within the clinic.
5.2.1 Methods
The aforementioned baboon sepsis dataset was retrospectively analyzed for this work due to
the temporally rich data and because pre-hospital times are a non-issue with animal data
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[109]. Some baboons had occasional missed measurements, but many biomarkers were mea-
sured at [−0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 1112, 23, 24, 35, 36, 47, 48, 72, 73, 144] hours post E. Coli
infusion. Some baboons had a 672-hour measurement if they belonged to the long-term
survival cohort where they had a final measurement taken prior to sacrifice at the 28-day
mark.
The risk of death was associated with global tissue damage. Logistic regression (LR)
mathematically characterized the risk of death for each baboon via biomarker odds ratios.
Odds ratios multiplied by baboon-specific biomarkers characterized the baboon’s risk of
death and level of tissue injury. A discrete time equation was formulated to generate damage
based on the odds ratios obtained from LR.
Biomarker selection was performed statistically with no a priori bias applied. Initial pre-
processing reduced the set of biomarkers to 63 by eliminating predictors that were not fully
measured for each of the 33 baboons. Collinearity was checked between the 63 biomarkers.
Each biomarker, across all time points, was compared to each other using the Spearman
rank correlation coefficient. A cutoff of Spearman’s rho (|ρ| ≤ 0.75) removed collinear
biomarkers. Finally, a univariate analysis was performed on the biomarkers to identify the
time points at which they were significant with respect to mortality outcome. Student’s
t-test was used to test the remaining biomarkers for significance with respect to mortality
at each temporal measurement (p ≤ 0.10 to provide a larger pool of biomarkers). Any
biomarkers that were deemed insignificant across all time points were subsequently removed.
The remaining biomarkers were further filtered based on their ease-of-measurement in order
to improve the translatability of this approach into the clinic. The significant time point
measurements of the easy-to-measure biomarkers served as inputs into LR models.
LR models were created for each time point from 0.5 hours to 144 hours post infusion,
with biomarkers as the input and mortality probability as the output. Mortality output
was defined as the interval (0, 1), with 0 being survival and 1 being non-survival. For each
time point, all significant biomarkers from the 0.5 hour time point up to the current time
point were included as inputs. This strategy was chosen in order to capture changes between
biomarkers at different time points. All LR models were calibrated against the experimental
mortality outcomes of the baboons. Baboons that were sacrificed at 144 hours post-infusion
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were assumed to be survivors. Each LR model was trained with one hundred replicates of
three-fold cross-validation. The odds ratios across replicate models were averaged to obtain
mean odds ratios for each biomarker.
Elastic net regularization was applied to each LR model in order to reduce the number of
inputs in the higher time point models. Elastic net regularization is a mixture of lasso regu-
larization and ridge regularization and provides the benefits of predictor selection when the
number of predictors exceeds the number of observations and predictor coefficient shrinkage
[110].
min β
1
2N
∑
i = 1N(yi − xTi β)2 + λ
[
(1− α)1
2
||β||2 + α||β||1
]
(5.2)
A parameter, α, determines this regularization mixture, with α = 0 being fully lasso regular-
ization and α = 1 being fully ridge regularization. α = 0.25 was used to prioritize biomarker
selection. Elastic net employs a single regularization parameter, λ, to control both ridge and
lasso regularization. In order to select the regularization penalty, λ, a vector of evenly spaced
λ in natural log space was generated and LR models were fit for each λ. The model with
the best area under the receiver operating curve (AUROC) was compared. λ = e−6 yielded
consistently high AUROC (near maximum) for the majority of the time point LR models.
For consistency, elastic net regularization with this value of λ was applied to LR at all time
points. The ensemble of beta coefficients associated with this λ (3000 sets of coefficients, due
to 3 folds and 1000 replicates) were averaged to produce a set of time-varying odds ratios
for each clinical predictor.
A discrete time damage equation was implemented due to the irregular sampling rate
of biomarkers. Time was discretized into intervals of 0.5 hours to accommodate the fastest
sampling time in the data. The formulation, shown in Equation 5.3, consists of a damage
elimination term and a generation term. The negative term including k represents the body’s
healing rate. A linear mechanism was proposed as a best-case scenario; in reality, high levels
of injury typically result in cascading organ failures that impede a patient’s healing ability.
The value of k was defined as 0.1768, which corresponded to a damage half-life of about
4 hours. Humans may take months to recover from endotoxemia challenges while murine
models demonstrate remarkably fast recovery in the order of hours [8]. The value of k was
set to characterize a similarly fast damage recovery rate in baboons. Damage was generated
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by the logit (the mean odds ratio multiplied by the value of the associated biomarkers at
that time) obtained from the time relevant LR model.
DMG(`+ 1) = DMG(`)− k ∗DMG(`) + exp(β`X`) (5.3)
Two cases were defined for missing data. In the case of a missing measurement, the logit
was calculated by multiplying the most recently measured biomarker by the current odds
ratio, β`. For example, a baboon has one missing biomarker measurement at hour 47. That
specific term was calculated with β47X36. In the case of an ` at a time point that was not
sampled, the logit was calculated by multiplying the most recently measured biomarker by
the most recently calculated odds ratio. For example, the next measurement after 6 hours
post infusion was 11 hours. To calculate damage at hours 6.5 through 10.5, the logit at hour
6 was used: exp(β6hrX6hr).
5.2.2 Results
5.2.2.1 Damage Trajectories
Pre-processing reduced the pool of biomarkers from 73 to 27. 10 biomarkers were removed
because they were unavailable among all 33 baboons. 30 biomarkers were removed due to
identified collinearities in the data. Student’s t-test on the remaining 33 biomarkers revealed
6 biomarkers that were not significant at any time point. However, certain time points such
as hour 23 revealed seventeen different significant biomarkers. To satisfy the requirements
of low measurement burden (assessing 17 measurements to evaluate damage would be an
unreasonable task) and ease of measurements (quick, commonly taken measurements in the
clinic), 20 additional biomarkers were excluded, leaving 13 biomarkers. These biomarkers
are listed in Table 5.6.
A total of 18 LR models were created: one for each time point. Each LR model was
performed with three-fold cross-validation and 1000 replicates. The predictor selection fre-
quency resulting from regularization was tabulated and normalized between 0 and 1. A
specific predictor can appear in an LR model a maximum of 3000 times (appears in each
of the three cross-validation models across all 1000 replicates). Additionally, a predictor at
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Table 5.6: Acronym dictionary of biomarkers for damage results.
Acronym Meaning Measurement Method
HR Heart Rate Straightforward
MAP Mean Arterial Pressure Calculated
TEMP Temperature Straightforward
HB Hemoglobin Vein Blood Sample
PHA Arterial PH Arterial Blood Sample
ABEA Acid Base Excess Arterial Blood Sample
RR Respiratory Rate Straightforward
SHUNT Amount non oxygenated blood returning to heart Calculated
PAO2 Partial arterial pressure of Oxygen Arterial Blood Sample
PLT Platelet Count Vein Blood Sample
LACTATE Lactate Vein Blood Sample
GLUCOSE Finger Stick
RAP Right Atrial Pressure Need Central Line*
*While central line measurements are hard to obtain due to the risks associated with their insertion, severely
septic patients typically have one inserted.
time 0.5 hour can appear in all 18 LR models while a predictor at time 144 hour can only
appear once. Normalization accounted for both of these factors when scaling down the se-
lection frequency. Figure 5.4 presents the predictor selection frequency for all 18 LR models.
For example, the ensemble of LR models selected 30-minute measurements of right atrial
pressure (RAP) quite often and arterial pH (PHA) roughly 50% of the time.
The odds ratios from all 18 LR models were used to calculate the logit in Equation 5.3
and a damage trajectory was generated for each of the 33 baboons. Figure 5.6 shows all
of the trajectories. Some baboons’ trajectories were incomplete due to right-censoring via
sacrifice in accordance with experimental protocol. Trajectories with straight line segments
were the result of the zero order hold assumption. Survivor and nonsurvivor trajectories
were distinct from one another and complete separation occurs at 7-8 hours post infusion.
Intuitively, nonsurviving baboons with high damage levels die at earlier time points while
nonsurviving baboons with lower damage levels die at later time points. Interestingly, cer-
tain nonsurvivor trajectories exhibited rapid decreases of damage. However, these baboons
eventually succumbed to the septic shock. Surviving baboon trajectories were characterized
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Figure 5.4: Predictors (and their frequency) used to generate damage curves. Y-axis specifies the
predictors and X-axis specifies the time point of measurement at which the predictors were used.
White cells indicate that the corresponding predictor at that time point was not used due to a lack
of significance from Student’s t-test. Colored cells indicate that the corresponding predictor was
selected by the regularized LR model with a frequency corresponding to that color: dark red means
frequently (a maximum of 3000 times) and dark blue means very few (a minimum of 0 times) and
everything in between.
by an initial damage spike followed by a steady decline to steady states within 10−1− 10−3.
The rate of damage was assumed to be constant across all baboons, which indicated that the
survivor trajectory declivities may be attributed to the resolution of infection and inflam-
mation. Furthermore, damage levels for survivors stayed below a magnitude of 10, which
suggested a threshold of no return in terms of cascading organ damage.
To further test the robustness of this algorithm to missing measurements, entire time
points of measurements were removed from those shown in Figure 5.4 to emulate missed
measurements and/or sampling limitations in the clinic. Figure 5.5 illustrated the remain-
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Figure 5.5: Predictors (and their frequency) used to generate damage curves in a missed measure-
ment scenario. This heatmap is organized in the same fashion as in Figure 5.4. However, a sparse
measurement scenario was enacted, causing many of the measurements in Figure 5.4 to be missed.
Of the remaining predictor measurements (non-white cells), selection frequencies by regularized LR
are shown.
ing predictors and time points. The algorithm was re-applied to this set of predictors and
the updated color cells represented new LR selection frequencies. Once fully trained, these
LR models were used to recalculate the logits in Equation 5.3. The damage trajectories
that were recreated are shown in Figure 5.7. The missing measurements at early time points
(1, 3, 5, 11, 12, 23 hours post infusion) contributed to the significantly slower separation. Sep-
aration occurred at 25-26 hours, which indicate that once new measurements were available
(the last set of measurements were at hour 6), damage levels updated to reflect new informa-
tion. Additionally, overall nonsurvivor damage magnitudes decreased as compared to those
of Figure 5.6. However, the damage threshold of 10 still appeared to hold in this sparse data
scenario.
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Figure 5.6: Systemic tissue damage trajectories for baboons using easy to measure biomarkers.
Green trajectories represent baboons that ultimately survived sepsis while the purple trajectories
represent nonsurvivors. Within the baboon survivors, many were sacrificed at the end of 6 days
as per experimental protocol, which is represented by the red circles capping those trajectories.
Nonsurvivors’ times of death are represented by a red x capping the end of their trajectories. There
was a clear separation of survivors versus nonsurvivors by hour 11, where nonsurvivors exceeded
a damage of 101 and proceeded to increase sharply. While some survivors may have reached this
level of damage, their bodies recovered.
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Figure 5.7: Systemic tissue damage trajectories for baboons using sparse biomarkers. Damage
trajectories were calculated from significantly missing data (see Figure5.5. Separation was achieved
after a longer period of time (24 hours) due to missing measurements and the zero-order-hold rule.
However, whenever new data became available, the damage trajectories moved appropriately in
the survivor/nonsurvivor directions. 101 appeared to remain a valid damage cutoff in determining
mortality.
5.2.3 Discussion
Predictor selection frequency via LR identified several key biomarkers that were currently
used to calculate disease severity scores such as SOFA and APACHE II. For example, the
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method identified and favored biomarkers MAP (cardiovascular health), WBC (immune
capability),PaO2 (respiratory health), and PLT (coagulation) across many points in time.
Initial tests, prior to selecting only for biomarkers that were easily measured, revealed other
biomarkers used to calculate SOFA or APACHE II including bilirubin (liver health) and
creatinine (kidney health). These biomarkers were identified purely out of statistical methods
and a priori information from existing damage scoring systems was not taken into account.
Figure 5.6 suggests that early organ support is critical to shift subjects towards a surviv-
ing trajectory. For the first 12 hours, nonsurviving subjects had a characteristic rising-only
damage trajectory, indicating that their organ systems were worsening by the hour. Alter-
natively, survivor trajectories began declining between 6 to 12 hours post infection. This
indicated that organ function began returning in the survivors because the healing term in
Equation 5.3 dominated the dynamics.
While multiple organ failure is not clearly defined within baboons, Figures 5.6-5.7 clearly
demonstrate that there were levels of catastrophic systemic damage after which surviving
was not possible. These damage trajectories, combined with the fact that many of the
selected predictors chose known organ damage biomarkers, suggest that this approach can
be translated into the clinic.
The algorithm proposed here serves as a proof of concept of a damage assessment method
that can both be feasible and practical in a clinical setting. The biomarkers used for predic-
tions in the sparse measurement scenario demonstrated the robustness of this algorithm with
respect to extreme missing measurements. Furthermore, the easy-to-measure set of identified
biomarkers included vital signs and venous and arterial blood samples, all of which are easy
and fast to obtain. A large and temporally rich sepsis database, combined with knowledge
of pre-hospital times (estimated or otherwise) would be suitable to validate the algorithm.
This method may be possible to translate to the ProCESS trial, which is one of the
largest and richest sepsis databases in existence. Preliminary testing revealed that complete
cases of the easy-to-measure biomarkers yielded a large enough convenience cohort to apply
this algorithm. Pre-hospital times (such as those estimated from Chapter 3) would need to
be accounted for because the algorithm is heavily dependent on calibrating the logit term
in Equation 5.3 via comparable population data. One potential fallacy that the current
109
algorithm does not account for would be the issue of therapy. The baboons within the
experiment only received fluid resuscitation while the subjects in the ProCESS trial received
interventions. The current algorithm is currently unable to process interventions as an input
into the ensemble of LR models. As a result, clear mortality separation is currently difficult
to achieve because a potentially life-threatening state, which would otherwise be predicted by
the LR to die, may be modulated by some intervention and survive the initial septic shock.
As a result, future work is warranted to explore the effects of treatment and therapies on
damage.
5.2.4 Summary
A data-driven algorithm was introduced to quantify sepsis-induced systemic tissue damage.
The premise of this method was to identify subjects who perished due to septic shock and
calibrate the model with the state of these subjects’ various organ systems. Biomarkers
deemed to be significant with respect to mortality via Student’s t-test served as proxies
of the health of organ systems and tissue that were significantly affected by septic shock.
At each time point, an ensemble of LR models was trained on the data available. Organ
damage was calculated as odds ratio and characterized by the logit portion in Equation 5.3.
This approach was able to characterize the initial inflammatory-induced damage to sepsis
in all subjects sepsis and demonstrated that nonsurvivors exceeded a damage threshold of
no return. These results are applicable in the clinic because subjects remained in a state of
uncertainty for several hours before setting upon a trajectory that sealed their fates. This
demonstrates both the existence of a clinical therapeutic window and the possibility of the
ability to modulate a trajectory from a “death” state to a surviving one. Combined with the
ability to estimate pre-hospital time, this systemic damage algorithm may provide clinicians
the power to apply and time preventative therapies to improve patient outcomes. This
algorithm is ready for translation and testing with human subjects.
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6.0 RELEVANT MODELING TOOLS
Several tools are introduced here to assist with the challenging task of mathematical modeling
of sepsis dynamics. First, a network optimizer is introduced to assist with the establishment
of a model framework structure. This optimizer analyzes time series data that has been con-
verted into Boolean variables (two states: on/off) and uses mixed integer linear programming
to optimize the best network that produces the data. Second, a Markov Chain Monte Carlo-
based algorithm is introduced that focuses on parameter fitting. This algorithm is written
with user-friendliness in mind and focuses on algorithmic speed, efficiency, and ease-of-use.
These tools are intended to be used in harmony; the former produces latent relationships
within the data inform and refine model structure and the latter tackles the inverse-problem
of parameter fitting to said model.
6.1 BOOLEAN-LP, A NETWORK PATHWAY OPTIMIZER
A major problem associated with mathematical modeling of sepsis is the sheer number of
potential biomarkers and the myriad of interactions between them [39]. Compounded with
the sparsity of human sepsis data, it is often difficult to pinpoint why few mathematical
models of sepsis have been validated against literature: model structure problems, failure of
the inverse-problem algorithms, or a combination of both.
Boolean Linear-Programming (Boolean-LP) is introduced as a tool to assist with the
initial steps of model creation. Boolean-LP was created in an effort to identify the underlying
inflammatory pathways between elderly and young mice (Mochan, Zhang, et al, Discrete
111
dynamical modeling of influenza infection suggests age-dependent differences in immunity;
submitted to the Journal of Virology).
Model structure development is one of the initial phases of mathematical modeling,
where the modeler combines literature knowledge and intuition to propose a mathematical
characterization of certain dynamical behaviors. This begins an iterative process of fitting
data to this proposed model and then making structural model changes to accommodate
missing behaviors or other issues. Boolean-LP speeds up this approach by taking a set of
proposed network pathways between model states and identifying the network pathway that
best describes the given data.
Boolean-LP first requires the user to first discretize the data into Boolean variables.
Second, the user needs to propose a set of model pathways via Boolean rules. For example,
the rule C(t+ 1) = A(t)and not B(t) may be proposed, describing the production of state C
by state A but this process is inhibited by state B. A set of rules describing the relationships
between states A, B, and C and data are provided to Boolean-LP and it returns the rule
that best describes the data. In the case of a solution pool (multiple rules yield the same
objective function), Boolean-LP will return all of the possibilities.
To find the optimal set of Boolean rules that best described the data, the rule discovery
problem may be formulated as a mixed integer linear programming (MILP) problem. A
similar formulation has been previously reported [111]. We define our objective function as
the minimum difference between the model and the measured data, given by equation (6.1).
min
∑
s∈S
∑
t∈Ts
|Dt,s −Mt,s| (6.1)
This was later reformulated as a linear objective function using dummy variables (see Section
6.1.2, specifically equation 6.17) in order to conver the problem into a mixed-integer linear
programming (MILP). Dt,s and Mt,s represents the measured data and model, respectively,
for state s at time t.
All potential Boolean rules were expressed as a series of logical equivalences (if and
only if statements: clause1 ↔ clause2). These rules were expanded into their equivalent
conjunctive normal form, which is the conjunction (AND) of several inclusive OR clauses.
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This form allows us to represent each of the OR clauses with a single linear inequality [112].
As long as each of these linear inequalities are satisfied, the overall conjunction expression
is satisfied. The result is:
Q1 ∧Q2 ∧ · · · ∧Qn
Q1 = P11 ∨ P12 ∨ · · · =⇒ y11 + y12 + · · · ≥ DV
Q2 = P21 ∨ P22 ∨ · · · =⇒ y21 + y22 + · · · ≥ DV
(6.2)
where yij represents the Boolean value of expression Pij and DV is a Boolean decision
variable. The decision variable allows the optimizer to apply this constraint (DV = 1) or
turn it off (DV = 0).
6.1.1 MILP Formulation of Network Optimizer Problem
Specifically, all Boolean Rules can be expressed in the conjunctive normal form, which com-
prises of a series of overarching AND clauses consisting of OR operators:
RuleR = Q1 ∧Q2 ∧ · · · ∧Qn (6.3)
Qi = Pi1 ∨ Pi2 · · · ∨ Pir (6.4)
Pi1 ∈ 0, 1 (6.5)
where Qi is a series of inclusive OR operators. Let yi represent the Boolean value of clause
Pi. Each of the Qi logical OR constraints can be expressed as
Pi1 ∨ Pi2 · · · ∨ Pir ⇒ y1 + y2 + · · ·+ yr ≥ 1 (6.6)
The AND constraint, R, does not need to be explicitly constrained because (6.6) ensures
that each of its sub-clauses, Qi, are true. NOT clauses, ¬P1, can be expressed as:
1− y1 (6.7)
Implications, e.g. P1 ⇒ P2, can be expressed as ¬P1 ∨ P2, which is an OR constraint:
1− y1 + y2 ≥ 1 (6.8)
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Using this framework, we can formulate this as a MILP. Potential rules are always of the
form: Si,t+1 ← St, where St represents a series of logical operations acting upon the states
at the current time t. This logical clause will generate an update to the ith state, Si, at time
t+1. If this rule were true, then Si,t+1 ⇔ St for all time, t. Applying the above equivalences,
we obtain:
¬Si,t+1 ∨ St
¬St ∨ Si,t+1
(6.9)
which we expand into the conjunctive normal form and apply the appropriate linear con-
straints.
Finally, in order to perform rule optimization, Boolean decision variables, DVij, are
initialized for every proposed rule j in each state i. The k OR constraints generated from
the conjunctive normal form of Rule ij is now represented as:
Constraint 1: y1 + y2 + · · ·+ yr ≥ DVij
Constraint 2: y1 + y2 + · · ·+ yr ≥ DVij
· · ·
Constraint k: y1 + y2 + · · ·+ yr ≥ DVij
(6.10)
which represents a slight modification from equation (6.6) in order to allow the optimizer to
turn a constraint on or off. If DVij is 0, the values of yi are unconstrained and potential rule
ij does not apply. If DVij is 1, the rule applies. A final constraint is set:
J∑
j=1
DVij == 1 (6.11)
such that each state i may only have 1 rule selected.
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6.1.2 Detailed Formulation Example
As a detailed example, take a rule governing Interleukin-6, activated macrophages (ActiveM),
and Interleukin-8 (IL-8, a neutrophil attractant): ActiveM(t+1)← IL8(t)∧IL6(t) Working
out one implication at a time, this is equivalent to constraints (6.13),(6.14), (6.16).
ActiveM(t+ 1)⇒ [IL8(t) ∧ IL6(t)] = ¬ActiveM(t+ 1) ∨ [IL8(t) ∧ IL6(t)]
=
[¬ActiveM(t+ 1) ∨ IL8(t)] ∧ [¬ActiveM(t+ 1) ∨ IL6(t)] (6.12)
1− ActiveM(t+ 1) + IL8(t) ≥ DV (6.13)
1− ActiveM(t+ 1) + IL6(t) ≥ DV (6.14)
[
IL8(t) ∧ IL6(t)]⇒ ActiveM(t+ 1) = ¬[IL8(t) ∧ IL6(t)] ∨ ActiveM(t+ 1)
= ActiveM(t+ 1) ∨ ¬IL8(t) ∨ ¬IL6(t)
(6.15)
ActiveM(t+ 1) + 1− IL8(t) + 1− IL6(t) ≥ DV (6.16)
To further simplify the problem, the nonlinear objective function from equation (6.1)
may be linearized via the introduction of dummy variables At,s:
minimize
∑
s∈S
∑
t∈Ts
At,s
subject to Dt,s −Mt,s ≤ At,s
Dt,s −Mt,s ≥ −At,s
(6.17)
where Dt,s and Mt,s represents the measured data and model, respectively, for state s at
time t.
A Python (version 3.5) package was written to accept Boolean data and a list of potential
rules for each state. This package reformulates the inputs into a MILP problem for use with
the Python Optimization Modeling Objects package (Pyomo) [85, 86]. Pyomo then converts
this script into a solver-friendly file, which was then solved by the IBM ILOG CPLEX
optimization studio. CPLEX was set to populate all optimum solutions via its solution pool
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feature. Finally, our Python package parses through this solution pool and returns all valid
rules that yield the minimum objective function value. The GLPK solver was successfully
tested, but it was significantly slower then CPLEX and lacked the ability to populate a
solution pool in the case of multiple solutions. Boolean LP is available as an open source
project on GitLab.
6.1.3 Applications in Age-related Immune Pathways
The BooleanLP algorithm was created to address optimization problems in a project quan-
tifying the immunosenescence (age-related) differences in immune pathways between adult
and elderly mice. Adult (12-16 weeks) and elderly (72-76 weeks) BALB/c mice were subject
to an innocula of the Influenza virus [113]. Near daily sacrifices (in triplicate) were taken
from each group for measurements of inflammatory markers (chemokines and cytokines)
and white blood cells, including day zero baseline measurements. An ANOVA analysis was
conducted (p ≤ 0.05) to convert the entire dataset into zero (off) and one (on). A library
of possible immune pathway rules were generated and BooleanLP was applied to identify
the optimum inflammatory network that best described the data. BooleanLP indicated no
age-dependent changes in macrophage recruitment between the elderly and adult mice, but
macrophage cytokine expressions were different. Cytokine and chemokine pathways differed
vastly between the age groups and was responsible for the two day delay in the immune
response within elderly mice. The manuscript of this work is currently being updated after
the first round of reviewers.
6.2 APT-MCMC, A C++/PYTHON IMPLEMENTATION OF MARKOV
CHAIN MONTE CARLO FOR PARAMETER IDENTIFICATION
While Boolean-LP provided a method to quickly identify the optimal model structure from
a potential list of possibilities, the next daunting step is the inverse problem. The inverse
problems that mathematical modelers tackle are often very challenging due to parameter
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dimensionality, parameter correlation, and multiple optima. A topical and popular set of
inverse problems is fitting parameters to a system of ordinary differential equations (ODEs).
Most deterministic optimization algorithms can be broken down into two types: line search
and trust region [114]. During nonlinear fitting, these algorithms often get trapped within lo-
cal minima because they are highly dependent on the provided starting point. Additionally,
many advanced solvers calculate or estimate the Jacobian or Hessian of the objective func-
tion, a process which may not converge for complex ODE parameter-fitting problems. This
results in heuristic implementations that employ multi-start optimization to characterize the
optimal parameter space, and parameter estimates that are likely only locally optimal and
for which confidence intervals cannot necessarily be easily constructed. These problems are
very topical in the case of modeling the dynamics of sepsis due to the sparsity of human data
and the tightly regulated interactions that persist throughout the inflammatory response.
Markov Chain Monte Carlo (MCMC) is a stochastic sampling technique typically used
to gain information about a probability distribution that lacks a closed form. It has been
described as a “bad method” for parameter estimation to be used when all alternatives are
worse [115]. MCMC has been used in a variety of fields, such as cryptography, statistical
mechanics, and astrophysics [116, 117]. Long runtimes, simulation stochasticity, and the lack
of a robust convergence and stationarity criteria contribute to the stigma against MCMC.
However, MCMC is immediately relevant to ill-posed ODE inverse problems. Unlike deter-
ministic algorithms, MCMC is not dependent on the starting point and does not require the
computation of Jacobians or Hessians. Furthermore, an MCMC simulation provides param-
eter probability distributions, which can help elucidate parameter correlations and identify
multiple optima (see Figure 6.1).
MCMC is formulated as a stationary Markov Chain with a transition probability derived
from the parameter probability distribution. Bayesian formalism is used to reformulate a
parameter fitting problem as a search for probability distribution. That distribution can be
sampled using MCMC. Equation (6.18) describes Bayes theorem, where θ is a parameter
and D is the data.
P (θ|D) = P (D|θ)P (θ)
P (D)
(6.18)
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Figure 6.1: MCMC results from exploring a highly correlated probability function. A: Contour
plot for an anisotropic distribution. Epsilon was set to 0.001. B and C: MCMC results yields
marginal probability distributions for x1 and x2. D: These distributions can be combined into a
joint distribution plot to identify parameter correlations.
The P (θ|D) term is the Bayesian posterior probability, which represents the probability of
the parameter set, θ, given the data. The first term in the numerator describes the likelihood
of obtaining the data, D, given the parameters, θ. The objective function for a parameter
fitting problem, reformulated as a likelihood, is used here. The second term in the numerator
describes the prior distribution of the parameters. This can vary depending on the problem,
but the simplest case is a bounded uniform distribution to provide upper and lower bounds
on θ. The denominator is a normalization constant that represents the probability of the
data, typically an unknown, but constant, term. This term is not necessary for MCMC
simulation, as shown in Equation (6.18).
To recover the Bayesian posterior distribution from a parameter fitting problem, MCMC
needs to generate many samples from the parameter space in accordance to Equation (6.18).
The MCMC sampler stochastically proposes the next parameter set, θproposed, based on
the location of the current parameter set, θcurrent [118, 119] . The Metropolis-Hastings
criterion is typically used to accept or reject θproposed by calculating the posterior probability,
P (θproposed|D). If this value is higher than the posterior probability of the current parameter
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set, P (θcurrent|D), then θproposed will be accepted with 100% probability. If the probability is
lower, then θproposed may be accepted with the nonzero probability calculated by Equation
(6.21) (with T=1). This step is repeated many times to allow the samplers to fully explore
the parameter space.
Over the course of an MCMC simulation, all the values of θ (derived from each MCMC
sample via the calculation of Equation (6.18)) are preserved for post-hoc analysis. The
posterior distribution can be recovered via histogram analysis or kernel density estimations
from the chain of θ values. θ may be broken down into its individual parameters to ob-
tain a marginal posterior probability distribution for each fitted parameter. These marginal
distributions can yield generate parameter confidence intervals, identify inter-parameter cor-
relations via joint probability distributions, and to identify the locations of multiple minima
in the parameter space based on multi-modal marginal parameter distributions. Further-
more, irreducibility and aperiodicity properties of Markov Chains guarantees convergence of
the posterior distribution [115]. The major benefit of these properties is that an MCMC
simulation will yield the correct Bayesian posterior based on the data and model structure
in finite time.
Despite the guarantee of convergence, it is impossible to test if a MCMC sampler has
converged towards its equilibrium distribution or a temporary meta-stable distribution [115].
As a result, MCMC simulations typically sample a very large number of points. The initial
samples that are taken prior to reaching the equilibrium distribution may bias the posterior
distribution. The two ways possible ways to deal with this issue are: (i) discard some initial
percentage of simulation samples or (ii) run a long simulation to minimize the bias. In either
scenario, simulations take a long time because a large number of samples are needed for
convergence.
Many variations have been proposed over the years in order to improve the efficiency of
the sampling. One issue is that MCMC samplers may get trapped in local minima for a long
time before escaping. An escape consists of several consecutive low probability parameter
moves because it requires movement towards increasing deviation from the data. At any
point, the MCMC sampler may change direction and move back into the local minima.
Parallel tempering addresses this by employing multiple MCMC interacting simulations in
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parallel [52, 120]. Each simulation is assigned a temperature and the Boltzmann distribution,
Equation (6.21), is used to accept a parameter proposal. The Bayesian posterior probability
for the proposed and current parameter vectors are calculated as normal (Equation (6.18)),
but are treated as energies (Equations (6.19)-(6.20)) in order to fit the formalism of the
Boltzmann distribution. These energies, E1 and E0, are scaled by the simulation temperature
before determining the proposal acceptance probability. In effect, the objective function is
divided by temperatures so that samplers have higher probabilities of escaping local minima.
Figure 6.2 demonstrates how the energy “landscape” of a probability distribution can change
given a high enough temperature. The higher temperature landscape at T = 3 or T = 10
demonstrates the relative ease at which an MCMC sampler can explore the entire parameter
space compared to the lower temperature landscape where the sampler may be prone to
getting trapped in local minima.
E1 = logP (θproposed|D) (6.19)
E0 = logP (θcurrent|D) (6.20)
Parameter Acceptance = min(1, exp
(
E1 − E0
T
)
) (6.21)
Swap Acceptance = min
[
1, exp
(
−(Ei − Ej)( 1
Ti
− 1
Tj
)
)]
(6.22)
These energies, E1 and E0, are scaled by the simulation temperature before determining the
proposal acceptance probability. In effect, the objective function is divided by temperatures
so that samplers have higher probabilities of escaping local minima. Figure 6.2 demonstrates
how the energy “landscape” of a probability distribution can change given a high enough
temperature. The higher temperature landscape at T = 3 or T = 10 demonstrates the
relative ease at which an MCMC sampler can explore the entire parameter space compared
to the lower temperature landscape where the sampler may be prone to getting trapped in
local minima.
A unique feature of parallel tempering algorithms is that the tempered Monte Carlo
chains are allowed to evolve independent of each other for some time. After a user-set hy-
perparameter, nsteps (a “swap interval”) has passed, an inter-chain swap of parameters is
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Figure 6.2: Effects of varying temperatures on the Boltzmann distribution. Shown is a single pa-
rameter, θ, and the system’s energy at that parameter value. The steep local minima are difficult
to escape because the escape probability as defined by Metropolis-Hastings criterion becomes ex-
ponentially smaller. Higher temperatures modulate the energy landscape such that local minima
become shallow and easier to escape.
attempted to pass the information about potential energy minima (higher probability pa-
rameter locations) from higher temperature samplers to the lower temperature samplers.
This swap probability is calculated with Equation (6.22) by comparing the energy and tem-
perature of chain i against those of chain j [121]. If a higher temperature sampler is in a
parameter location with a larger energy value (higher Bayesian posterior and more favorable
location), then that information will pass down to a lower temperature sampler with 100%
probability. The opposite scenario, where a swap is proposed to provide a low temperature
sampler with a lower energy parameter location (less favorable), is possible, but less prob-
able (small, nonzero swap acceptance). The net effect is that high temperatures perform a
broad search over the parameter landscape and pass locations of local minima to the lower
temperatures, which conducts a depth search within these minima.
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An issue that often arises from inverse problems that estimate ODE parameters is pa-
rameter correlation. Correlations cause parameter distributions to be highly anisotropic.
Figure 6.1A illustrates a highly anisotropic system that would be very difficult for MCMC
to efficiently sample. The significant correlation between x1 and x2 can be clearly seen in the
joint probability distribution in Figure 6.1D. The majority of MCMC samples will lie outside
regions of interest and provide no information that can be used to recover the probability
distribution. As a result, to uncover the marginal distributions of x1 and x2, as illustrated
in Figures 6.1B and C, a lengthy simulation would be required. To improve the sampling
efficiency of anisotropic distributions, Goodman and Weare proposed an MCMC variant that
utilizes an ensemble of samplers with affine invariance [122]. The affine invariance property
of this algorithm means that sampling efficiency is unaffected by the anisotropic nature of a
parameter topology. This means that the ensemble of samplers can sample from the distri-
bution in Figure 6.1A just as efficiently as it can sample from an isotropic distribution (e.g.
a perfectly circular density plot).
ODE parameter fitting can greatly benefit from MCMC techniques, but several barri-
ers of entries prevent it from being commonly adopted. Most existing packages suffer from
shortcomings related to one of two categories. First, many packages exist in “prototyping
language” such as Python, R, or MATLAB in order to facilitate the coding process. Proto-
typing an MCMC simulation is more convenient, but the user pays for it greatly with the
lengthy simulation time. The second category of packages are those written in “fast lan-
guages” such as C(++) or FORTRAN. MCMC simulations compiled from these languages
are considerably faster, but suffer from the opposite problem: difficulty of programming. A
large barrier to entry needs to be overcome before research code can pass through the layers
of abstraction into a “fast language.” APT-MCMC is a C++ implementation of MCMC with
the aforementioned parallel tempering and affine-invariant ensemble of samplers [52, 122].
It aims to bridge the gap of programming accessibility by allowing the user to define their
simulation solely within a Python package, which provides code conversion to compilable
C++ code.
The rest of this section is structured as follows. First, a description of the APT-MCMC
software is provided, including a brief user guide. Second, results of a standard series of
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optimization benchmark are presented. APT-MCMC is shown to converge to the optimal
parameter set and are shown to be comparable to a popular Python MCMC package, em-
cee. Finally, generalizable MCMC hyperparameters are explored and tested against these
optimization benchmarks; hyperparameter tuning heuristics are provided.
6.2.1 Methods
6.2.1.1 APT-MCMC Package
APT-MCMC (Affine-invariant ensemble of samplers with Parallel Tempering Markov Chain
Monte Carlo) began as a C++ implementation of MCMC merging PTempEst, a parallel
tempering MCMC algorithm with Boltzmann distribution acceptance in MATLAB, and em-
cee (http://dan.iel.fm/emcee/), a (parallel tempering optional) affine invariant ensemble
of samplers MCMC algorithm in Python [52, 117]. APT-MCMC initializes with nchains con-
current ensembles at temperatures arranged in a geometric progression. The geometric step
was taken from the source code of emcee [117]. Within each ensemble, nensemble samplers
simultaneously generate the next proposed parameter step according to the “stretch-move”
technique from Goodman and Weare [122]. In short, the stretch-move utilizes the location
of another parameter set within the same ensemble to determine a movement direction. The
proposed parameter is the result of a random movement along this direction and is deter-
mined by a step size hyperparameter. This value, z, allows movement between [1
z
, z] times
the distance between the two parameters. Proposed parameter acceptance is governed by
Equation (6.21). Samplers within each temperature ensemble are allowed to move indepen-
dently of other temperature ensembles for nsteps, after which, a parameter location swap is
attempted between another sampler in a higher temperature ensemble. The probability of
this swap is governed by Equation (6.22). Table 6.1 summarizes the nomenclature used in
this work.
Despite the impossibility of determining convergence in an MCMC simulation, APT-
MCMC computes two statistical tests to provide evidence for convergence: integrated auto-
correlation and the potential scale reduction factor (PSRF) of the simulation [115, 123]. The
PSRF is a value that compares the parameter distributions between and within ensembles.
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Table 6.1: Overview of the Markov Chain Monte Carlo nomenclature used.
Nomenclature Meaning
nsteps Hyperparameter Number of MCMC sampler steps to take before a parameter location
swap is attempted between tempered chains
nensemble Hyperparameter Size of MCMC ensemble of samplers within each tempered chain
nchains Hyperparameter Number of tempered chains to simultaneously explore the problem
Swap Length Hyperparameter Number of proposed parameter location swaps among tempered chains;
determines simulation length
τ Statistical Measure Integrated autocorrelation, measure the how well an MCMC
simulation explored the parameter space (lower is better)
PSRF Statistical Measure Potential scale reduction factor, a measurement of simulation variance
between tempered chains and within-chain ensembles (lower is better)
Values close to 1.0 are desired because this statistic provides evidence for convergence by
indicating that the inter- and intra-ensemble distributions are identical [123]. APT-MCMC
calculates the PSRF value using the Welford’s variance algorithm. Integrated autocorrela-
tion time, τ , measures the correlation of a signal at every possible time lag and is calculated
according to Equations (6.23)-(6.24), where θt refers to the state of the Markov Chain (a
parameter vector) at a point in time and M represents the length of the MCMC simulation.
A property of Markov Chains is that each state depends solely on the one before it. As a
result, a high autocorrelation indicates that the Markov Chain was correlated to multiple
previous states, suggesting that the simulation was stuck in a certain parameter region. In
contrast, a low autocorrelation indicates that the simulation sampled the parameter effi-
ciently and provides evidence that the simulation has reached the true distribution of the
system [115]. APT-MCMC uses Goodman’s Acor C code in order to calculate the integrated
autocorrelation value of the simulation [122].
C(t) =
1
M − t limt′→∞
[
θt+t′ − 〈θ〉
][
θt′ − 〈θ〉
]
(6.23)
τ = 1 + 2
∞∑
t=1
C(t)
C(0)
(6.24)
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A property of Markov Chains is that each state depends solely on the one before it. As a
result, a high autocorrelation indicates that the Markov Chain was correlated to multiple
previous states, suggesting that the simulation was stuck in a certain parameter region. In
contrast, a low autocorrelation indicates that the simulation sampled the parameter effi-
ciently and provides evidence that the simulation has reached the true distribution of the
system [115]. APT-MCMC uses Goodman’s Acor C code in order to calculate the integrated
autocorrelation value of the simulation [122].
ODE solving is handled by Sundials CVODE v2.6.2 [124]. Each temperature ensemble
can be run in parallel and is handled by OpenMP. It is recommended to have at least one
processor thread per temperature ensemble. The stretch-move step is nested-parallelizable
if additional threads are available (threads ≥ 2x number of temperature ensembles). Initial-
ization code to set the sequence of temperatures for a simulation was ported from Python
package emcee [117]. Random number generation is handled by TRNG, a package designed
for use with parallel Monte Carlo simulations [125]. TRNG provides a leapfrog technique,
which ensures statistically-independent pseudo-random number streams for each parallel
thread. Initial seeds for random number generators are provided by the current time plus
the thread number.
As depicted in Figure 6.3, the user is responsible for providing the parameters and their
prior distributions, the likelihood/objective function (the P (D|θ) portion from equation
6.18), fitting data, and MCMC options/hyperparameters to setup a simulation. This can be
performed in C++ or by using the Python auto-generator package tailored for ODE inverse
problems. APT-MCMC has been extensively tested on a Linux-64 platform, but it compiles
and runs under OSx with the appropriate developer tools and under Windows 10 x64 under
Cygwin and the Windows 10 Ubuntu Subsystem.
For user convenience, APT-MCMC comes with a Python 3 package to automatically
generate the necessary C++ files to run a simulation. Equation 6.25 shows the type of
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Figure 6.3: Schematic of generating an APT-MCMC simulations. Users need to specify their
parameter-fitting problem using Usermodel.cpp and set MCMC options in options.hpp. The Python
3 package can autogenerate these files by providing the ODE states and their equations, parameter
lower and upper bounds, and the dataset(s) for fitting.
problems that the package generates.
minimize
p
∑
t
[
log(Data(t))− log(X(t))]2 (6.25)
subject to X˙(t) = f(X, θ, t, u(t))
X(0) = X0
X represents states, p represents a parameter set, t represents time, u represents an input
(optional). This encompasses most parameter-fitting usage cases. The user defines the pa-
rameters, ODE equations, fitting data, and MCMC options within an “aptmodel” object.
Data handling is done by defining experiment(s), where each experiment represents a sep-
arate dataset to simultaneously fit. This Python object will then generate readable and
compilable C++ code. Advanced features such as implementation of ODE inputs, fitting
unknown initial conditions, and adjusting CVODE integration options are supported within
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the Python interface. Within the objective function, the sum of squared error term is cal-
culated after taking the natural log of the data and states to prevent numerical overflow.
This addresses magnitude differences between data and model states, but may be toggled
off within the Python code.
At runtime, APT-MCMC provides information on the status of each temperature ensem-
ble, current energies, as well as the location of the best parameter set found since starting the
run. Best parameter sets are identified to the θ that minimizes Equation (6.25). Once the
simulation is completed, all relevant simulation results and variables are saved in a binary
file with a “.mcmc” extension. Python and MATLAB code is provided to read this file into
a results object for post-processing and analysis.
6.2.1.2 APT-MCMC Performance Evaluation
To evaluate the performance of APT-MCMC, several optimization benchmark functions
were tested. They were selected from the list provided by Jamil, et al [126]. APT-MCMC was
tested for its ability to recover the optimal parameter set for each function and for its runtime
and memory usage. The functions tested were Ackley 1, Adjiman, Alpine 1, Bard, Beale,
Bird, Bohachevskey 3, Booth, Bukin 6, Corana, Damavandi, Devilliers-Glasser, Eggholder,
and Griewank (most functions are visualized in Figure 6.4). They were chosen to represent
a large variety of functional landscapes: basins, valleys, multiple optima, dimensionality,
and differentiability. Function equations may be found in Appendix B. Simulations were
performed for each benchmark function in order to test if APT-MCMC reaches the optimum
parameter set. All simulations were performed with the hyperparameter values noted in
Table 6.2. Parameter histograms for each benchmark are available in the Appendix B. A
bounded uniform prior was used to provide upper and lower bounds on the parameters
specified by each benchmark function. Simulation autocorrelation and PSRF was calculated
for each benchmark.
Speed and memory for the benchmarks were compared against the popular Python
MCMC package emcee, which also features an MCMC algorithm using parallel tempering and
sampler ensembles. However, several differences exist between the two packages. First, em-
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(a) Ackley 1 (b) Adjiman (c) Alpine 1
(d) Beale (e) Bird (f) Bohachevsky
(g) Booth (h) Bukin 6 (i) Davamandi
(j) Eggholder (k) Griewank
Figure 6.4: Visualizations for the benchmarks tested. Bard, Corana, Devilliers-Glasser are not
shown due to high parameter dimensionality.
cee attempts a temperature swap after every attempted stretch-move whereas APT-MCMC
will make a user-specified number of “stretch-moves” before attempting a swap. Second, the
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Table 6.2: Simulation settings for benchmark tests.
Hyperparameter Setting
nchains 4
nensemble 100
nsteps 25
Burn-In Phase 1000
Swap Length 104*
*: Devilliers Glasser swap length set to 106
“burn-in” phase in emcee is performed by running the MCMC simulation and initializing
at the last location. Within APT-MCMC, this is handled by sampling from the parameter
priors for a user-specified number of times and then initializing at the locations of the best
samples. To ensure comparable testing, benchmark simulations were repeated with different
settings from that of Table 6.2. nsteps was set to 1 in APT-MCMC to attempt a temperature
swap after every single stretch-move. “Burn-in”, while not entirely similar between the two
algorithms, was set to 1 in both emcee and APT-MCMC, which effectively initializes the
MCMC simulation with a single sample from the prior. Simulation settings were set to four
temperatures, eight processor threads, an ensemble size of 100, and a total swap length of
1e4.
At the end of the tests, this swap length was determined to be sufficient for both al-
gorithms to reach convergence for each benchmark. All of the aforementioned benchmarks
were tested in triplicate for each algorithm. All tests were performed on the same machine
with the following specifications: 2x Intel Xeon E5-2670 v3, 256GB DDR4 memory, and
Ubuntu 14.04. APT-MCMC and emcee memory benchmarks were performed by requesting
the resident memory usage from the Linux kernel via the readproc command.
The hyperparameters required by APT-MCMC were tested to provide heuristic guide-
lines. Specifically, APT-MCMC introduces certain hyperparameters that the user must set:
nensemble, nchains, step size, and nsteps. Each hyperparameter was tested over a range of values
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and each value was tested with 100 replicate simulations. For comparability, the random
number generator for each replicate simulation was seeded from a predetermined value for
each replicate. All other hyperparameters were kept equal according to Table 6.2 (unless
otherwise noted). To quantify the effects of each hyperparameter, two statistics were used:
simulation parameter percent error (or deviation if optimum parameter is 0) and maximum
parameter autocorrelation.
The ensemble size parameter was tested as a function of problem dimensionality. The
Ackley benchmark was chosen for its dimensional scalability. A 5, 10, 20, and 30 dimensional
problem was tested and ensemble size was set at 1x, 2x, 5x, 10x, and 20x the number of
parameters for each problem. In order to prevent ensemble sizes from biasing the number
of simulation samples, swap length was adjusted each time to ensure that a total of 600,000
samples were taken per simulation. The step size parameter controls how far the MCMC
samplers traverse the parameter space with each iteration. It was tested against a parameter
fitting benchmark, the Bard function. The parameter dictating the number of moves per
swap attempt controls the swap attempt frequency. This adjusts how long the lower tem-
perature simulation is able to search a parameter location of interest before it potentially
jumps to another optimum. This technique can greatly aid in highly multimodal problems
and therefore the 10 dimension Ackley and the Griewank benchmarks were tested. The
number of temperatures may be beneficial in highly multimodal problems due to the higher
temperature ensemble’s ability to identify optima. It was tested against the 10 dimension
Ackley and the Bukin benchmarks.
A −−→
kAB
B −−→
kBC
C
2A −−→
kAD
D
(6.26)
APT-MCMC was tested against a sample ODE fitting problem using the classic Van
de Vusse reaction scheme (see Equation 6.26). It was assumed that this reaction takes
place within an isothermal continuously stirred tank reactor and the feed is pure A with
the following properties: F
V
= 4/7min−1 and CAI = 10 mol/L. The resulting ODE system
is presented in Equation 6.27. Unsteady startup data for this system was generated for
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states A(t), B(t), C(t), and D(t) at 0.5 minute increments from 0 to 10 minutes and subject
to a sampling noise of N (µ = 0, σ2 = 0.1). APT-MCMC fit the three kinetic parameters
kAB, kBC , kAD to concentration data of species. Simulation settings were set the those in
Table 6.2 with the exception of swap length set at 103. Each parameter was bounded within
[0, 10].
dCA(t)
dt
=
F
V
(CAI − CA(t))− kABCA(t)− kADCA(t)2
dCB(t)
dt
= −F
V
CB(t)− kBCCB(t) + kABCA(t)
dCC(t)
dt
= −F
V
CC(t) + kBCCB(t)
dCD(t)
dt
= −F
V
CD(t) +
1
2
kADCA(t)
2
kAB = 0.833, kBC = 1.667, kAD = 0.167
(6.27)
APT-MCMC also tested a bioreactor system describing glucose to ethanol fermentation
by Saccharomyces cerevisiae in a batch tank reactor [127]. The equations describing this reac-
tor are shown in Equation 6.28. The goal was to fit six parameters: µmax, KS, kd, YS/C ,m, YP/C
against time-series data for each state, CC(t) (yeast concentration), CS(t) (glucose concentra-
tion), CP (T ) (ethanol concentration), at 0.5 hour increments up to 14 hours. Noise sampled
from N (µ = 0, σ2 = 2) was added to the data. The initial yeast, glucose, and product
concentrations were set to 1.0 g/dm3, 250 g/dm3, and 0.0 g/dm3. Each parameter prior was
set to a bounded uniform prior about [0, 20] to test APT-MCMC’s ability to recover the
parameters given a large uninformative prior.
131
rg(t) = µmax
(
1− CP (t)
C∗P
)0.52
CC(t)CS(t)
KS + CS(t)
dCC(t)
dt
= rg − kdCC(t)
dCS(t)
dt
= −YS/Crg −mCS(t)
dCP (t)
dt
= YP/Crg
µmax = 0.33h
−1, KS = 10.7g/dm3, kd = 0.01h−1,
YS/C = 12.5g/g,m = 0.03g/(g cells h), YP/C = 0.45g/g, C
∗
P = 93g/dm
3
(6.28)
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6.2.2 Results
6.2.2.1 Benchmarks
Table 6.3: Overview of APT-MCMC Performance on several benchmark functions.
Benchmark τ PSRF Param 1 Param 2 Param 3 Param 4 Param 5
Ackley 1.16 1.00 5.58∗10−3 (0) -1.53 ∗10−2 (0) 9.78 ∗10−1 (0)
Adjiman 1.85 1.03 2.00 (2) 9.60∗10−2 (0.106)
Alpine 2.34 1.00 6.80∗10−2 (0) 0.143 (0) 3.19∗10−2 (0) 1.52∗10−2 (0) 2.67∗10−2 (0)
Bard 1.85 1.20 8.11∗10−2 (8.24∗10−2) 1.09 (1.13) 2.38 (2.34)
Beale 1.95 1.06 3.00 (3) 0.500 (0.5)
Bird 4.05 1.02 -1.58 (-1.58) -3.13 (-3.13)
Bohachevsky 1.18 1.00 1.86∗10−3 (0) 1.33∗10−3 (0)
Booth 1.85 1.02 1.00 (1) 3.00 (3)
Bukin 1.85 1.05 -10.56 (-10) 0.753(1)
Corana 1.93 1.00 3.86 ∗10−2 (0) 8.42∗10−3 (0) 3.29∗10−2 (0) 4.76∗10−2 (0)
Damavandi 1.85 1.00 2.00 (2) 2.00 (2)
Devilliers 1.95 1.18 53.9 (53.81) 1.27 (1.27) 2.95 (3.01) 65.0 (2.13) .507 (.507)
Eggholder 1.85 1.35 512 (512) 404 (404.23)
Griewank 1.10 1.00 -4.05∗10−2 (0) 3.58∗10−2 (0)
Benchmark functions are provided in Appendix B. For each benchmark, the integrated autocorrelation
time(τ), potential scale reduction factor (PSRF), the best parameter set, and the true optimum in parenthesis
are reported. Each simulation was performed using the hyperparameters in Table 6.2.
Table 6.3 shows the maximum likelihood parameter for each benchmark function. The
swap length of simulations were arbitrarily chosen to be 10,000; however, the low values of
the autocorrelation and PSRF statistics in Table 6.3 support that simulations converged over
this run length. APT-MCMC returned accurate parameter estimates for most benchmarks.
For example, the Damavandi benchmark contains a very large local minimum well near
(7, 7)(Figure 6.4i), but APT-MCMC was able to locate the global minimum at (2, 2). The
Bukin benchmark (Figure 6.4h) contains a sharp ridge with multiple minima and APT-
MCMC was able to get close to this point.
The notable exception is with the DeVilliers-Glasser function, represented in equation
6.29. This benchmark is a sum of squares parameter fitting problem and, despite not being
previously reported, appears to contain multiple global minima. The highly multimodal
histogram (see Appendix B) for parameter x4 and the bimodality of x1 suggest that this
problem has multiple solutions. The hyperbolic tangent is an odd function and its sym-
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metricity explains the bimodal distribution at x1 ±54. The cyclical nature of sin(x) explains
the multimodal nature of x4.
24∑
i=1
[
x1x
ti
2 tanh[x3ti + sin(x4ti)] cos(tie
x5)− yi
]
ti = 0.1(i− 1)
yi = (53.81)(1.27
ti) tanh[3.012ti + sin(2.13ti)] cos(tie
0.507)
xi ∈ [−500, 500] i = 1, 2, ..., 5
(6.29)
The head-to-head comparison tests between APT-MCMC and emcee is summarized in
Table 6.4. For each benchmark tested, APT-MCMC was many times faster than the Python
counterpart. This speed came at the cost of using 14% more memory during simulations. The
reported times for APT-MCMC do not include generation time (time required for Python
to generate C++ code) nor do they include C++ compilation time, but the inclusion of
those times (roughly an extra 5-7 seconds) will not significantly change Table 6.4. These
results are expected due to Python overhead as an interpreted language. While useful for
prototyping, the slower execution speed is less desirable MCMC simulations. As a result,
APT-MCMC may lack some of the flexibility of emcee but succeeds in being the faster tool
at runtime. Lastly, the symmetric mean absolute percentage error was computed for each
benchmark simulation instead of percentage error to deal with division by zero issues. The
error calculations demonstrate that APT-MCMC is able to achieve similar a computational
performance with emcee.
6.2.2.2 Hyperparameters
The nensemble hyperparameter dictates how many simultaneous samplers exist for each
temperature ensemble. These samplers utilize each other‘s locations to generate search di-
rections for the next state. Test results for nensemble are shown in Figure 6.5. Autocorrelation
increases with problem dimensionality due to the increasing amounts of local minima that
are introduced. Parameter error was unaffected by ensemble size. In general, the higher
the ensemble sizes (as a function of problem dimensionality) resulted in lower integrated
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Table 6.4: Comparison of computing resources used by APT-MCMC and Python package emcee.
emcee APT-MCMC
Benchmark Time (s) Memory (MiB) Error Time (s) Memory (MiB) Error
Ackley 118 189 9.63 ∗ 10−01 2 193 9.63 ∗ 10−01
Adjiman 125 159 9.73 ∗ 10−03 2 194 9.50 ∗ 10−03
Alpine 110 251 9.63 ∗ 10−01 3 255 9.63 ∗ 10−01
Bard 118 190 7.05 ∗ 10−01 2 193 1.86 ∗ 10−02
Beale 128 160 2.58 ∗ 10−04 2 193 5.34 ∗ 10−04
Bird 124 157 1.14 ∗ 10−05 2 193 6.67 ∗ 10−01
Bohach 116 158 9.63 ∗ 10−01 2 193 9.63 ∗ 10−01
Booth 116 158 2.06 ∗ 10−04 2 193 1.98 ∗ 10−04
Bukin 115 158 4.89 ∗ 10−01 2 193 1.01 ∗ 10−01
Corana 118 220 9.63 ∗ 10−01 3 255 9.63 ∗ 10−01
Damavandi 116 157 5.35 ∗ 10−01 2 193 2.86 ∗ 10−04
deVilliersGlasser 187 252 8.90 ∗ 10−01 9 255 2.88 ∗ 10−01
Eggholder 114 157 6.48 ∗ 10−06 2 193 1.40 ∗ 10−04
Griewank 116 158 9.63 ∗ 10−01 2 193 9.63 ∗ 10−01
Average 123 180 5.32 ∗ 10−01 2 206 4.21 ∗ 10−01
Results shown are averaged from n = 3 test simulations. Memory was the physical resident memory in
mebibytes, as reported by the Linux kernel. Each benchmark function simulation was set according to the
hyperparameters in Table 6.2 with the exception of nsteps = 1 (for comparability between APT-MCMC
and emcee). Burn-in for both algorithms were set to 1 iteration. APT-MCMC was faster and used less
memory for each case. The error columns represent the calculated symmetric mean absolute percentage
error averaged over all parameters and across replicates.
autocorrelation values. Larger ensemble sizes reduced autocorrelation while utilizing the
same amount of computational resources (simulation times were similar among each prob-
lem dimensionality). The reduced autocorrelation is because larger ensembles offer more
varied and robust search directions. For smaller problems such as the 5 parameter case,
there were no distinguishable effects due to the ease of convergence. For large problems,
preference should be given towards increasing ensemble size rather than swap length. As
a reference, the source code behind emcee enforces the minimum ensemble size at 2x the
problem parameter dimensionality [117].
The nchains hyperparameter in a simulation helps the system explore highly modal pa-
rameter spaces by running many tempered simulations simultaneously. Samplers in high-
temperature ensembles can locate alternative energetically favorable regions (potential lo-
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Figure 6.5: 100 repeated simulations were used to test the effects of the nensemble hyperparameter
by using the dimension-scalable Ackley benchmark function. The value of nensemble was set as a
function of the dimensionality of the Ackley function and denoted by #x nPar (multiplier x # of
parameters). Mean ± SEM of best parameter error and integrated autocorrelation shown. Raw
parameter error is reported because the optimum parameters are located at 0. Problems benefit
from larger ensemble sizes, but this comes at the cost of increased computation time.
cations of local minima) with higher probabilities and pass this information to the lower
temperature samplers for minima identification. Figure 6.6a shows the results of the Bukin
benchmark. There were diminishing decreases of autocorrelation at a higher number of
chains, which indicate that this benchmark function had local minima that were relatively
easy to escape from. In contrast, Figure 6.6b shows the results for the 10-dimension Ackley
benchmark and demonstrates a linear relationship between autocorrelation and the number
of chains. The 10-dimension Ackley benchmark contains more local minima than the Bukin
benchmark and benefits more from the additional chains. nchains cannot be set lower than
2 because parameter swapping would not be possible with a single temperature Markov
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(a) 2-dimension Bukin benchmark function (b) 10-dimension Ackley benchmark function
Figure 6.6: 100 repeated simulations were used to test the effects of the nchains hyperparameter by
using benchmark functions Bukin and Ackley. Mean ± SEM of integrated autocorrelation shown
and parameter error shown. Additional temperature ensembles decreased simulation autocorrela-
tion, although there were diminishing returns after 4. A higher number of temperatures results
in improved parameter mixing and simulation efficiency. There was no significant effect on the
accuracy of the maximum likelihood parameter vector.
Chain. Increasing nchains increases the magnitude of the temperature sequence and higher
magnitudes benefit from the aforementioned favorable region exchange. This information
exchange leads to a faster exploration of the parameter space and therefore lower autocorre-
lation values. While the number of tempered chains increases computational cost, they can
in parallel and scale well via OpenMP. As a result, this hyperparameter can be set to equal
the number of CPU threads available on the machine running the simulation. APT-MCMC
is able to utilize up to the number of detected CPU threads (logical cores) on the machine it
runs on. OpenMP synchronization locks in the APT-MCMC OpenMP code ensure that all
chain movements are completed prior to a swap attempt. Setting nchains to a value that ex-
ceeds the number of CPU threads will greatly increase simulation time because some threads
have to calculate multiple tempered chains while others are forced to idle. Computational
resources are better spent on longer simulations with an nchains equivalent to the number of
cores. It is recommended to set nchains to as many available CPU cores as possible because
simulation efficiency improves and parallelization offsets any computational trade-offs.
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(a) 2-dimension Griewank benchmark function (b) 10-dimension Ackley benchmark function
Figure 6.7: 100 repeated simulations were used to test the effects of the nsteps hyperparameter by
using benchmark functions. Mean ± SEM of best parameter error and integrated autocorrelation
shown and parameter error shown. Increasing the steps per swap decreased maximum autocorre-
lation but increased the simulation time. Parameter error decreased only in the Griewank case.
The nsteps hyperparameter describe how much a sampler ensemble explores a local region
of the parameter space before it is potentially swapped to a different parameter location.
The effect of this hyperparameter is shown in Figure 6.7a for the Griewank benchmark. Both
autocorrelation and parameter error decreases with increasing nsteps. In contrast, simulation
time increased. Figure 6.7b shows the results for the 10-dimension Ackley function, which
demonstrate similar trends. Larger nsteps allow for the ensemble of samplers to explore a
region of interest for longer before they are potentially transferred to a different region. Very
small values may prevent the samplers from exploring optima sufficiently. As nsteps became
larger, autocorrelation was unaffected, but simulation time increased. For both benchmark
functions, there were diminishing returns in autocorrelation decreases compared to the in-
creases in simulation time. Values within 20-30 offered trade-offs between autocorrelation,
simulation time, and parameter accuracy.
The step size hyperparameter determines how far a proposed parameter can move in
accordance with the stretch-move scheme. Small step sizes prevent proper parameter space
exploration. High step sizes allow potential movements farther away from the rest of the en-
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Figure 6.8: 100 repeated simulations were used to test the effects of the step size hyperparameter by
using the 2-dimension Bard benchmark function. Mean ± SEM of best parameter percent error and
integrated autocorrelation shown. The minimum autocorrelation was achieved at a clear optimum
at 2.5-3. There was no effect on the accuracy of the maximum likelihood parameter vector.
semble samplers. Figure 6.8 shows the results for the Bard benchmark. The suggested value
for this hyperparameter is between 2-3 where there is a clear minimum in autocorrelation.
As a reference, Goodman and Weare suggested a value of 2 for this hyperparameter [122].
6.2.2.3 Van de Vusse Reaction Scheme
Figure 6.9 illustrates the Bayesian posterior results from an ODE parameter fitting prob-
lem involving the Van de Vusse reaction scheme. Parameter histograms are shown along with
a fitted kernel density estimation. The peaks of each parameter’s probability density corre-
spond with the true parameters used to generate the data for the Van de Vusse reactions.
Furthermore, the best parameter vector from the simulation (associated with the highest
likelihood) demonstrated 1%-3% difference from the true parameter vector. The fit from the
best parameter set is shown in Figure 6.10.
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Figure 6.9: Parameter histogram from simulation to fit 3 parameters to Van de Vusse reaction
data. The vertical line in each subplot represents the true parameter values used to generate the
data. The smooth line in each subplot is a kernel density estimation of the histogram.
Figure 6.10: Data and best parameter fit for the Van de Vusse reaction scheme system. Simulated
state data (with noise) are shown as dots in either graph. Concentration trajectories from the best
parameter fit are shown as lines for each state.
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Figure 6.11: Parameter histogram from simulation to fit 6 parameters in a batch bioreactor. The
vertical line in each subplot represents the true parameter values used to generate the data. The
smooth line in each subplot is a kernel density estimation of the histogram.
Figure 6.12: Data and best parameter fit for the bioreactor system. Simulated state data (with
noise) are shown as dots in either graph. Concentration trajectories from the best parameter fit
are shown as lines for each state.
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6.2.2.4 Bioreactor
Figure 6.11 illustrates the Bayesian posterior results from the ODE fitting of a bioreac-
tor. Histogram peaks for most of the parameters matched the true values. The histogram
peaks for the YS/C and YP/C were under-predicted. This was likely due to the difficulty the
algorithm had in fitting KS, a Michaelis-Menten half-max concentration term, as indicated
by the high variance within the KS distribution. As a result, the biomass growth term, rg,
differed from the true growth rate and the two yield parameters were used to compensate.
Michaelis-Menten half-maximum constants are difficult to fit without carefully characterized
reaction rate data that are often experimentally challenging to collect. If such data were
available, the parameter estimates would be significantly improved based on the tightening
of the bounds on the KS parameter. Regardless, this example highlights a major benefit of
APT-MCMC. Compared with traditional nonlinear least squares fitting algorithms such as
the trust region reflective or Levenburg-Marquardt, APT-MCMC does not require a good
set of initial conditions to achieve a promising model fit; instead, the use of broad parameter
bounds is sufficient to estimate parameter values and distributions, which is especially useful
when some parameters may prove difficult to identify from the available data. The fit from
the best parameter set is shown in Figure 6.12.
6.2.2.5 Limitations
One current limitation is associated with the Python auto-generation package. It assumes
uniform priors on all parameters and a sum of squared error likelihood function. However,
the C++ code can be easily modified to overcome these limitations. Should the user require
additional features for advanced fitting procedures, the user can auto-generate the files with
Python and then modify the appropriate C++ functions to their needs. Any problem that
can be posed as a maximum likelihood can be programmed into APT-MCMC, but C++
programming of Usermodel.cpp is required.
Another limitation is the lack of a termination criterion, which is inherent to MCMC
techniques. While APT-MCMC seeks to alleviate this issue by calculating the autocorrela-
tion and PSRF values, MCMC statistics are necessary but not sufficient tests of convergence.
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Practically, the user should set the simulation to a very long swap length. While the sim-
ulation proceeds, the user should analyze the partial APT-MCMC results as they become
available and make a stopping decision based on the statistical tests and in determining if
the distributions of the parameter posterior histograms are still changing. MCMC simula-
tions may also get stuck in a meta-stable convergence state (which is not testable either),
but a popular solution is to run multiple MCMC simulations from distinct initial conditions
[115]. The second simulation can be run with tighter bounds on each parameter based on the
posteriors from the first simulation and one can verify if simulations converge in the same
parameter location.
6.2.3 Summary
APT-MCMC is presented as a fast MCMC platform tailored for use in solving parameter-
fitting problems. User-convenience was prioritized during the creation of APT-MCMC. Tra-
ditionally, MCMC packages are provided in either easy-to-prototype, but slow, or difficult-
to-learn, but fast, languages. The Python auto-generation package serves to provide users
with an easy way to prototype and set up simulations while retaining the speed associated
with a compiled and static language (C++). Additionally, MCMC hyperparameters are
provided based on tests using common optimization benchmarks. APT-MCMC is ready for
use and exists as an open source project on GitLab.
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7.0 SUMMARY AND FUTURE WORK
The focus of this dissertation was the identification of sepsis endotypes. To achieve this, a
variety of mathematical models from were developed to provide insight into the time course
and the mechanisms of the syndrome. Hierarchical clustering revealed the existence of several
distinct clusters primarily described by the level of cytokinemia (high, medium, low) and clin-
ical features pertaining to the sequential organ failure assessment score. Membership within
these clusters was confounded by the issue of variable pre-hospital time: sepsis patients arrive
in the clinic at variable times along their inflammatory trajectory. In response, a systems
analysis approach was developed to simultaneously model each subject (along with their
pre-hospital times) and cluster the responses. This method revealed five sepsis endotypes
with distinct behaviors of the pro- and anti-inflammatory response to infection. Endotypes
are the different manifestations of disease due to mechanistic differences between patients.
These five endotypes were explored with applied statistics, machine learning techniques, and
ODE mathematical models. Applied statistics revealed that the traditional “baseline” ap-
proach (defined by when the subject arrives in the clinic) cannot segregate patients with
different endotypes. Machine learning techniques, trained on six hours of temporal clini-
cal features, also demonstrated difficulty in segregating endotypes. A mathematical ODE
model revealed that macrophage cell death and cytokine degradation may contribute to the
underlying pathomechanistic differences between endotypes.
In conjunction with the endotyping work, other mathematical models were explored
to tackle other clinical challenges in sepsis: specifically, unknown pre-hospital time and
unknown systemic damage for a septic subject. Knowledge of these two features can improve
clinical decision-making, as well as improve the aforementioned mechanistic model. First, a
nearest-neighbor model was constructed. Three sets of animal data and one set of human
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trauma data demonstrated the feasibility of applying a clinical tool to estimate pre-hospital
time. Second, an ensemble of regularized logistic regression models that were trained on
baboon sepsis data yielded an exploratory approach to quantify the systemic inflammatory
damage suffered during sepsis as a function of time.
Finally, to support this body of work, two mathematical tools were created. In exploring
age-related immune pathway differences between old and young mice, a tool was created that
automatically parses a list of potential immune pathways, formulates a mixed integer linear
programming problem, and solves it via Pyomo and CPLEX. APT-MCMC was born out of
the need for a faster MCMC ODE parameter-fitting algorithm during the development and
calibration of the aforementioned mathematical ODE model of sepsis.
7.1 CONTRIBUTIONS
7.1.1 Endotype Identification and Prediction in the Clinic
The hierarchical heatmap clustering approach in Chapter 2 revealed that cytokinemia and
organ dysfunction biomarkers in the ProCESS data contribute to differing 14-day all-cause
mortality and multiple organ failure rates. Heatmaps provided a way to aggregate and
visualize all of the factors a clinician takes into account when developing treatment plans
for septic subjects. The distinctive patterns among clusters paved the way towards a novel
clustering approach that (i) accounted for individual patient pre-hospital times, (ii) modeled
patients using a mathematical model of the inflammatory response, (iii) recovered patient
cluster dynamics from censored trajectories (Chapter 3). The result was five endotypes, each
with their own characteristic master inflammatory-responses model.
The endotypes encompassed a variety of responses: overwhelming inflammation in en-
dotype 1, sustained anti-inflammation in endotype 2, immunosuppression in endotype 3,
sustained inflammation in endotype 4, and immunodeficiency in endotype 5 (refer to sum-
mary Table 3.2). The difference in response behaviors of these endotypes suggests that
certain immuno-modulatory therapies may be inappropriate for certain endotypes (for ex-
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ample, anti-inflammatory therapy is not suitable for an immunosuppressed subject). This
insight may explain why many sepsis clinical trials fail to demonstrate positive mortality
benefits. While some groups of subjects may have benefited from a certain therapy, others
may have been adversely affected.
7.1.2 Mechanistic Ordinary Differential Equation Model of Sepsis
The proposed ODE model in Chapter 4 is among the first models of sepsis to be calibrated
on human sepsis data. The model captures many of the complex interactions between white
blood cells (neutrophils and monocytes), cytokines, and pathogens. The model, combined
with the estimated pre-hospital times from Chapter 3, demonstrated an ability to fit many
of the ProCESS patients well. White blood cell recruitment drew from marginal sources first
during the first days of infection. After 4-5 days, immature white blood cell recruitment from
the bone marrow occurred to replenish depleting marginal reserves. TNF was able to trigger
monocyte recruitment into the tissue. Resident macrophages and the recruited monocytes
(now macrophages) were able to sustain production of cytokines to emulate the cytokine
storm. The model demonstrated an ability to capture the fast changes (both rise and fall
within 6 hours) of both cytokines and white blood cell data. A population-level analysis
of parameters revealed that macrophage death dynamics were important contributors to
endotype-specific behavior. Furthermore, within some endotypes, cytokines seemed to have
prolonged lifespans in the blood. Macrophage death dynamics and cytokine lifespans may
begin to explain the causes of cytokinemia and may provide suitable pharmaceutical targets
for future sepsis therapy.
7.1.3 Quantifying Pre-hospital Time and Systemic Damage
Chapter 5 describes two mathematical models to tackle other challenges that clinicians face
with sepsis patients. A statistical model, based on nearest-neighbors, was introduced to
address the issue of variable, unknown pre-hospital times in septic subjects. This approach
was developed independently from the transfer function model in Chapter 3 to serve as a
stand-alone method that precluded the need for serial cytokine measurements over a 72 hour
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period. One-nearest-neighbors achieved high accuracy in estimating pre-hospital times in
one baboon model of sepsis and two porcine models of sepsis. The measurement burden was
demonstrably low: using temporal vital signs and a single, blood-based, point measurement
was sufficient to achieve an accuracy between 70−95%, depending on the length of temporal
data. Furthermore, this method worked well on human trauma data. Ambulatory and
emergency room measurements of vital signs and organ-health biomarkers yielded up to
82% accuracy in estimating the original time of trauma. The translatability of this method,
low measurement burden and temporal density requirements, and high accuracy properties of
the nearest-neighbors approach indicate a promising way to provide clinicians with valuable
pre-hospital/infection onset information about their sepsis patients.
The second statistical model related the risks of early mortality with important clinical
features using an unbiased, feature selection algorithm. Time-varying odds ratios of mortality
were calculated using ensembles of elastic-net logistic regression models. Elastic-net offered
improved feature selection over traditional methods (ridge or lasso) and identified several key
clinical features, such as lactate, glucose, hemoglobin, and platelet count, that contribute
towards early sepsis deaths with varying odds ratios. Systemic organ damage, as a function
of time, were calculated from odds ratios and revealed clear mortality separation within
the first 12 hours of infection. Nonsurviving subjects demonstrated increasing-only damage
trajectories, indicating that large amounts of early sepsis-induced organ damage may lead
to a mortality bifurcation. Surviving subjects demonstrated one or more organ systems that
were able to recover, indicating that early organ support may be a key factor in shifting
sepsis patients towards better outcomes. Although the method required measurements of
high temporal density, it was designed using a set of easy-to-measure biomarkers to reduce
the overall measurement burden and is ready for translation with a suitable human dataset.
7.1.4 Efficient MCMC Sampling Software for Parameter-Fitting
Chapter 6 introduced APT-MCMC, a software that can perform MCMC sampling faster
than its Python counterpart without sacrificing user-friendliness. APT-MCMC was tailored
for parameter-fitting problems and integrated MCMC techniques that improved the search
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process. Parameter landscapes for inverse problems, especially for complex models such
as the one introduced in Chapter 4, are highly multi-modal and anisotropic. APT-MCMC
solved benchmark functions with a variety of properties: basins, valleys, non-differentiability,
and multiple global optima. APT-MCMC addresses these issues by design and offers the
usability of Python to automate the task of designing simulations in C++. The utility
of APT-MCMC extends beyond fast and effective simulations: convergence statistics are
automatically provided at the end of simulations and visualization software is provided in
the Python package to aid in the post-hoc analysis of posterior distributions. APT-MCMC
is open-source to benefit the community and can be an important utility in a modeler’s
toolbox.
7.2 FUTURE WORK
7.2.1 Predicting Organ Failure
The endophenotypes identified within heatmaps can be improved by adding clinical outcomes
to the heatmap; a breakdown of organ failures for each main organ system (liver, coagulation,
respiratory, nervous, renal, and cardiovascular) will provide correlations between the health
states of specific organ systems and baseline clinical features such as lactate or cytokinemia.
Such visualizations may reveal facets in the ProCESS data that can be used to develop
statistical models to identify patients at risk of certain organ failures. A potential clinical
tool that can be derived from this work is a hazards model. Gray’s hazard model has been
demonstrated to effectively model the time-varying covariates of sepsis mortality [62, 128].
Another application of this model is to use patient comorbidities and time-varying clinical
features to reveal the contributing factors to sepsis-related organ failure.
7.2.2 Early Endotype Classifier
The next step in the mixture-model endotype work is to transition to impulse-response
transfer function models that decay to zero, which is a better biological representation of
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the inflammatory response. Preliminary work, described in Chapter 3.3.1, demonstrated
that this step is a difficult one since the mixture-models collapsed into one single cluster.
Additional exploration is warranted to refine this approach. If this step is successful, the
machine learning classification tool should be updated to reflect the new endotypes. Finally,
the ProCESS data should be further evaluated for new endotype-predictors to improve the
accuracy of this classification tool.
7.2.3 Improving Neutrophil Dynamics with Damage
The mechanistic ODE model lacked several key neutrophil dynamics that were ignored due
to the ProCESS data granularity. Once a suitable damage model has been developed (see
Chapter 5.2), a damage state can be added to the model and fitted against the calculated
time-varying damage values. Neutrophils would be the main contributor to this state. Bio-
logically, neutrophils are misdirected during the cytokine storm phase of sepsis and recruited
into healthy organs, where they cause damage to healthy tissue [9, 91]. This dynamic may
be characterized by:
fNrecruitment = Vn8Nc
IL8T
Kn8 + IL8T
(7.1)
dNT
dt
= ...+
(
IL8B
Kdirected + IL8B
)
fNrecruitment (7.2)
dNmisdirected
dt
=
(
1− IL8B
Kdirected + IL8B
)
fNrecruitment − µntNmisdirected (7.3)
(7.4)
where fNrecruitment represents the total IL-8 directed neutrophil recruitment into tissue. A
percentage of these neutrophils, dictated by a Michaelis-Menten kinetic, are appropriately re-
cruited into the site of infected tissue (Equation (7.2)) and the rest are misdirected (Equation
(7.3)). Furthermore, the current ODE model uses neutrophil apoptosis to drive the anti-
inflammatory state but does not model neutrophil necrosis, which also increases damage. A
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proposed formulation is:
fdeath = µntNT
(
1− TNFT
Ktn + TNFT
)
(7.5)
dIL10T
dt
= ...+
Macro
Km10 +Macro
fdeath (7.6)
dDamage
dt
= ...+ (1− Macro
Km10 +Macro
)fdeath (7.7)
where Equation (7.5) represents fdeath, the death rate of Tissue compartment neutrophils.
fdeath may be split into anti-inflammatory apoptosis (given the presence of nearby macrophages,
Equation (7.6)) or damage-inducing necrosis (Equation (7.7)). Finally, the proposed damage
compartment may be structured as follows:
dDamage
dt
= VDN (Nmisdirect + µntNmisdirected) + (1−
Macro
Km10 +Macro
)fdeath − µdDamage
(7.8)
where a systemic damage state is increased by the presence of misdirected neutrophils (dam-
aging healthy tissue), the eventual necrosis of misdirected neutrophils, and the necrosis of
properly directed neutrophils (term from Equation (7.7)). Damage heals itself at a rate µd,
which is an optimistic scenario given the notion of cascading systemic failures. This damage
state would then be used to increase the production of pro-inflammatory cytokines TNF,
IL-6 and IL-8.
7.2.4 Estimator of Pre-hospital Time
Pre-hospital estimation accuracy can be further via a deeper exploration of the human
trauma GLUE grant data. After demonstrating the translatability of the nearest-neighbor
approach on human data, the next step would be to test the algorithm on nosocomial (in-
hospital infection) sepsis data. If the technique is successful, it can be applied in the clinic
almost immediately.
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7.2.5 Optimization of Therapy and Damage
The addition of damage to the mechanistic ODE model enables personalized treatment
optimization. Thang Ho’s dissertation described a numerical optimization-based approach to
formulate chemotherapy treatments that minimize cancerous tumor growth without reaching
dangerously low levels of white blood cells [129]. A reduced ODE model highlighting damage,
neutrophil, and pathogen interactions would be a suitable candidate for an optimization
approach. Supposing a subject has been monitored sufficiently to parameterize the ODE
model, the following problem may be posed:
minimize
x
∑
t
fpathogen(x, θ, t) + fIL6(x, θ, tend) (7.9)
subject to
dfi(x, θ, t)
dt
= RHSi(x, θ, t), i = Model States, ∀t ∈ [tbegin, tend] (7.10)
fdamage(x, θ, t) ≤ 10 ,∀t ∈ [tbegin, tend] (7.11)
where x represents a combination of immunomodulatory drugs and/or antibiotics, θ repre-
sents the ODE model parameters, fi(x, θ, t) represents the model states, and fdamage(x, θ, t)
is constrained to never go above 10, which was a damage threshold discovered in Chapter
5.2 that set subjects on a non-surviving trajectory. Neutrophils and antibiotics both have
deleterious effects on the body and the effect is quantified into fdamage(x, θ, t). The goal
of this optimization is to enable the elimination of pathogen without allowing the inflam-
matory collateral damage to exceed a threshold. Finally, the second term in the objective
function penalizes nonzero values of the inflammatory mediator IL-6 to prevent a sustained
inflammatory state at the end of the simulation.
Within the ProCESS data, the majority of subjects did not survive the year after sepsis.
This may be attributed to complications downstream of sepsis, which indicate that even
after patients survive the initial onset of sepsis (survive the first 14 days), they are still in
danger. Optimized personalized treatment has the potential to reduce mortality rates in
sepsis in both the short and long term.
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7.2.6 Updates to APT-MCMC
APT-MCMC will be semi-actively maintained. Major bugs will be addressed, but active
development will cease for the time being. APT-MCMC will be open-source to encourage
community forks for the purposes of code peer-review and feature additions.
A short-term feature is planned to modify the Python package of APT-MCMC to facil-
itate the easy use of non-uniform priors. In its current form, the Python package assumes
bounded uniform distributions. Many priors are currently supported, but require the user to
make the appropriate changes in C++ code. The selection of priors can affect the posterior
distributions and may be dependent on the type of data used (such as population-level versus
individual data or the density of data available) [130].
A long-term feature upgrade is eventually planned to explore the option of using Hamiltonian-
MCMC techniques [115]. Intuitively, a Hamiltonian sampler views a parameter landscape
as a ball on a hill and may “accelerate” down a hill towards the bottom. Mathematically,
the sampler calculates a Jacobian at its current location and moves toward the optimal
objective function direction with momentum. This type of movement may or may not be
accomplished with an affine ensemble of samplers. Jacobian calculations are computationally
expensive and Broyden’s method may be occasionally used to alleviate the computational
requirements. Such a sampling technique involves directed search rather than random walks
and can greatly reduce the autocorrelation and improve simulation efficiency.
7.3 IMPROVING SEPSIS CLINICAL OUTCOMES WITH
MATHEMATICAL MODELS
The disconnect between animal and human sepsis clinical trials may be attributed to three
aspects. First, the level of variability within humans is great while animal clinical trials are
controlled to remove variability. Second, therapy timing is currently impossible for humans
while in animals, therapies are tested at exact times relative to the onset of sepsis. Third,
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experimental controls for animal trials ensure consistent levels of sepsis-related damage while
there is currently no way to assess this level of damage in humans.
The work presented in this dissertation uses a variety of mathematical models to address
all three of these aspects. While the applicability of these models to the clinic is in the
nascent stages, such models may improve the translatability of sepsis research from animal
models to clinical trials.
The long-term extension of this dissertation is to generate a single, bedside tool that takes
a series of clinical measurements and cytokines over a small time frame and provides the
clinician with a subject’s endotype, pre-hospital time/how long they have been septic for, and
current level of systemic damage. Armed with this panel of information, a clinician can design
and tailor a treatment unique to this subject. Furthermore, access to this information will
enable new types of sepsis therapies such an endotype-specific treatments, timing-dependent
therapies, and providing early organ support. The existence of such a decision support
system rejects the status quo of a “one-size-fits-all” approach to sepsis and may usher in a
new paradigm of personalized medicine and improved clinical outcomes in sepsis.
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APPENDIX A
DETAILED RESULTS FOR NEAREST-NEIGHBOR PRE-HOSPITAL TIME
ESTIMATION TOOL
This section contains additional results from the analysis involved with the nearest-neighbor-
based estimation tool for subject pre-hospital times.
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Table A1: Time-of-infection estimation accuracy over varying right censor values (temporal dura-
tions) for all biomarkers tested.
Baboon Accuracy Pig Peritonitis Accuracy Pig LPS Accuracy
Biomarker R 1 R 2 R 3 R 4 Mean R 1 R 2 R 3 Mean R 1 R 2 R 3 Mean
WBC 51.8% 67.0% 83.0% 93.1% 73.7% 60.7% 58.6% 76.8% 65.4% 46.5% 64.4% 73.4% 61.4%
HR 42.1% 58.2% 74.6% 84.8% 65.0% 64.6% 83.8% 87.0% 78.5% 47.2% 61.0% 69.1% 59.1%
HCO3A 48.5% 56.2% 67.8% 75.3% 62.0% - - - - - - - -
SVR 32.7% 59.3% 72.0% 79.7% 60.9% 50.0% 57.4% 63.0% 56.8% 50.7% 63.6% 66.0% 60.1%
HB 34.8% 58.2% 70.8% 79.2% 60.8% 53.6% 67.1% 83.9% 68.2% 52.8% 73.7% 84.0% 70.2%
CO 33.6% 54.5% 68.9% 84.8% 60.5% 46.3% 51.5% 64.8% 54.2% 45.8% 55.1% 63.8% 54.9%
CI 32.1% 51.9% 72.0% 84.4% 60.1% - - - - - - - -
CcO2 33.9% 55.9% 70.8% 79.7% 60.1% - - - - - - - -
ABEA 44.8% 51.5% 65.9% 74.5% 59.2% 59.8% 73.5% 77.8% 70.4% 50.4% 63.9% 69.6% 61.3%
MAP 33.0% 50.8% 65.9% 82.7% 58.1% 43.9% 50.0% 61.1% 51.7% 53.5% 65.3% 77.7% 65.5%
PVR 38.5% 52.5% 66.7% 74.5% 58.0% - - - - - - - -
PaO2 45.2% 49.5% 63.6% 70.6% 57.2% 53.7% 51.5% 64.8% 56.6% 47.2% 49.2% 61.7% 52.7%
RBC 29.7% 49.8% 67.4% 78.8% 56.4% 52.4% 74.3% 87.5% 71.4% 54.2% 73.7% 83.0% 70.3%
CAO2 30.9% 51.2% 64.0% 77.1% 55.8% 51.2% 50.0% 57.4% 52.9% 47.9% 56.8% 57.4% 54.0%
PLT 50.9% 49.2% 56.1% 60.6% 54.2% 61.9% 70.0% 82.1% 71.3% 41.5% 50.0% 61.7% 51.1%
aPO2 40.3% 49.5% 56.4% 62.8% 52.3% - - - - - - - -
HCT 28.8% 45.5% 62.9% 70.1% 51.8% 53.6% 72.9% 91.1% 72.5% 50.0% 65.3% 81.9% 65.7%
PWP 34.5% 53.2% 54.2% 63.6% 51.4% 45.1% 64.7% 81.5% 63.8% 38.0% 46.6% 66.0% 50.2%
RAP 28.8% 46.5% 58.7% 70.6% 51.1% 43.9% 63.2% 70.4% 59.2% 41.5% 51.7% 64.9% 52.7%
PaCO2 39.4% 52.2% 51.5% 61.0% 51.0% 51.2% 50.0% 57.4% 52.9% 47.9% 56.8% 57.4% 54.0%
TEMP 32.7% 49.8% 56.1% 62.8% 50.3% 54.9% 67.6% 83.3% 68.6% 59.9% 66.1% 79.8% 68.6%
O2DEL 31.8% 41.4% 54.5% 73.6% 50.3% - - - - - - - -
SATAO2 34.5% 45.8% 53.8% 62.8% 49.2% 62.2% 58.8% 70.4% 63.8% 55.6% 55.9% 73.4% 61.7%
MPAP 37.0% 43.8% 48.9% 58.0% 46.9% 59.8% 52.9% 61.1% 57.9% 47.2% 57.6% 85.1% 63.3%
RR 29.1% 35.4% 45.5% 59.3% 42.3% 50.0% 73.5% 77.8% 67.1% 36.6% 44.1% 53.2% 44.6%
HOROW 28.2% 38.0% 47.3% 54.1% 41.9% 52.4% 61.7% 72.2% 62.1% - - - -
QUOTIENT 28.2% 36.0% 43.6% 53.7% 40.4% - - - - - - - -
PHA 27.9% 38.7% 44.3% 48.1% 39.7% 42.7% 57.4% 75.9% 58.7% 55.6% 65.3% 76.6% 65.8%
AADO2 27.6% 32.3% 45.1% 51.5% 39.1% - - - - - - - -
Mean Null 26.6% 29.0% 32.3% 36.7% 31.2% 38.1% 44.7% 55.0% 45.9% 42.7% 49.1% 57.7% 49.8%
Results were generated with available biomarkers from the baboon data and then sorted by mean accuracy.
All tested biomarkers are shown in addition to the null hypothesis. The null hypothesis, tested with
randomized biomarkers, performed worse than all of the tested biomarkers. This method was repeated on
the two porcine data sets for validation. Only 3 right censor durations were tested due to the sampling rate
and duration limitations of those experiments.
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Table A2: Prediction accuracy of longitudinal vital signs with a single blood biomarker on porcine
peritonitis experiment.
Accuracy
Right Censor Vitals Point No Point W/ Point Time Series
HR HGB 83.6% 84.9% 80.8%
HR pH 83.6% 82.2% 82.2%
HR PLT 83.6% 80.8% 78.1%
Temp HR HGB 87.7% 86.3% 82.2%
SATAO2 HR HGB 80.8% 86.3% 84.9%
2 SATAO2 HR PHA 80.8% 83.6% 83.6%
Temp SATAO2 HR HGB 84.9% 86.3% 87.7%
Temp SATAO2 HR PHA 84.9% 83.6% 83.6%
Temp SATAO2 HR PLT 84.9% 82.2% 82.2%
Temp MAP SATAO2 HR SBE 72.6% 79.5% 78.1%
Temp MAP SATAO2 HR HGB 72.6% 79.5% 75.3%
Temp MAP SATAO2 HR PaO2 72.6% 76.7% 78.1%
HR HGB 89.7% 93.1% 89.7%
HR PHA 89.7% 89.7% 89.7%
Temp HGB 89.7% 86.2% 89.7%
Temp HR HGB 89.7% 91.4% 91.4%
SATAO2 HR HGB 89.7% 91.4% 89.7%
3 SATAO2 HR PHA 89.7% 91.4% 89.7%
Temp SATAO2 HR PLT 87.9% 91.4% 86.2%
Temp SATAO2 HR PHA 87.9% 89.7% 87.9%
Temp MAP HR HGB 82.8% 87.9% 87.9%
Temp MAP SATAO2 HR HGB 82.8% 86.2% 86.2%
Temp MAP SATAO2 HR WBC 82.8% 82.8% 86.2%
Temp MAP SATAO2 HR SBE 82.8% 82.8% 82.8%
The combinatorial vitals+1 biomarker search was repeated for pig peritonitis experiment. This search
analyzed combinations of vitals in time-series and a single point measurement of a blood-derived biomarker.
The top results of this search are shown.
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Table A3: Prediction accuracy of longitudinal vital signs with a single blood biomarker on porcine
LPS experiment.
Accuracy
Combined Groups (n=22) 1 µg/kg/h Dose Group 10 µg/kg/h Dose Group
Right Censor Vitals Point No Point W/ Point Time Series No Point W/ Point Time Series No Point W/ Point Time Series
Temp PaO2 66.1% 74.6% 63.6% 78.3% 78.3% 70.0% 64.6% 62.5% 54.2%
Temp PHA 66.1% 73.7% 72.9% 78.3% 76.7% 80.0% 64.6% 62.5% 66.7%
Temp HGB 66.1% 71.2% 74.6% 78.3% 71.7% 83.3% 64.6% 52.1% 60.4%
Temp SATAO2 PHA 74.6% 77.1% 79.7% 88.3% 88.3% 90.0% 62.5% 66.7% 66.7%
Temp HR PHA 76.3% 76.3% 77.1% 71.7% 70.0% 70.0% 58.3% 62.5% 56.3%
2 MAP SATAO2 PHA 71.2% 76.3% 75.4% 81.7% 81.7% 81.7% 66.7% 64.6% 64.6%
Temp MAP SATAO2 WBC 75.4% 78.0% 78.8% 83.3% 81.7% 78.3% 62.5% 62.5% 85.4%
Temp MAP SATAO2 PHA 75.4% 78.0% 78.8% 83.3% 83.3% 83.3% 62.5% 62.5% 62.5%
Temp MAP HR WBC 69.5% 76.3% 75.4% 80.0% 71.7% 71.7% 58.3% 60.4% 70.8%
Temp MAP SATAO2 HR WBC 72.9% 77.1% 77.1% 86.7% 75.0% 73.3% 56.3% 66.7% 72.9%
Temp MAP SATAO2 HR PLT 72.9% 77.1% 72.9% 86.7% 71.7% 75.0% 56.3% 68.8% 70.8%
Temp MAP SATAO2 HR PaO2 72.9% 75.4% 68.6% 86.7% 83.3% 76.7% 56.3% 58.3% 56.3%
MAP PaO2 77.7% 84.0% 73.4% 93.8% 89.6% 95.8% 68.4% 76.3% 73.7%
Temp PHA 79.8% 83.0% 80.9% 85.4% 89.6% 91.7% 63.2% 73.7% 73.7%
MAP WBC 77.7% 81.9% 85.1% 93.8% 93.8% 91.7% 68.4% 71.1% 89.5%
Temp SATAO2 PHA 87.2% 87.2% 86.2% 91.7% 91.7% 91.7% 78.9% 78.9% 76.3%
Temp MAP WBC 73.4% 86.2% 85.1% 93.8% 91.7% 89.6% 65.8% 71.1% 89.5%
3 MAP SATAO2 WBC 84.0% 85.1% 83.0% 93.8% 87.5% 91.7% 71.1% 78.9% 89.5%
Temp SATAO2 HR HGB 78.7% 85.1% 84.0% 72.9% 75.0% 85.4% 73.7% 81.6% 71.1%
Temp MAP SATAO2 WBC 81.9% 84.0% 84.0% 95.8% 89.6% 89.6% 71.1% 76.3% 86.8%
MAP SATAO2 HR WBC 76.6% 84.0% 84.0% 91.7% 83.3% 81.3% 73.7% 78.9% 84.2%
Temp MAP SATAO2 HR WBC 80.9% 85.1% 85.1% 93.8% 83.3% 79.2% 71.1% 78.9% 81.6%
Temp MAP SATAO2 HR HGB 80.9% 81.9% 84.0% 93.8% 93.8% 95.8% 71.1% 73.7% 68.4%
Temp MAP SATAO2 HR PHA 80.9% 80.9% 80.9% 93.8% 93.8% 93.8% 71.1% 71.1% 71.1%
The combinatorial vitals+1 search was repeated for pig LPS. This search analyzed combinations of vitals
in time-series and a single point measurement of a blood-derived biomarker. The top results of this search
are shown. Comparable results for each of the LPS dosing groups are shown because ANOVA revealed
significant differences
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APPENDIX B
DETAILED BENCHMARK FUNCTIONS USED TO VALIDATE
APT-MCMC
This section lists the benchmark functions used as well as the APT-MCMC distributions for
their parameters. Functions were taken from Jamil, et al [126].
B.0.1 Ackley
fackley(x) = −20e−0.02
√∑D
i=1 x
2
i /D − e
∑D
i=1 cos(2pixi)/D + 20 + e
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B.0.2 Adjiman
fadjiman(x) = cos(x1) sin(x2)− x1
x22 + 1
160
B.0.3 Alpine
falpine(x) =
D∑
i=1
∣∣xi sin(xi) + 0.1xi∣∣
161
B.0.4 Bard
fbard(x) =
1∑
i=1
5
[
yi − x1 − ui
vix2 + wix3
]2
yi = [0.14, 0.18, 0.22, 0.25, 0.29, 0.32, 0.35, 0.39, 0.37, 0.58, 0.73, 0.96, 1.34, 2.10, 4.39]
ui = i
vi = 16− i
wi = min(ui, vi)
162
B.0.5 Beale
fbeale(x) = (1.5− x1 + x1x2)2 + (2.25− x1 + x1x22)2 + (2.625− x1 + x1 + x32)2
163
B.0.6 Bird
fbird(x) = sin(x1)e
(1−cos(x2))2 + cos(x2)e(1−sin(x1))
2
+ (x1 − x2)2
164
B.0.7 Bohachevsky
fbohachevsky(x) = x
2
1 + 2x
2
2 − 0.3 cos(3pix1 + 4pix2) + 0.3
165
B.0.8 Booth
fbooth(x) = (x1 + 2x2 − 7)2 + (2x1 + x2 − 5)2
166
B.0.9 Bukin
fbukin(x) = 100
√
||x2 = 0.01x21||+ 0.01||x1 + 10||
167
B.0.10 Corana
fcorana(x) =

∑4
i=1 0.15(zi − 0.5sign(zi))2 , |xi − zi| < 0.05
dix
2
i , otherwise
zi = 0.2b
∣∣ xi
0.2
∣∣+ 0.49999csign(xi)
di = [1, 1000, 10, 100]
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B.0.11 Damavandi
fdamavandi(x) =
[
1−
∣∣∣∣sin[pi(x1 − 2)] sin[pi(x2 − 2)]pi2(x1 − 2)(x2 − 2)
∣∣∣∣5][2 + (x1 − 7)2 + 2(x2 − 7)2]
169
B.0.12 Devilliers-Glasser
fdevilliers(x) =
1∑
i=1
6
{
x1x
ti
2 tanh [x3ti + sin(x4ti)] cos(tie
x5 − yi)
}2
ti = 0.1(i− 1)
yi = 53.811.27
ti tanh [3.012ti + sin(2.13ti)] cos(tie
0.507)
170
B.0.13 Eggholder
feggholder(x) =
m−1∑
i=1
[− (xi+1 + 47) sin√|xi+1 + xi/2 + 47| − xi sin√|xi − (xi+1 + 47)|]
171
B.0.14 Griewank
fgriewank(x) =
n∑
i=1
x2i
4000
−
n∏
i=1
cos
(
xi√
i
+ 1
)
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